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Background 
As defined by the World Health Organisation (WHO), disease burden of chronic 
disorders is not solely confined to primary organ failure1. Several chronic 
disorders as chronic obstructive pulmonary disease (COPD) and chronic heart 
failure (CHF) are characterised by clinically relevant systemic complications 
that contribute to increased morbidity and decreased exercise capacity 
independent of primary organ dysfunction. These include increased circulatory 
levels of pro-inflammatory cytokines e.g. tumour necrosis factor alpha (TNF-α) 
and peripheral skeletal muscle abnormalities2. Both muscle wasting and 
impaired functioning of the remaining muscle contribute to reduced muscle 
strength and endurance in chronic inflammatory diseases and lead to 
progressive disability and poor health status2,3. Besides the presence of muscle 
atrophy, it is well established that peripheral skeletal muscle oxidative 
phenotype is disturbed in these disorders. This includes a fiber type shift 
towards a more glycolytic phenotype, impaired mitochondrial functioning and 
reduced activity levels of enzymes involved in substrate oxidation2,4-8. 
Traditionally, research addressing the impact of inflammatory events on 
skeletal muscle tissue has mainly focused on the process of skeletal muscle 
atrophy. Several experimental models have clearly shown that there is a causal 
relation between inflammatory events and loss of muscle mass9,10. The nature 
of the relationship between inflammation and muscle atrophy in human 
subjects however remains to be determined. In addition, the etiology of 
impaired muscle oxidative phenotype in chronic inflammatory disorders is still 
unclear. In the last decade, the PGC-1α/PPAR pathway has emerged as one of 
the major signalling cascades regulating skeletal muscle oxidative phenotype. 
Activation of this pathway potently up-regulates skeletal muscle oxidative 
capabilities and induces a phenotype reminiscent of that induced by exercise 
training11,12. Whether or not this pathway is impaired in skeletal muscle of 
COPD patients is unknown. Since an increased inflammatory status is a 
common denominator of several chronic disorders, which are characterised by 
impaired skeletal muscle oxidative phenotype, a role for inflammatory 
mediators in impaired functioning of muscle in these disorders might be 
postulated. In support of this, in COPD, it has been shown that exercise 
capacity is inversely associated with plasma inflammatory markers13. Yet, 
whether inflammation affects skeletal muscle oxidative phenotype and, if so, 
which signalling pathways are involved remains to be fully elucidated. 
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Aims and outline of the thesis 
The overall aim of the work presented in this thesis was to investigate the 
molecular basis for loss of muscle oxidative phenotype in COPD by adopting a 
molecular biology approach and subsequent translation of experimental 
findings to the patient. Three specific aims are addressed in this thesis: 
 
1. To evaluate whether the PGC-1α/PPAR signalling pathway is impaired in 
skeletal muscle of COPD patients and if this is associated with the loss of 
muscle oxidative phenotype and inflammation. 
2.  To elucidate the role of inflammatory mediators and subsequent 
inflammatory signalling on the regulation of skeletal muscle oxidative 
phenotype. 
3. To investigate potential bi-directional interplay between inflammatory 
signalling pathways and the PGC-1α/PPAR pathway. 
 
Chapter 2 elaborates on the concept of skeletal muscle pathology, 
inflammation and implication of the PGC-1α/PPAR pathway in COPD systemic 
pathology. An extensive overview of the current literature on COPD systemic 
pathology is provided and the therapeutic potential of modulation of the PGC-
1α/PPAR pathway in targeting distinct aspects of systemic complications of the 
disease including alleviation of inflammatory status and skeletal muscle 
dysfunction is discussed. The role of the PGC-1α/PPAR pathway in 
development of skeletal muscle oxidative phenotype during myogenic 
differentiation is unclear. Therefore, in chapter 3, a model of cultured skeletal 
muscle cells was used to investigate these markers in relation to the 
development of skeletal muscle oxidative phenotype during myogenesis. Since 
PGC-1α and PPARs are implicated in the regulation of skeletal muscle 
oxidative phenotype11,12, content and expression levels of constituents and 
targets of the PGC-1α/PPAR pathway in skeletal muscle of COPD patients and 
their relation with the presence of systemic inflammatory mediators was 
investigated in chapter 4. Associations between the presence of a systemic 
inflammatory response and impairment of exercise capacity have been 
demonstrated in COPD13. Since the direct impact of inflammation on muscle 
oxidative phenotype is unknown, chapter 5 was aimed at investigating the 
direct effects of inflammatory mediators on regulation of skeletal muscle 
oxidative phenotype. TNF-α was chosen as a model inflammatory mediator, as 
it has been shown that not only circulatory levels, but also muscular protein 
content of this cytokine is elevated in COPD patients14,15. The transcription 
factor nuclear factor kappa B (NF-κB) which is activated in the musculature of 
severe COPD patients16, is a key intra-cellular pathway relaying inflammatory 
signals17. Parameters of oxidative phenotype, involvement of the NF-κB 
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pathway and impact of the NF-κB cascade on the PGC-1α/PPAR pathway 
were investigated upon chronic stimulation of muscle cells with TNF-α. To 
address the bi-directional nature of the interaction between the NF-κB and 
PGC-1α/PPAR pathway in skeletal muscle, chapter 6 investigated the ability of 
different PPAR isoforms to interfere with pro-inflammatory cytokine-induced 
NF-κB activation. In chapter 7 the implications of the experimental findings of 
the different studies described in this thesis are discussed. 
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Abstract 
Extra-pulmonary pathology significantly impairs clinical outcome in COPD. The 
peroxisome proliferator-activated receptors (PPARs) are implicated in the 
regulation of several hallmarks of systemic COPD pathology, including 
cachexia, decreased oxidative muscle metabolism, oxidative stress and 
systemic inflammation. Recently, expression of PPARs and related co-factors 
was shown to be reduced in peripheral skeletal muscle of patients with 
moderate to severe COPD and muscle weakness. We hypothesise that 
impaired PPAR signalling may underlie some of the muscular disturbances in 
COPD. Proposed mechanisms as well as the therapeutic potential of PPAR 
modulation in treatment of skeletal muscle dysfunction will be outlined in this 
perspective. 
Thesis_Remels_v1.pdf
 Peroxisome proliferator-activated receptors: a therapeutic target in COPD? 
15 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a lung disease characterised 
by irreversible airway obstruction and an abnormal chronic inflammatory 
response of the airways. Dominant symptoms are dyspnoea and impaired 
exercise capacity. These symptoms lead to progressive disability and poor 
health status but poorly correlate with severity of local impairment in the lungs. 
Surprisingly, even in the most recent international guidelines for diagnosis of 
COPD, staging is still based on severity of airway obstruction only1. However, 
there is increasing evidence in the literature that COPD should not be 
considered as a localised pulmonary disorder but as a systemic disease 
involving pathology in several extra-pulmonary tissues. Well characterised 
systemic features are a chronic low grade systemic inflammation and altered 
protein metabolism which, in a subgroup of severe COPD patients, results 
initially in muscle atrophy only (commonly referred to as sarcopenia) and in 
later stages also in cachexia2,3. Muscle atrophy is associated with increased 
mortality risk independent of disease staging4. Besides muscle atrophy, it is 
well established that intrinsic abnormalities in structure and metabolism are 
present in the remaining muscle in moderate to severe COPD.  Muscle atrophy 
and muscle dysfunction contribute to reduced strength and endurance of the 
muscle which in turn limits exercise capacity. A recent meta-analysis showed 
that skeletal muscle in patients with moderate to severe COPD shows a fiber 
type shift from type I oxidative fibers to type II glycolytic fibers5. In addition, 
skeletal muscle in patients is characterised by a reduced oxidative capacity and 
recently in vitro impaired mitochondrial respiration was even shown in 
underweight patients with severe COPD6. It is still unclear whether the 
molecular mechanisms of muscular impairment in COPD are governed by 
disease-specific factors or common denominators of chronic wasting disease. 
The elucidation of these mechanisms is a crucial step towards developing 
specific therapies aimed at improving functionality and health status of these 
patients. Intriguingly, oxidative capacity and fiber type composition of skeletal 
muscle are controlled or affected by signalling through the nuclear receptor 
family of peroxisome proliferator-activated receptors (PPARs)7. Moreover, 
PPARs have also been shown to possess important anti-inflammatory 
properties by modulation of inflammatory signalling through the nuclear factor 
kappa B (NF-κB) pathway8. These combined actions could make PPARs an 
attractive target for therapeutic intervention aimed at alleviating skeletal muscle 
weakness in COPD as will be highlighted in this perspective.  
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Peroxisome proliferator-activated receptors (PPARs) 
and COPD 
Three PPAR isoforms can be distinguished: α, β/δ and γ. All three exhibit 
tissue-specific expression, ligand-specific activation and the ability to 
heterodimerise with retinoid X receptors (RXR) resulting in the transcription of 
target genes. During the past decade, PPARs have been implicated in several 
physiological processes such as the regulation of lipoprotein and lipid 
metabolism, glucose homeostasis, the inflammatory response and cellular 
differentiation9.  
 
PPAR-α is expressed in many oxidative tissues, including skeletal muscle. The 
primary role of PPAR-α in skeletal muscle is regulation of fatty acid 
homeostasis and transcriptional control of lipid regulatory genes10. Additionally, 
PPAR-α is involved in the regulation of amino acid metabolism by down-
regulating blood- and tissue branched chain amino acid (BCAA) levels11. Other 
effects of PPAR-α activation include attenuation of inflammatory responses 
through inhibition of NF-κB-driven gene transcription12. Interestingly, secretion 
of inflammatory mediators in the lung decreased upon PPAR-α activation in a 
mouse model of chronic lung inflammation13. PPAR-α is activated by a number 
of naturally occurring, lipid-derived molecules including long-chain fatty acids, 
eicosanoids and leukotriene B4, while the fibrate class of hypolipidemic drugs, 
including fenofibrate and gemfibrozil, serves as synthetic PPAR-α ligands. 
 
Although most abundant in adipose tissue, PPAR-γ is expressed at low levels 
in skeletal muscle. Interestingly from a pulmonary perspective, PPAR-γ is also 
expressed in the human lung. PPAR-γ regulates the storage of fat in adipose 
tissue and reduces plasma glucose, lipid and insulin levels in animal models of 
type 2 diabetes mellitus, as well as in humans14. Like PPAR-α, PPAR-γ is 
involved in attenuation of the inflammatory response by reducing NF-κB DNA-
binding and repression of NF-κB activation through inhibition of the IκB kinase 
complex activity12,15. Anti-inflammatory effects of PPAR-γ activation in the lung 
have been shown consistently in experimental models of asthma and other 
airway diseases, such as COPD16. PPAR-γ is the main target of the 
thiazolidinedione (TZD) class of insulin-sensitizing drugs, which are currently a 
mainstay of therapy for type 2 diabetes mellitus. Besides these synthetic 
ligands, PPAR-γ is activated by several naturally occurring compounds, such 
as prostaglandin J2 derivates and polyunsaturated fatty acids (PUFAs)17.  
 
PPAR-δ is a powerful regulator of fatty acid utilization and energy homeostasis 
in several tissues including the heart and skeletal muscle7. Consistent with 
such a role, PPAR-δ protein content is increased during physiological 
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conditions characterised by elevated fatty acid utilization, such as physical 
exercise or fasting. However, as PPARs are transcriptional regulators, their 
functionality is not only determined by abundance, but also by their activity. 
This may explain apparently contradictory reports showing increased PPAR-δ 
expression in skeletal muscle following short term fasting versus decreased 
PPAR-δ expression after longer periods of fasting18,19. Therefore, selection of 
different time points, as well as PPAR abundance and activity measurements 
are necessary to clarify the actual sequence of events in skeletal muscle during 
metabolic adaptation. Over-expression of PPAR-δ or its activation by synthetic 
agonists strongly increases the lipid catabolic activities of skeletal muscle, not 
only by up-regulating genes involved in this metabolic pathway, but also by 
inducing mitochondrial biogenesis and by promoting an increment of oxidative 
fibers20. PPAR-δ is characterised by the large size of its ligand-binding pocket 
which allows interaction with a greater variety of activators when compared 
with other nuclear hormone receptors. PPAR-δ is activated by PUFAs, 
prostacyclin and synthetic molecules like phenoxyacetic acid derivates (e.g. 
GW 501516 and GW 0742)17. 
 
We recently showed that PPAR-δ protein content is reduced in skeletal muscle 
of COPD patients compared to healthy control subjects. In addition, mRNA 
levels of the PPAR co-activator 1α (PGC-1α), which is a PPAR co-activator and 
a master regulator of mitochondrial biogenesis, were lower in muscle of COPD 
patients compared to controls while mRNA levels of PPAR-α were significantly 
lower in cachectic patients compared to non-cachectic patients21. Muscle 
oxidative phenotype, which is positively influenced by PPAR-δ, PGC-1α and 
PPAR-α, is reduced in COPD6. This suggests that a reduced PPAR-δ and/or 
PPAR-α content or function in this disease may be involved in the observed 
reduction in muscular oxidative capacity that may even lead to mitochondrial 
dysfunction. Many pathological hallmarks of COPD have been shown to exert a 
negative effect on PPAR expression and activity. Hypoxia and inflammation 
could be responsible for lower PPAR expression levels or protein content as 
there are several reports that suggest a negative influence of these parameters 
on PPAR levels22-24. Furthermore, a sedentary lifestyle which is often adopted 
by COPD patients due to disease-specific limitations can also underlie reduced 
levels of PPAR and PGC-1α in skeletal muscle as it has been shown that 
physical activity level is an important factor regulating these factors25,26. 
Intriguingly, in other disease models, as congestive heart failure (CHF) and 
diabetes mellitus (DM), both characterised by systemic inflammation and 
physical inactivity, a decreased oxidative capacity of skeletal muscle is also 
associated with a decreased expression of PGC-1α, PPAR-α and PPAR-δ 
mRNA suggesting a prominent role for inflammation and physical activity level 
in controlling PPAR and PGC-1α levels27-29. Furthermore, it would be 
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interesting to investigate PPAR and PGC-1α expression levels at different 
stages of COPD to increase insight in the etiology and pathological 
mechanisms governing the observed decrease in skeletal muscle oxidative 
capacity in these patients. 
PPARs and regulation of skeletal muscle function  
Inflammation 
Systemic inflammation is an important factor in the pathogenesis of weight loss 
and muscle wasting30-32. Many inflammatory responses are mediated by 
signalling through NF-κB. In its inactive form, NF-κB is bound to its inhibitor I 
kappa B alpha (IκBα) and is located in the cytosol. After activation, NF-κB is 
released and translocates to the nucleus where it initiates the transcription of 
its target genes, including those encoding inflammatory mediators33. NF-κB 
activation per se is sufficient for the induction of muscle atrophy34. Conversely, 
inhibition of NF-κB restored muscle mass in a number of experimental atrophy 
models including denervation and cancer cachexia34. Interestingly, NF-κB 
activation has been shown in skeletal muscle of severely underweight COPD 
patients by decreased content of the inhibitory protein of NF-κB (IκBα) and 
increased DNA binding of NF-κB35. Data regarding expression of inflammatory 
genes in relation to NF-κB activation are however lacking. Furthermore, some 
studies reported increased levels of inflammatory markers, including TNF-α 
protein, in skeletal muscle of COPD patients36,37, while others did not38. This 
discrepancy may be related to differences in COPD phenotypes and muscle 
studied. Additional studies measuring inflammatory mediators in skeletal 
muscle of different COPD phenotypes (cachectic vs non-cachectic) are needed 
to elucidate the exact implication of inflammatory signalling in the process of 
skeletal muscle wasting and cachexia in COPD. 
 
Potent anti-inflammatory properties have been described for different PPAR 
isoforms. It was shown that specific PPAR-α activators effectively reduced 
NF-κB activation and re-established control over pro-inflammatory cytokine 
production, such as interleukin 6 (IL-6) and tumour necrosis factor alpha 
(TNF-α), in various mouse tissues39. In addition, PPAR-α activators were found 
to induce expression of the NF-κB inhibitory factor IκBα in primary smooth 
muscle cells40. PPAR-γ may also play an important role in the regulation of 
inflammation. Several PPAR-γ ligands have been shown to possess anti-
inflammatory properties. For example, 15d-PGJ2 was shown to inhibit matrix 
metalloproteinase-9, IL-1β, IL-6 and TNF-α production by human 
monocytes/macrophages41,42. The TZD troglitazone decreased plasma levels of 
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TNF-α in obese human subjects and effectively reduced nuclear localisation of 
NF-κB in mononuclear cells, suggesting a reduction in NF-κB-mediated 
transcription43. Besides inhibition of nuclear translocation, PPAR-γ activation 
can also interfere with NF-κB signalling by a mechanism involving competition 
for transcriptional co-factors44. Furthermore, PPAR-γ activation can repress 
NF-κB activity by reducing NF-κB DNA-binding activity and preventing IκBα 
degradation45. Reports on anti-inflammatory effects of PPAR-δ are scarce. 
However, a recent study showed that PPAR-δ activation in C2C12 mouse 
skeletal muscle cells displayed anti-inflammatory properties46.  
 
In summary, convincing data implicate inflammation as a trigger of cachexia, 
which may be modulated by systemic delivery of PPAR agonists by 
suppressing inflammatory- and subsequent atrophy signalling in skeletal 
muscle.  
Oxidative stress 
Development and progression of skeletal muscle atrophy in COPD has also 
been associated with an imbalance between reactive oxygen species (ROS) 
production and antioxidant capacity47,48. Oxidative stress is present 
systemically as well as locally in skeletal muscle of COPD patients49. 
Experimental studies have shown that ROS can increase muscle proteolysis, 
inhibit muscle-specific protein expression, and increase muscle cell 
apoptosis50-52. Moreover, several studies demonstrated that markers of 
nitrosative stress are also enhanced in skeletal muscle of COPD patients. 
Inducible nitric oxide synthase (iNOS) expression and/or nitrotyrosine formation 
were found to be enhanced in skeletal muscle of COPD patients in several 
independent studies suggesting that, in addition to oxidative stress, skeletal 
muscle is also exposed to nitrosative stress, which may contribute to the 
process of protein degradation as well35,37,53. In contrast, it has been shown 
that nitric oxide (NO), at modest concentrations (i.e. when it appears to act as a 
signalling molecule causing reversible post-translational modifications) 
stimulates the formation of metabolically active new mitochondria through 
activation of the AMPK/SIRT1/PGC-1α/PPAR-δ signalling pathway54,55. Based 
on the latter, it can not be excluded that NO may serve to counteract 
mitochondrial dysfunction in conditions characterised by muscle degeneration, 
such as COPD and further studies are necessary to properly address this 
issue. 
 
A bulk of evidence points towards an inhibitory and attenuating effect of PPAR-
α on oxidative stress. PPAR-α agonists can directly attenuate oxidative stress 
by preventing ROS generation, as it was shown that PPAR-α activation in mice 
restored impaired cellular redox balance, evidenced by a lowering of tissue lipid 
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peroxidation and elimination of constitutively active NF-κB39. Furthermore, 
PPAR-α activation by fish oil feeding and fenofibrate administration to mice, 
down-regulated hydroxysteroid markers of ROS production in the liver56. 
Several studies demonstrated that activation of PPAR-α in vivo also causes an 
up-regulation in a number of antioxidant enzymes, including catalase, Cu2+ and 
Zn2+ superoxide dismutase (SOD) and mediators of the glutathione pathway57. 
More recent research confirms previous reports that PPAR-α activation in rats 
increases the antioxidant capacity and thereby modulates the oxidant-
antioxidant balance in favour of the latter58,59. In addition, cardiac-specific 
PPAR-α deficiency was accompanied by a decrease in cardiac manganese 
SOD expression and activity and a subsequent increase in oxidative/nitrosative 
damage60. Besides PPAR-α agonists, PPAR-γ agonists are also able to reduce 
ROS formation61,62. Two different PPAR-γ ligands were found to increase 
catalase mRNA expression and activity in endothelial cells63. Furthermore, 
glutathione and ascorbic acid levels in the hearts of diabetic rabbits were 
increased after PPAR-γ activation when compared to diabetic non-treated 
animals64. The exact mechanisms involved in the reduction of oxidative stress 
by PPAR-α and PPAR-γ agonists remain elusive.  
 
Oxidative stress has been demonstrated consistently in skeletal muscle of 
COPD patients53. As PPAR activation diminishes oxidative stress in multiple 
tissues, it is reasonable to expect similar effects in skeletal muscle, which may 
be beneficial in alleviating skeletal muscle dysfunction in COPD. 
Oxidative metabolism 
 
A decrease in the type I slow oxidative muscle fibers and a concomitant 
increase in type II fast twitch glycolytic fibers is reported in peripheral skeletal 
muscles of COPD patients, indicative of a relative shift from oxidative to 
glycolytic capacity65. Because type II muscle fibers have a lower resistance to 
fatigue, this fiber type shift may result in reduced endurance as observed in 
peripheral skeletal muscle of COPD patients. In concordance with this fiber 
type shift, analyses of enzyme activities also reveal an overall increase in 
glycolytic and decrease in oxidative activities in peripheral skeletal muscles of 
these patients affecting muscle substrate metabolism6,66. 
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Figure 2.1 Negative effects of inflammation, oxidative- and nitrosative stress on muscle mass and 
oxidative phenotype and the different levels of modulation by peroxisome proliferator-
activated receptors (PPARs). Inflammation, oxidative- and nitrosative stress negatively 
affect muscle mass and oxidative capacity. Different PPAR subtypes inhibit 
inflammatory signalling and oxidative- and nitrosative stress at the indicated levels and 
may prevent or restore loss of muscle mass and oxidative phenotype. In addition, 
PPAR-δ and PPAR-γ co-activator-1α (PGC-1α) may positively modulate muscle mass 
and oxidative phenotype and may oppose the effects of inflammation and oxidative-
nitrosative stress. NF-κB = Nuclear Factor kappa B, iNOS = inducible nitric oxide 
synthase, NO = nitric oxide, ROS = reactive oxygen species. Dotted lines indicate a 
negative effect on muscle mass and/or muscle oxidative phenotype. Full lines indicate 
a positive effect on muscle mass and/or muscle oxidative phenotype. Blocked 
arrowheads indicate an inhibitory signal and regular arrowheads represent a 
stimulatory signal. 
 
 
Expression of muscle genes that promote selective utilisation of lipid substrates 
is augmented during physiological states that are associated with increased 
systemic delivery of free fatty acids, such as exercise. Interestingly, many of 
the same muscle genes are also up-regulated by in vivo administration of 
PPAR-α activators. It is observed that PPAR-α protein content is increased by 
exercise training and induced during myocyte differentiation, two conditions 
characterised by an increase in oxidative capacity67,68. In addition, PPAR-α 
regulates fatty acid utilisation and expression of several genes involved in fatty 
acid β-oxidation in primary human skeletal muscle cells69. Skeletal muscle 
expresses high levels of PPAR-δ and activation of the δ-subtype increases 
fatty acid β-oxidation as well as mRNA levels of several classical PPAR-α 
target genes in both rodent and human skeletal muscle cells70. Over-
expression of PPAR-δ in C2C12 myotubes, in vitro, resulted in an increment in 
Inflammation
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Muscle mass
PPAR-α
PPAR-γ
PPAR-δ
ROS
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NO
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fatty acid oxidation after activation by a synthetic ligand71,72. In addition, 
analysis of rat myotubes treated with the PPAR-δ subtype selective agonist, 
GW 501516, revealed that PPAR-δ controls fatty acid oxidation by regulating 
genes involved in fatty acid transport, β-oxidation, and mitochondrial 
respiration73,74. These results, showing a significant overlap in the functions of 
PPAR-α and PPAR-δ, indicate that both subtypes play an important role in 
mediating lipid-induced regulation of oxidative pathways.  
 
A recent study examining mice over-expressing PPAR-δ in muscle showed that 
the number of succinate dehydrogenase (SDH) positive fibers (as a measure 
for oxidative fibers) was considerably increased in various muscles. This 
remodelling was due to hyperplasia and/or conversion of SDH negative to SDH 
positive fibers, similar to what is observed upon endurance training71,75. These 
histological observations were confirmed by the finding that muscle-specific 
PPAR-δ over-expression led to an increase of other oxidative enzymes, such 
as citrate synthase and β-hydroxyacyl-CoA dehydrogenase. In addition, 
mitochondrial biogenesis was also enhanced. Conversely, activities of 
glycolytic enzymes remained unchanged75. Conversion of glycolytic fibers to 
oxidative fibers has also been reported in genetically altered animals that over-
express PGC-1α, which is a PPAR co-activator and a master regulator of 
mitochondrial biogenesis. Notably, putative type II muscles from PGC-1α 
transgenic mice also express proteins characteristic of type I fibers, such as 
troponin I (slow) and myoglobin, and show a greater resistance to fatigue. 
These data indicate that, in addition to PPAR-δ, PGC-1α is also a principal 
factor regulating muscle fiber type determination and skeletal muscle exercise 
capacity76.  
 
Given the strong involvement of the PPARs and PGC-1α in regulation of 
skeletal muscle oxidative phenotype, the fact that skeletal muscle oxidative 
phenotype is impaired in COPD and the observation of reduced PPAR 
expression levels in skeletal muscle of COPD patients, it is tempting to suggest 
a possible therapeutic role for PPAR activators in muscle metabolism in COPD. 
How to modulate PPAR activity in COPD? 
COPD management requires an integrated approach aimed at pulmonary and 
extra-pulmonary manifestations. In addition to therapies aimed at alleviating the 
primary lung impairment, evidence is accumulating that therapies targeting 
skeletal muscle dysfunction have a significant positive effect on quality of life 
and may even improve survival. Experimental studies have shown that PPAR-α 
and PPAR-γ can exert anti-inflammatory effects in the pulmonary compartment, 
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which, with additional research, may translate into an interesting therapeutic 
avenue in the context of COPD lung pathology13,66,67. Moreover, based on the 
evidence described in the present review, it is tempting to suggest that a 
reduced content and activity of the PPARs may underlie some of the muscular 
disturbances in COPD. Nutritional intervention and exercise may positively 
influence PPAR content and activity in skeletal muscle. Indirect support for this 
notion is the beneficial effect of pulmonary rehabilitation on mitochondrial (fat) 
oxidative capacity and hence on skeletal muscle function in skeletal muscle of 
COPD patients77. PUFAs are common components of fatty fish and olive oil 
and are known PPAR activators. Interestingly, a recent Randomised Clinical 
Trial showed that nutritional supplementation with PUFAs as adjunct to 
exercise training in COPD patients markedly enhanced exercise capacity 
compared to the placebo-treated group78. The time point of intervention with 
PPAR activators is also a point of interest. Two different aspects must be kept 
in mind. First, the positive influence of PPAR activators on skeletal muscle 
oxidative capacity and second the potent anti-inflammatory capacities of these 
agents. Concerning the effects on muscle oxidative capacity the rationale 
would be to introduce PPAR activators clinically to patients for whom daily life 
activities are limited by the decreased oxidative capacity of their lower limb 
skeletal muscles. On the other hand, PPAR activators can be used to alleviate 
inflammatory status of COPD patients, for example, after exacerbations or in 
late stage COPD to ameliorate the systemic inflammatory process. Also, it is 
conceivable that PPAR agonists can delay or inhibit disease-specific 
processes, such as inflammation, if applied at early stages of disease 
development. 
 
In conclusion, single or combined PPAR agonists may represent a novel class 
of pharmacological agents that could be helpful in management of this disease. 
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Abstract 
Pathways involved in mitochondrial biogenesis associated with myogenic 
differentiation are poorly defined. Therefore, C2C12 myoblasts were 
differentiated into multi-nucleated myotubes and parameters/regulators of 
mitochondrial biogenesis were investigated. Mitochondrial respiration, citrate 
synthase- and β-hydroxyacyl-CoA dehydrogenase activity as well as protein 
content of complexes I, II, III and V of the mitochondrial respiratory chain 
increased 4-8 fold during differentiation. Additionally, an increase in the ratio of 
myosin heavy chain (MyHC) slow vs MyHC fast protein content was observed. 
PPAR transcriptional activity and transcript levels of PPAR-α, the PPAR co-
activator PGC-1α, mitochondrial transcription factor A and nuclear respiratory 
factor 1 increased during differentiation while expression levels of PPAR-γ 
decreased. In conclusion, expression and activity levels of genes known for 
their regulatory role in skeletal muscle oxidative capabilities parallel increases 
in oxidative parameters during the myogenic program. In particular, PGC-1α 
and PPAR-α may be involved in the regulation of mitochondrial biogenesis 
during myogenesis. 
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Introduction 
Intrinsically, skeletal muscle is a tissue characterised by a high level of 
plasticity. The potential to alter muscle size, metabolic properties and/or protein 
isoform expression gives skeletal muscle the ability to adapt to the different 
challenges that may be placed upon it1. Events triggering skeletal muscle 
adaptive changes include endurance- and strength training, overload, aging, 
disuse, starvation, chronic illness and degenerative disorders2-4. Growth and 
repair (regeneration) of skeletal muscle tissue is inextricably linked to the action 
of a group of myogenic precursor cells, called satellite cells. Upon activation, 
these cells proliferate, differentiate and ultimately fuse with existing myofibers5. 
The irreversible transition from the proliferation-competent myoblast stage into 
fused multi-nucleated myotubes is known as myogenic differentiation and 
recapitulates developmental and regenerative myogenesis6.  
 
Oxidative phenotype (OXPHEN) of a muscle depends on its oxidative capacity 
(determined by the activity of mitochondrial enzymes involved in oxidative 
substrate metabolism) and fiber type composition (e.g. ratio type I oxidative 
(slow-twitch) vs type IIB/X glycolytic (fast-twitch) fibers. The peroxisome 
proliferator-activated receptors (PPARs), especially the PPAR-δ and PPAR-α 
isoforms, and related co-activator molecules as PGC-1α are highly implicated 
in regulation of skeletal muscle OXPHEN7,8. Accordingly, muscle-specific over-
expression of PPAR-δ or PGC-1α in mice potently up-regulated oxidative 
capabilities of the muscle and mediated a fiber type shift towards an increased 
OXPHEN9,10. Moreover, PGC-1α and the PPARs govern mitochondrial 
biogenesis through control over other regulatory proteins including nuclear 
respiratory factor 1 (NRF-1) and the master mitochondrial regulator mito-
chondrial transcription factor A (Tfam)11,12. An improved muscle OXPHEN may 
be established during the process of myogenesis (i.e. the formation, repair or 
hypertrophy of muscle), or through alterations within the pre-existing muscle 
fibers, independent of myogenic differentiation. The regulation of oxidative 
profile in existing muscle fibers has been described quite extensively in the 
literature9,10,13 whereas knowledge regarding the development of muscle 
oxidative profile and the involvement of key regulators herein during myogenic 
differentiation is rather limited.  
 
Studying the molecular events governing regulation of mitochondrial biogenesis 
during myogenesis is of clinical relevance for a number of pathological 
conditions including chronic inflammatory myopathies and degenerative muscle 
conditions as e.g. Duchenne’s muscular dystrophy14,15, but also in conditions 
characterised by loss of OXPHEN in skeletal muscle, such as COPD4. 
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It has been shown that mitochondria play a mechanistic role not only in 
myoblast proliferation16,17, but also in myogenesis by targeting key regulators of 
myogenic differentiation as myogenin17 and cellular oncogens as c-myc18. 
Moreover, blocking mitochondrial biogenesis potently inhibits myogenic 
differentiation17,19. This demonstrates that mitochondria display a retrograde 
signalling to regulate their own biogenesis as well as cell cycle progression20, 
which subsequently implies that the investigation of myogenic differentiation is 
inevitably coupled to studying the process of mitochondrial biogenesis.  
 
Although markers of OXPHEN (including mitochondrial biogenesis) during 
myogenesis have been described previously16,17,20-23, information about the 
expression profile of key regulators during the entire myogenic program is 
incomplete. Therefore, the aim of the present study was to chart the 
development of multiple aspects of mitochondrial biogenesis during the full 
length of the differentiation process of skeletal muscle cells in order to increase 
our understanding of the key regulatory molecules of OXPHEN during 
myogenesis.  
Materials and methods 
Cell culture 
The murine skeletal muscle cell line C2C12 was obtained from the American 
Type Culture Collection (ATCC CRL1772; Manassas, VA, USA). These cells 
are able to undergo differentiation into spontaneously contracting myotubes 
after growth factor withdrawal24. Myoblasts were cultured in growth medium 
(GM) composed of low-glucose Dulbecco’s Modified Eagle's medium (DMEM) 
containing antibiotics (50 U/ml penicillin and 50 µg/ml streptomycin) and 9% 
(v/v) foetal bovine serum (FBS) (all from GIBCO, Rockville, MD, USA). Cells 
were plated at 104 cells/cm2 and cultured in GM for 24 h. To induce 
differentiation, cells were washed in Hank’s Balanced Salt solution (HBSS) and 
GM was replaced with differentiation medium (DM), which contained DMEM 
with 0.5% heat-inactivated FBS and antibiotics. C2C12 cells were grown on 
Matrigel (BD Biosciences, Bedford, MA, USA) (1:50 in DMEM) (Becton 
Dickinson Labware, Bedford, MA, USA), which contains constituents of the 
natural extracellular matrix of skeletal muscle fibers including collagen IV, 
laminin, heparin sulfate proteoglycan and entactin. 
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Transfections and plasmids 
For assessment of PPAR-dependent transcriptional activity, C2C12 cells were 
stably transfected with a PPAR-sensitive luciferase reporter plasmid containing 
3 PPAR responsive elements in tandem derived from the promoter region of 
the acyl CoA oxidase (ACO) gene (pSG5, Stratagene, La Jolla, CA, USA). 
Cells were grown to 70% confluency and transfected by Lipofectamine 
according to manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA). 
Transfection was performed in the presence of 3.75 µg ACO luciferase plasmid 
DNA (pSG5, Stratagene) and 0.25 µg of a plasmid containing the neomycin 
resistance gene (pSV2-Neo, Stratagene). For selection of positive clones, cells 
were cultured in GM containing 800 µg/ml G418 (Calbiochem, Nottingham, 
United Kingdom). 
May-Grunwald Giemsa staining 
As a morphological parameter of differentiation, the myogenic index was 
defined as the number of nuclei residing in cells containing three or more nuclei 
divided by the total number of nuclei in May-Grunwald Giemsa stained cells. 
Cells were grown on Matrigel-coated 60 mm dishes and differentiation was 
induced. After 0, 3 or 7 days of differentiation cells were washed 2x in 
phosphate buffered saline (PBS) (room temperature), fixed in methanol and 
stained in May-Grunwald Giemsa (Sigma, Saint Louis, MO, USA) according to 
manufacturer’s instructions.  
Reporter assays 
The PPAR-sensitive reporter cell line was plated in 35 mm dishes and allowed 
to grow to 70% confluency. After induction of differentiation (day 0), cells were 
differentiated into myotubes for 3, 5 or 7 days after which cells were harvested. 
Cells were washed 2x with cold PBS and subsequently lysed by adding (100 
µl) 1x Reporter Lysis Buffer (Promega, Madison, WI, USA) and incubation on 
ice for 10 min. Cell lysates were centrifuged (13 000 g, 1 min), and 
supernatants were snap-frozen and stored at -80 °C for later analysis. 
Luciferase activity was measured according to manufacturer’s instructions 
(Promega) and corrected for total protein content (Biorad, Hercules, CA, USA). 
Real time quantitative PCR (QPCR) 
Total RNA was extracted using the acid guanidium thiocyanate-phenol-
chloroform extraction method (Ambion Ltd., Ijssel, The Netherlands). RNA 
concentration was determined using a spectrophotometer. One µg of RNA per 
sample was reverse transcribed into cDNA according to the manufacturer’s 
instructions (Reverse-iT™ 1st strand synthesis, Abgene, Leusden, The 
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Netherlands). cDNA was PCR amplified with SYBR Green Fluorescein Mix 
(Westburg, Leusden, The Netherlands) on a Biorad PCR apparatus (Biorad). 
Specificity of the amplification was verified by melt curve analysis and 
evaluation of efficiency of PCR amplification. Primers were designed to 
generate a PCR amplification product of 100 to 150 bp (Table 3.1). Transcript 
levels for the constitutive housekeeping gene products cyclophilinA, 
Hypoxanthine phosphoribosyltransferase (HPRT), β-actin and Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) were quantitatively measured in each 
sample to control for sample-to-sample differences in RNA concentration. 
Additionally, geNorm software was applied to calculate a normalisation factor 
based on the expression levels of these 4 housekeepers. geNorm calculates 
the gene expression stability measure M for a reference gene as well as the 
average pairwise variation V for that gene with all other tested reference genes. 
Stepwise exclusion of the gene with the highest M value allows ranking of the 
tested genes according to their expression stability. The underlying principles 
and calculations are described in Vandesompele et al.25. Gene expression was 
quantified and expressed as arbitrary units (AU).  
 
Table 3.1  Primer details. 
 QPCR primer sequences 
Primer Forward 5’-3’ Reverse 5’-3’ 
PPAR-α AGTGCCCTGAACATCGAGTGT AAGCCCTTACAGCCTTCACATG 
PPAR-δ GAGCAAGTGGCCACGGGTGAC CCACCTGAGGCCCATCACAG 
PPAR-γ TGGGGATGTCTCACAATGCCA TTCCTGTCAAGATCGCCCTCG 
PGC-1α AAACCACACCCACAGGATCAG TCTTCGCTTTATTGCTCCATGA 
Tfam CGGAGTTCCCACGCTGG CCGTCCGGTTCGTCTCAC 
NRF-1 CCTCCAAACCTGCATCTCAC TCGCACCACATTCTCCAAAG 
COXVa TGCGAGCATGTAGACGGTTAAAT GAGGTCCTGCTTTGTCCTTAACA 
COXVIIc GGCCAGAGTATCCGGAGGTT CCACTGAAAATGGCAAATTCTTC 
COXII CCATCCCAGCCCGACTAA ATTTCAGAGCATTGGCCATAGAA 
COXIII GGTCTCGGAAGTATTTTTCTTTGC CAGCAGCCTCCTAGATCATGTG 
CyclophilinA TTCCTCCTTTCACAGAATTATTCCA CCGCCAGTGCCATTATGG 
GAPDH CAACTCACTCAAGATTGTCAGCAA TGGCAGTGATGGCATGGA 
HPRT TGGATATGCCCTTGACTATAATGAGTAC AGGACTCCTCGTATTTGCAGATTC 
β-actin  CTGAATGGCCCAGGTCTGA CCCTCCCAGGGAGACCAA 
Peroxisome proliferator-activated receptor: PPAR; PPAR-γ co-activator 1 alpha: PGC-1α; 
Mitochondrial transcription factor A: Tfam; Nuclear respiratory factor 1: NRF-1; Cytochrome c 
oxidase: COX; Glyceraldehyde 3-phosphate dehydrogenase: GAPDH; Hypoxanthine 
phosphoribosyltransferase: HPRT. 
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Western blotting 
Abundance of proteins involved in oxidative phosphorylation (OXPHOS) as well 
as myosin heavy chain (MyHC) protein content was evaluated by Western 
blotting. Cells were washed in PBS and whole cell lysates were prepared by the 
addition of lysis buffer (20 mM Tris, 150 mM NaCl, 1% (v/v) Nonidet P-40, 1 
mM DTT, 1 mM Na3VO4, 1 mM PMSF, 10 µg/ml leupeptin, and 1% (v/v) 
aprotenin). Lysates were incubated on ice for 30 min, followed by 30 min of 
centrifugation at 13 000 g. A fraction of the supernatant was saved for protein 
determination and 4 x Laemmli sample buffer (0.25 M Tris·HCl; pH 6.8, 8% 
(w/v) SDS, 40% (v/v) glycerol, 0.4 M DTT, and 0.04% (w/v) bromophenol blue) 
was added, followed by boiling of the samples for 5 min and storage at –20°C. 
Total protein was assessed using the Biorad DC protein assay kit (Biorad) 
according to the manufacturer's instructions. 25 µg or 2 µg of protein (OXPHOS 
and MyHC respectively) was loaded per lane and separated on a 10% 
polyacrylamide gel (Mini Protean 3 system; Biorad), followed by transfer to a 
0.45 µm nitrocellulose membrane (Biorad) by electro blotting. The membrane 
was blocked for 1 h at room temperature in 5% (w/v) non-fat dry milk. 
Nitrocellulose blots were washed in PBS-Tween 20 (0.05%), followed by 
overnight incubation (4°C) with a polyclonal antibody specific for OXPHOS 
proteins (Cell Signaling, Beverly, MA, USA) or MyHC fast or slow (Sigma). After 
three wash steps of 20 min each, the blots were probed with a peroxidase-
conjugated secondary antibody (Vector Laboratories, Burlingame, CA, USA) 
and visualised using SuperSignal West Pico chemiluminescent substrate 
(Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's 
instructions.  
Enzyme activity assay 
Cells were washed twice in ice-cold PBS and subsequently lysed by 10 min 
incubation with 200 µl of 0.1% Triton-X100 dissolved in PBS. Cells were 
harvested by scraping, using rubber policemen, and transferred to an 
Eppendorf tube containing 45 µl 5% bovine serum albumine (BSA). After 
vortexing for 10 sec, samples were centrifuged (10 min, 13 000 g, 4°C), and the 
supernatant was used for spectrophotometrical assessment of the following 
enzyme activities:  HAD; EC 1.1.1.35; see Ref.26, CS; EC 2.3.3.1 ;see Ref.26 
and CK; EC2.7.3.2 see Ref.27) (Multiskan Spectrum; Thermo Labsystems, 
Breda, The Netherlands). Enzyme activities were corrected for total protein 
content (Biorad). 
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Mitochondrial respiration 
C2C12 myoblasts or differentiated myotubes were harvested in trypsin, washed 
twice with MIRO5 respiration medium (37ºC) (prepared according to MiPNet 
protocols) (Oroboros Instruments, Innsbruck, Austria) and, after a 5 min 
centrifugation at 500 g, resuspended in 2.0 ml of MIRO5 respiration medium. 
Protein content was determined in dishes that were cultured in a parallel 
experiment. Measurement of respiration was performed by a polarographic 
oxygen sensor in a 2 ml glass chamber of the respirometer Oxygraph 2K 
(Oroboros Instruments). The amplified signal from the oxygen sensor was 
recorded on a computer at sampling intervals of 2 seconds using DatLab 
acquisition software (Oroboros Instruments). The respiration medium was 
equilibrated with air at 37°C and stirred until a stable signal was obtained for 
calibration at air saturation. After calibration the medium was replaced by 
aerated cell suspensions at a volume of 2.0 ml. After insertion, cells were 
permeabilised using 1 µl of digitonin (0.5 µg/ml final concentration) and 
substrates were added in chronological order (volume; final concentration): 
malate (5 μl; 2 mM), followed by glutamate (10 μl; 10 mM) or pyruvate (5 μl; 
5 mM) or palmitoyl-carnitine (10 μl; 50 μM) followed by ADP (20 μl; 5 mM). At 
the end of the substrate trace a titration with the uncoupling agent FCCP was 
performed (1 μl; 0.5 μM titration). Oxygen consumption (pmol/ml.s) was 
calculated as a negative time derivative of oxygen concentration (nmol/ml). 
Respiration rates were corrected for total protein content to correct for 
variability in cellular input.  
Mitochondrial DNA copy number 
Mitochondrial DNA (mtDNA) copy number was determined as a marker for 
mitochondrial density using QPCR. Total DNA was isolated from the cells 
according to manufacturer’s instructions (Nucleospin, Machery Nagel, Ede, The 
Netherlands). A serial dilution standard curve was prepared from a pool of all 
the samples. Real-time PCR was carried out at the following parameters: 
15 min denaturation step at 95°C, followed by 40 cycles at 95°C for 15 sec and 
60°C for 45 sec, 30 sec at 95°C and 30 sec at 60°C followed by a stepwise 
increase of 0.5°C until 95°C was reached (melt curve analysis). Mitochondrial 
DNA copy number was calculated from the ratio COXII/cyclophilinA or 
COXIII/cyclophilinA. 
Statistical analysis 
Data was analysed according to the guidelines of Altman et al. using SPSS 
(Statistical Package for the Social sciences, SPSS Inc., Chicago, IL, USA)28. 
Kruskal-Wallis tests were applied for mean comparisons as a function of time 
and non-parametric tests were used to detect significant differences between 
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individual time-points. Data are represented as the mean ± SD. A two-tailed 
probability value of less than 0.05 was considered to be significant. 
Results 
Markers of myogenic differentiation 
In order to characterise myogenic differentiation of C2C12 cells we compared 
biochemical and structural markers of differentiation in myoblasts vs 
differentiating/differentiated myotubes. Results are summarised in Table 3.2 
and are illustrative of good morphological and biochemical differentiation. 
 
Table 3.2  Parameters of myogenic differentiation. 
 Myoblasts Myotubes (day 3) Myotubes (day 7) 
MyHC fast (AU) 0 1.7 ± 0.4* 3.9 ± 0.6* 
CK (U/mg protein) 0.010 ± 0.003 0.081 ± 0.023* 0.734 ± 0.087* 
Myogenic index 0 0.22 ± 0.04* 0.51 ± 0.08* 
Values are expressed as mean ± SD from 3 independent experiments. Significance of difference 
compared to myoblasts: * p<0.001. MyHC: myosin heavy chain; CK: creatine kinase; Myogenic 
index: the number of nuclei residing in cells containing three or more nuclei divided by the total 
number of nuclei in May-Grunwald Giemsa stained cells. 
 
Mitochondrial respiration in myoblasts and myotubes 
To investigate the development of oxidative capacity during C2C12 
myogenesis, we measured mitochondrial O2 consumption in proliferating 
C2C12 myoblasts and differentiated myotubes (differentiated 7 days) in 
response to different substrates. As depicted in Figure 3.1, basal respiratory 
rate was higher in myotubes when compared to myoblasts in the presence of 
endogenous substrates (basal respiration) (p=0.050). FCCP-induced 
respiration (maximal respiration), bypassing respiratory control by ATPase and 
thus reflecting maximal respiratory capacity, was 4-fold higher in myotubes 
compared to myoblasts (p=0.050). Shown in Figure 3.1 is the maximal 
respiratory capacity with palmitoyl-carnitine as a substrate. Differences in 
maximal respiratory capacity between myoblasts and myotubes were similar 
when other substrates were used (glutamate and pyruvate respectively, data 
not shown).  
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Figure 3.1 Mitochondrial respiration in C2C12 myoblasts vs differentiated myotubes. 
Mitochondrial respiration was measured in proliferating myoblasts and in myotubes 
which were differentiated for 7 days in DM. Cells were harvested and oxygen 
consumption was measured. Basal respiration (on endogenous substrates) was 
determined after adding the cells to the chambers. After permeabilisation with 
digitonin (1 μl; 0.5 µg/ml), the following substrates were added to the cells: malate 
(5 µl; 2 mM), glutamate (10 μl; 10 mM) or pyruvate (5 μl; 5 mM) or palmitoyl-
carnitine (10 μl; 50 μM) followed by ADP (20 µl; 5 mM) and oligomycin (1 µl; 1.66 
µg/ml). Maximal respiration was determined after titration with FCCP (1 μl; 0.5 µM 
titration). Respiration rates were corrected for total protein content. Data are 
represented as mean ± SD for 3 independent experiments. Oxygen consumption is 
given in pmol/mg·s. Significance of difference: * p≤0.050. 
Mitochondrial markers during myogenesis 
To gain insight in mitochondrial functioning and mitochondrial biogenesis 
during differentiation of C2C12 cells into mature myotubes, we measured 
several mitochondrial markers. These included activity levels of enzymes 
involved in substrate oxidation, to assess functionality of the citric acid cycle 
and fatty acid β-oxidation pathway, structural components of the respiratory 
chain (OXPHOS) and mtDNA copy number as a general marker for 
mitochondrial content. Additionally, we  also investigated mRNA transcript 
levels of cytochrome c oxidase (COX) subunits II and III (mitochondrial-
encoded) and subunits Va and VIIc (nuclear-encoded). Activity levels of 
enzymes involved in oxidative metabolism, CS (Krebs cycle) and HAD 
(β-oxidation), increased approximately 4-fold during myogenesis (p=0.016) 
(Figure 3.2A). Accordingly, protein levels of all investigated complexes of the 
respiratory chain increased up to 8-fold  (p=0.019, 0.023, 0.021 and 0.016 for 
complex I, II, III and V respectively) (Figure 3.2B) while mtDNA copy number 
was 4-fold higher in fully differentiated myotubes compared to myoblasts 
(p=0.025) (Figure 3.2C). As illustrated in Figure 3.2D, transcript levels of the 
mitochondrial-encoded subunits COX II and COX III as well as the nuclear-
encoded subunits Va and VIIc increased during differentiation (p=0.023 and 
0.026 respectively).  
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Myosin heavy chain isoform protein content during myogenesis 
To assess the distribution of MyHC isoforms during myogenesis, we 
investigated protein levels of MyHC fast (type II) and MyHC slow (type I) 
isoforms in C2C12 cells. MyHC protein levels are expressed as the ratio 
between the slow and fast isoform. Myoblasts expressed extremely low levels 
of both MyHC fast and slow isoforms whereas differentiated myotubes 
expressed significant amounts of both isoforms. During differentiation a relative 
higher increase in MyHC slow isoform was observed compared to MyHC fast 
isoform expression (p=0.025) (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Myosin heavy chain (MyHC) distribution in C2C12 cells during differentiation. 
C2C12 cells were harvested at different time points during differentiation (day 0, 3, 
5 and 7) and MyHC isoform protein levels were quantified by Western blot analysis. 
Protein levels of MyHC isoforms were corrected for total protein content. Data are 
represented as mean ± SD from triplicate samples from 3 independent experiments. 
Protein levels are given as arbitrary units (AU). Quantified MyHC protein levels are 
expressed as the ratio between the slow and fast isoform. Significance of difference 
compared to myoblasts (day 0): * p≤0.050.  
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PPARs and related factors during differentiation 
We determined mRNA transcript levels of PGC-1α and all PPAR isotypes at 
different time points during the differentiation process. As illustrated in Figure 
3.4, PGC-1α and PPAR-α mRNA expression levels increased (p=0.063 and 
0.024 respectively) while PPAR-γ showed decreased mRNA expression levels 
during differentiation (p=0.016). PPAR-δ mRNA expression levels were stable 
during the full myogenic program. Data was corrected for a normalisation factor 
derived from a geNorm analysis of 4 housekeepers (cyclophilinA, β-actin, 
GAPDH and HPRT). The average expression stability (M-value) for 
cyclophilinA, β-actin, GAPDH and HPRT was 0.473, 0.987, 0.688 and 0.470 
respectively. Pairwise comparison for inclusion of a fourth housekeeping gene 
(V3/4) was 0.244 indicating preferable use of 4 housekeeping genes. It must be 
mentioned that expression levels of all 4 investigated housekeeping genes 
decreased approximately 2-fold during differentiation of C2C12 cells (data not 
shown). However, similar patterns of expression of all genes of interest were 
observed when data was corrected for any of the 4 individual housekeepers or 
when correction based on the geNorm normalisation factor was applied. In 
addition to the PPARs and their co-activator PGC-1α, mRNA levels of 2 key 
regulators of mitochondrial biogenesis downstream of PGC-1α (NRF-1 and 
Tfam), were also determined during the myogenic program of C2C12 cells. 
Tfam and NRF-1 mRNA expression levels increased from day 0 until day 3 of 
the differentiation process and remained increased for the duration of the 
differentiation process (p=0.096 and 0.024 respectively) (Figure 3.5). Data 
corrected for the housekeeper cyclophilinA is shown as a representative 
housekeeper, but similar results were obtained with all other individual 
housekeeping genes as well as with the geNorm normalisation factor.  
PPAR-dependent transcriptional activity 
The PPARs as well as PGC-1α are highly implicated in the regulation of 
skeletal muscle oxidative capacity9,10,13. Therefore, we investigated PPAR-
dependent transcriptional activity during differentiation of C2C12 cells into 
multi-nucleated myotubes. As depicted in Figure 3.6, PPAR-dependent 
transcriptional activity increased  during differentiation (p=0.022).  
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Figure 3.5 Expression of Tfam and NRF-1 mRNA in C2C12 skeletal muscle cells during 
differentiation. Cells were differentiated in DM for 0, 3, 5, or 7 days and harvested. 
Expression levels of Tfam (A) and NRF-1 (B) were corrected for cyclophilinA as a 
representative housekeeper. Expression levels are expressed as % of day 0. Data 
are represented as mean ± SD from triplicate samples from 3 independent 
experiments. Similar results were observed when corrected for individual 
housekeeping genes as HPRT, β-actin or GAPDH or when the geNorm 
normalisation factor based on 4 different housekeepers was used. Significance of 
difference compared to myoblasts: * p≤0.050. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 PPAR-dependent transcriptional activity in C2C12 skeletal muscle cells 
during differentiation. C2C12 cells stably containing a PPAR sensitive reporter 
construct were differentiated in DM for 0, 3, 5, or 7 days and harvested. Cells were 
lysed; luciferase activity was determined and normalised to total protein content. 
Significance of difference compared to myoblasts: * p≤0.050. Error bars indicate the 
SD. Shown are the mean ± SD of 3 independent experiments. 
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Discussion 
In the present paper we show that multiple key determinants of OXPHEN 
develop during myogenic differentiation, which coincides with the initiation of 
mitochondrial biogenesis and increased expression and activity levels of key 
regulators of muscle OXPHEN. 
Constituents of OXPHEN 
During the process of myogenic differentiation a remarkable morphological 
transition from myoblasts into multi-nucleated myotubes is observed. In 
addition, myogenesis is accompanied by an increase in oxidative metabolism 
as we demonstrate in a detailed manner in the present study. We show an 
increased mitochondrial respiratory capacity, as well as increased protein 
content of the complexes of the inner mitochondrial membrane respiratory 
chain, which is the site of O2 consumption29. In addition, we observed 
increased enzyme activity levels of HAD and CS and more oxidative type 1 
MyHC slow protein in myotubes as compared to myoblasts. This is in 
concordance with previous studies and is illustrative of development of 
OXPHEN during myogenesis22,30. The observed increase in the activity level of 
CS (established marker of mitochondrial volume) as well as increased mtDNA 
copy number and increases in different COX mRNA levels confirm increased 
mitochondrial biogenesis31. This data collectively shows that myogenic 
differentiation of C2C12 cells is obviously associated with mitochondrial 
biogenesis. It can however not be excluded that, in addition to mitochondrial 
biogenesis, alterations in efficiency of mitochondria contribute to an increased 
mitochondrial capacity during myogenesis. 
Regulators of OXPHEN 
Coordination of the nuclear- and mitochondrial genome during mitochondrial 
biogenesis is regulated by a network of transcription factors including PGC-1α, 
PPARs, NRF-1 and Tfam32. In this signalling pathway, PGC-1α is the master 
regulator coordinating PPAR activity levels as well as mitochondrial biogenesis 
through activation of NRF-1-mediated transcription of Tfam33,34. In the present 
study, PGC-1α expression increased during myogenesis. The role of PGC-1α 
in positive regulation of oxidative capacity and fiber type composition of existing 
muscle is well established9. Our data now also suggests a role for PGC-1α in 
the development of OXPHEN during myogenic differentiation. In line with this 
notion, PGC-1α mRNA levels increased during mitochondrial biogenesis in a 
mouse model of skeletal muscle regeneration, although these authors did not 
demonstrate that the induction of PGC-1α expression was associated with 
myogenic differentiation or took place in pre-existing muscle fibers22. 
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The PPARs are known to be strongly involved in the control of genes encoding  
enzymes of the fatty acid oxidation pathway as e.g. HAD35. In concordance, we 
observed a clear induction of PPAR transcriptional activity and HAD activity 
during the initiation of myogenic differentiation. To the best of our knowledge, 
this is the first study investigating PPAR transcriptional activity during skeletal 
muscle cell differentiation. Typically, PPAR-α and PPAR-δ are the 2 isoforms 
most implicated in positive regulation of fatty acid oxidative capacity of skeletal 
muscle, whereas PPAR-γ is the isoform implicated in fatty-acid uptake and 
storage36-38. Therefore, it is conceivable that the increase in PPAR 
transcriptional activity is mainly due to increased PPAR-α and/or PPAR-δ 
transcriptional activity.  
 
In concordance with this suggestion, we found that PPAR-γ mRNA levels 
markedly decreased during differentiation. It has been shown that constitutive 
high expression levels of PPAR-γ in skeletal muscle cells can result in trans-
differentiation into adipocytes39. On the other hand, low critical levels of 
PPAR-γ expression are required to maintain the ability to differentiate 
properly36. Since C2C12 cell metabolism during differentiation is directed 
towards a more developed OXPHEN and PPAR-γ is implicated in storage of 
fatty acids, reduction of PPAR-γ expression may be a regulatory mechanism to 
ensure an adequate development of the oxidative capacity of the cell. In 
contrast to PPAR-γ, PPAR-α expression levels increased dramatically in our 
study. PPAR-δ mRNA levels on the other hand remained constant during the 
entire differentiation process despite its clearly established role in regulation 
and development of skeletal muscle oxidative capacity7,40. Kraft et al. 
previously showed a 10-fold increase in PPAR-α expression levels in 
differentiating C2C12 cells, although they only investigated the myogenic 
program up to 3 days of differentiation23. We now show that, in line with 
enzyme activity data, PPAR-α mRNA expression levels increase until day 5 of 
differentiation reaching a 40-fold higher level in myotubes compared to 
myoblasts. To date, no other studies have previously investigated PPAR-δ 
expression levels during skeletal muscle differentiation.  
 
The increase in expression levels of PGC-1α and PPAR-α during differentiation 
parallels the observed increase in markers of OXPHEN. In addition to their well 
established role as positive regulators of oxidative capacity of existing muscle 
fibers9,10,13, this therefore also suggests a role for these regulators in the 
development of oxidative capacity during myogenesis. Although whole-body 
knock-out PGC-1α animals only display a 20-30% reduction in mitochondrial 
content41,42, muscle-specific over-expression of PGC-1α does result in an 
increase in basal OXPHEN9. This implies that PGC-1α is a potent stimulator of 
mitochondrial biogenesis but may not always be required. Possibly, other co-
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factors in the PGC-1α family as PRC and PGC-1β compensate for the loss of 
PGC-1α in the PGC-1α knock-outs43,44. It must also be noted that the PGC-1α 
knock-out mouse is characterised by physical hyperactivity which may cause 
exercise-induced mitochondrial biogenesis and potentially obscures any loss of 
baseline mitochondrial biogenesis45. In addition to PGC-1α, our data also 
suggests a role for PPAR-α in mitochondrial biogenesis. It has been 
demonstrated that PPAR-α knock-out mice display reduced activity levels of 
fatty acid oxidation enzymes as HAD, however no loss of other mitochondrial 
enzymes was observed46. Future studies are therefore needed to address the 
requirement and the exact role of PPAR-α in skeletal muscle mitochondrial 
biogenesis. In contrast to PGC-1α and PPAR-α, our data suggests that 
differential expression levels of PPAR-δ protein are not implicated in the 
process of mitochondrial biogenesis during myogenic differentiation. This is in 
line with a recent paper from Kleiner et al. who demonstrated that PPAR-δ 
agonism activates fatty acid oxidation, which is confirmed in mice with skeletal 
muscle-specific PPAR-δ over-expression7, but fails to induce mitochondrial 
gene expression and function47. It can be speculated that  PPAR-δ activation 
directs the metabolic profile of existing fibers towards a more developed 
OXPHEN while PGC-1α-mediated PPAR-α activation may regulate 
development of oxidative capacity in new muscle fibers during myogenesis. 
Nevertheless, as PPAR-δ remains a specific regulator of fatty acid oxidation, 
which is part of the mitochondrial machinery, it still contributes to muscle 
OXPHEN. In line with a positive role in determining skeletal muscle OXPHEN, 
increased PGC-1α and PPAR-α mRNA expression levels during differentiation 
may mediate the observed increase in transcription of nuclear-encoded 
constituents of the mitochondrial respiratory chain. Next to being a co-activator 
for PPARs, PGC-1α also functions as a co-activator for NRF-1. Subsequently, 
PGC-1α/NRF-1 induces the expression of Tfam which is the master regulator 
of mitochondrial biogenesis11. In the present study, Tfam and NRF-1 
expression levels increased at the onset of differentiation, which is in line with 
the start of mitochondrial biogenesis in these cells at the beginning of the 
myogenic program. Since Tfam is a master regulator of the transcription and 
replication of mtDNA11, its observed up-regulation likely mediated the increased 
mtDNA content during C2C12 myogenic differentiation. Additionally, we 
observed increased mRNA levels of mitochondrial-encoded COX subunits 
which may also result from increased transcription of the mitochondrial genome 
by Tfam. 
 
In conclusion, in the present paper we describe temporal profiles of a number 
of key constituents of OXPHEN and mitochondrial capacity during the full 
myogenic program of C2C12 myoblasts. We show that expression and activity 
levels of genes known for their regulatory role in skeletal muscle oxidative 
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capabilities parallel the observed increase in oxidative parameters. Based on 
our results we propose that increased PGC-1α expression, either directly or 
through increased PPAR-α expression levels and PPAR transcriptional activity, 
mediates mitochondrial biogenesis and concurrent up-regulation of skeletal 
muscle OXPHEN during myogenic differentiation. 
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is reduced in skeletal muscle of  
COPD patients 
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Schols AM. Peroxisome proliferator-activated receptor expression is reduced in 
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Abstract 
COPD is a multi-organ systemic disease. Systemic features are skeletal 
muscle weakness and cachexia, the latter being associated with systemic 
inflammation. Exact mechanisms underlying skeletal muscle dysfunction in 
COPD remain obscure. Recent evidence suggests involvement of the 
peroxisome proliferator-activated receptors (PPARs) and PPAR-γ co-activator 
(PGC-1α) in regulation of skeletal muscle morphology and metabolism while 
the mitochondrial transcription factor A (Tfam) has been implicated in the 
process of mitochondrial biogenesis. The aim of this exploratory study was 
therefore to compare these factors in skeletal muscle of 9 healthy control 
subjects and 14 COPD patients stratified by cachexia. PPAR-α, PPAR-γ, 
PPAR-δ, PGC-1α and Tfam were measured at the mRNA- and protein level by 
real time QPCR and western blotting respectively. PPAR-δ and Tfam protein 
content as well as PGC-1α mRNA levels were decreased in skeletal muscle of 
COPD patients vs healthy controls. The cachectic COPD subgroup was further 
characterised by decreased PPAR-α mRNA expression and decreased Tfam 
protein and mRNA levels when compared to non cachectic COPD patients. In 
addition, PPAR-α mRNA levels in skeletal muscle correlated negatively with 
inflammatory markers in plasma. Therefore, a disturbed expression and/or 
content of these regulatory factors may well underlie the disturbed skeletal 
muscle functioning in COPD.  
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Introduction 
Skeletal muscle dysfunction has become a recognised hallmark of chronic 
obstructive pulmonary disease (COPD). Although it is obvious that impaired 
lung function inevitably leads to reduced exercise tolerance in this disorder, 
muscle dysfunction probably is an even stronger determinant of exercise 
capacity particularly in moderate to severe COPD1. Moreover, it has been 
convincingly shown that muscle wasting is a strong predictor of mortality risk in 
COPD, independent of the degree of airflow limitation2. Because current 
bronchodilating and anti-inflammatory medication primarily aimed at improving 
lung function is rather ineffective in reversing exercise intolerance, skeletal 
muscle function may be an interesting alternative target for novel therapies. 
Skeletal muscle dysfunction in COPD is characterised by the loss of muscle 
strength and endurance. The loss of muscle endurance is associated with a 
type IÆIIaÆIIx fiber type shift leading to a decreased oxidative phenotype of 
the muscle3. The loss of muscle strength is largely explained by the loss of 
muscle mass due to cachexia, which is commonly observed in moderate to 
severe COPD patients4. Other abnormalities pointing towards intrinsic muscle 
abnormalities in COPD pathogenesis are a decreased content of substrates 
such as specific amino acids, increased oxidative stress and decreased 
uncoupling protein 3 (UCP-3) content, a mitochondrial protein which serves as 
a putative protector against lipid induced mitochondrial damage5-7. In addition, 
COPD is also characterised by a chronic systemic low grade inflammatory 
status, which has been suggested as a trigger for the loss of muscle mass and 
muscle weakness8,9. The exact molecular mechanisms and key mediators that 
are involved in the loss of muscle strength and endurance in COPD remain to 
be identified. The peroxisome proliferator-activated receptors (PPARs) as well 
as PPAR-γ co-activator 1 alpha (PGC-1α), a strong co-activator of PPAR 
transcriptional activity, are key regulators of mitochondrial biogenesis and 
hence of skeletal muscle oxidative capacity10,11. Furthermore, they are potent 
mediators of a fiber type shift from type IIÆI and have been shown to possess 
anti-inflammatory properties12,13. Based on these findings, we hypothesise that 
expression and/or content of the PPARs is reduced in skeletal muscle of COPD 
patients. Therefore, the aim of the current study was to determine expression 
of the PPARs and PGC-1α on the mRNA- and protein level in skeletal muscle 
biopsies of COPD patients pre-stratified by cachexia and healthy control 
subjects.  
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Subjects and methods 
Subjects 
The study population consisted of Dutch patients with clinically stable GOLD 
stage II–IV COPD (n=14) and a group of healthy age-matched controls (n=9). 
All patients suffered from chronic airflow limitation, defined as measured forced 
expiratory volume in 1 second (FEV1) less than 70% of reference. Patients 
received standardised maintenance respiratory medication that consisted of 
inhaled bronchodilators, inhaled corticosteroids and, when indicated, 
theophyllines. Exclusion criteria were concurrent diseases such as 
malignancies, gastrointestinal or kidney abnormalities, metabolic or endocrine 
diseases, and inflammatory diseases. Written consent was obtained from all 
subjects and the study was approved by the ethical review board of the 
University Hospital Maastricht.  
Pulmonary function 
FEV1 and forced vital capacity (FVC) were assessed from the flow-volume 
curve using a spirometer (Masterlab, Jaeger, Würzburg, Germany). Carbon 
monoxide diffusion factor (DLCO) was determined using the single breath 
method (Masterlab). Lung functional parameters were expressed as a 
percentage of reference values. Blood was drawn from the brachial artery to 
analyse arterial oxygen tension (PaO2) and carbon dioxide tension (PaCO2) with 
a blood gas analyser (Radiometer, ABL 330, Copenhagen, Denmark).  
Blood sampling 
Fasting blood was collected in evacuated blood collecting tubes containing 
EDTA (Becton Dickinson Vacutainer Systems, Plymouth, U.K.) in the early 
morning (08.00–10.00 h). After centrifuging twice at 1000 g for 10 min at 4°C 
within 2 h of collection, plasma samples were stored at –80°C until analysis. 
Tumour necrosis factor (TNF-α) was determined with the Quantikine high 
sensitivity ELISA (R&D Systems, Minneapolis, U.S.A.) with a lower detection 
limit of 0.5 pg/ml for total TNF-α. Soluble TNF-R55 and sTNF-R75 were 
measured in duplicate by using the ELISA protocol as previously described by 
Leeuwenberg et al.14. 
Body composition 
Body mass index (BMI) was calculated as weight divided by height in squared 
metres (kg/m2). Body composition was measured using single frequency 
(50 kHz) bioelectrical impedance analysis (BIA; Xitron Technologies, San 
Diego, CA, USA) with subjects in the supine position. FFM of patients was 
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calculated using the disease-specific equation proposed by Schols et al. and 
described by Steiner et al.15. Fat-free mass index (FFMI) and fat mass index 
(FMI) were calculated as FFM or FM divided by height2 (kg/m2). Cachexia was 
defined as a BMI ≤21 kg/m2 and FFMI ≤16 kg/m2 for male patients and FFMI 
≤15 kg/m2 for female patients. 
Collection and processing of muscle tissue 
Post absorptive muscle biopsies of the lateral part of the quadriceps femoris 
were obtained under local anaesthesia by using the needle biopsy technique. 
The specimens were immediately snap frozen in liquid nitrogen and stored at 
−80°C until use. The frozen biopsies were weighed and subsequently 
homogenised using a Polytron PT 1600 E (Polytron® PT 1600 E, Kinematica 
AG, Luzern, Swiss). 
Muscle fiber type composition 
A 5% (w/v) homogenate was prepared by dispersion (Polytron® PT 1600 E, 
Kinematica AG, Luzern, Swiss) followed by 1 min sonication (Branson 2210, 
Branson Ultrasonics Corporation, Danbury, USA) of the tissue in SET buffer 
(250 mM sucrose, 2 mM EDTA, 10 mM TRIS, pH 7.4). Samples were 
centrifuged (10 min, 10000 g, 4°C). The supernatant was used for 
determination of citrate synthase (CS) activity as described by Gosker et al.16. 
The remaining pellet was resuspended in three volumes of ice-cold extraction 
buffer (100 mM Na4O7P2·10H2O, 5 mM EDTA, 1 mM DTT, pH8.5), incubated 
on ice for 30 min, and centrifuged (10 min, 10000 g, 4°C). From this, the 
supernatant was used for Myosin heavy chain (MyHC) isoform analysis. Gels 
were run for 22 h using a Protean II Cell gel electrophoresis system (Biorad, 
Veenendaal, The Netherlands) at 20 mA with increasing voltage to a maximum 
of 350 V. About 1.0 µg of protein was loaded per lane. Gels were silver-stained 
(Silver Stain Plus Kit, Biorad), scanned and photographed with a scanning 
densitometer (Fluor-STM MultiImager, Biorad), after which bands were 
quantified using Quantity One software (Biorad). I, IIA and IIX MyHC isoforms 
were expressed proportionally to each other. 
Real time quantitative PCR  
Total RNA was extracted using the acid guanidium thiocyanate-phenol-
chloroform extraction method (Ambion Ltd., United Kingdom). RNA 
concentration was determined using a spectrophotometer and quality was 
verified by agarose gel electrophoresis. Two micrograms of RNA per sample 
were reverse transcribed into cDNA according to the manufacturer’s 
instructions (iScript RT kit Biorad, Hercules, CA, USA). cDNA was PCR 
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amplified with Platinum Taq DNA polymerase (Invitrogen, Breda, the 
Netherlands) on a Biorad iCycler apparatus. Primers were designed to 
generate a PCR amplification product of 100 to 150 bp. Specificity of the 
amplification was verified by melt curve analysis and evaluation of efficiency of 
PCR amplification. Transcript levels for the constitutive housekeeping gene 
product 36B4 were quantitatively measured in each sample to control for 
sample-to-sample differences in RNA concentration. Gene expression was 
quantified and expressed as arbitrary units (AU). 
Western blot analysis of protein expression 
PPAR-δ and Tfam protein abundance was evaluated by Western blotting. 
Muscle biopsies were homogenised in PBS with PMSF (0.4 mM) and EDTA 
(1 mM) and sonicated 2 x 10 sec at 12 um and 1 x 5 sec at 20 um. 
Subsequently, samples were diluted 2:1 in sample buffer, containing 
2-mercaptoethanol and SDS, and boiled for 5 min. Equal amounts of protein 
were loaded on a 10% or 12% discontinue denaturating polyacrylamide gel 
(PPAR-δ and Tfam respectively) and electrophoresis was performed using a 
Mini-PROTEAN 3 Electrophoresis Cell system (Bio-Rad Laboratories, 
Hercules, CA). Primary antibodies used according to the manufacturer’s 
manual included anti-PPAR-δ diluted 1:5000 (Santa-Cruz, CA, U.S.A.) and 
anti-Tfam diluted 1:10 000 (Santa-Cruz, CA, U.S.A.). Secondary antibodies 
used (1:10 000) were Rabbit anti-Goat peroxidase (Dako Cytomation, CA, 
U.S.A.) and Swine anti-Rabbit peroxidase (Dako Cytomation, CA, U.S.A.) 
respectively. Detection was performed with Super Signal West Dura Extended 
Duration Substrate (Pierce Boston Technology Centre, Woburn, USA) on a 
CL-Xposure Film (Pierce Boston Technology Centre, Woburn, USA). 
Densimetric quantification was performed using Image Master VDS 
(Amersham Pharmacia Biotech, NJ, USA). A standard sample was included in 
every blot to correct for blot to blot variation. PPAR-δ and Tfam protein content 
were both expressed as AU. 
Statistical analysis 
Data was analysed according to the guidelines of Altman et al. using SPSS 
(Statistical Package for the Social sciences, SPSS Inc., Chicago, IL, U.S.A) 
with the unpaired student’s t-test (corrected for unequal variances if 
appropriate), 1-way ANOVA (with unpaired Student’s t-test as post hoc test), or 
the Pearson correlation test and with non-parametric tests when appropriate17. 
Data are represented as the mean ± SD. A two tailed probability value of less 
than 0.05 was considered to be significant. 
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Results 
Subject characteristics 
Characteristics of patients and control subjects are summarised in Table 4.1. 
No significant differences in age and pack years were observed between 
patients and controls, providing a correction for smoking behaviour between 
groups. Also, no significant differences were observed in lung function of 
cachectic COPD patients when compared with non cachectic patients.  
 
Table 4.1  Subject characteristics. 
 Controls COPD cachexia COPD non cachexia 
   N (M/F) 9 (6/3) 7 (4/3) 7 (4/3) 
   Age (yr)  65 ± 4  58 ± 13  67 ± 9 
   Height (cm)  166.1 ± 7.6  168 ± 10.5  167.2 ± 7.2 
Body composition    
   Weight (kg)  74.7 ± 10.4  59.0 ± 8.8##  72.5 ± 11.7 
   BMI (kg/m2)  27.1 ± 3.7  20.1 ± 1.3##  27.0 ± 3.4 
   FFM (kg)  50.5 ± 9.1  43.2 ± 5.9#  48.8 ± 8.05 
   FFMI (kg/m2)  18.0 ± 2.3  14.8 ± 0.7##  17.3 ± 2.2 
   FM (kg)  23.3 ± 8.1  15.8 ± 4.1#  23.7 ± 6.4 
   FMI ( kg/m2)  8.4 ± 3.5  5.4 ± 1.2##  8.9 ± 2.2 
Lung function    
   FVC(%pred)  100.4 ± 20.5**  74.0 ± 15.4  79.8 ± 17.5 
   FEV1 (%pred)  117.2 ± 19.8**  38.8 ± 11.6  41.4 ± 18.5 
   DLCO(%pred)  83.6 ± 29.2*  43.3 ± 18.8  60.9 ± 29.0 
   Pack years  35 ± 17  27 ± 14  35.7 ± 15 
   PaO2 (kPa)  9.7 ± 0.8  9.0 ± 1.5  9.4 ± 1.1 
   PaCO2 (kPa)  5.2 ± 0.4  5.3 ± 0.7  5.2 ± 0.9 
Values are expressed as mean ± SD; Significance of difference compared to patients: * p<0.05;  
** p<0.01. Significance of difference between COPD sub-groups: #<0.05; ##<0.01; BMI: body mass 
index; FFM: fat-free mass; FFMI: fat-free mass index; FM: fat mass; FMI: fat mass index; FVC: 
forced vital capacity; FEV1: forced expiratory volume in one second; DLCO: diffusion capacity for 
carbon monoxide; PaO2: arterial oxygen pressure; PaCO2: arterial CO2 pressure; % pred: 
percentage of predicted value 
 
Muscle fiber type composition 
The proportion of MyHC type I fibers tended to be lower in COPD patients 
when compared to control subjects (24.6±7.1 vs 30.6±6.7; p=0.114). There 
were no significant differences in the proportion of MyHC type IIa fibers 
between patients and healthy controls. The proportion of MyHC type IIx fibers 
was higher in patients vs controls (30.4±5.7 vs 19.4±10.9; p=0.044) (Figure 
4.1). No significant differences in fiber type composition were observed 
between cachectic and non cachectic patients.  
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Figure 4.1 MyHC fiber type distribution in the quadriceps femoris of COPD patients (n=13) and 
healthy control subjects (n=6). Significance of difference: * p<0.05. Error bars indicate 
the SD. 
PPAR-α 
There were no significant differences in PPAR-α mRNA expression in skeletal 
muscle of patients and control subjects. However, a trend of lower PPAR-α 
mRNA levels in patients compared to controls was observed (1.39±0.75 vs 
1.87±0.46; p=0.09) (Table 4.2). Interestingly, expression levels of PPAR-α 
mRNA were over 50% lower in cachectic COPD patients when compared to 
non cachectic patients (0.87±0.47 vs 2.14±0.69; p=0.008) and healthy controls 
(1.87±0.46; p=0.004) (Figure 4.2). In addition, PPAR-α mRNA levels in the 
patient group correlated positively and significantly with BMI and FFMI 
(r=0.700; p=0.005 and r=0.593; p=0.025 respectively) Although we tried 
several commercially available PPAR-α antibodies, none of these were of 
sufficient quality and specificity to detect PPAR-α protein content. 
 
 
Table 4.2  RNA expression levels in skeletal muscle. 
 Healthy controls COPD COPD cachectic COPD non cachectic 
PPAR-α 1.87±0.46 1.39 ± 0.75*  0.87 ± 0.47## 2.14 ± 0.69 
PPAR-δ 1.07±0.17 1.12 ± 0.34*  0.95 ± 0.33 1.29 ± 0.28 
PPAR-γ Undetectable Undetectable Undetectable Undetectable 
Tfam 1.00 ± 0.27 1.00 ± 0.34*  0.78 ± 0.27# 1.21 ± 0.25 
PGC-1α 1.38 ± 0.23 1.00 ± 0.49*  0.89 ± 0.43 1.11 ± 0.56 
Values are expressed as mean ± SD; significance compared to controls: * p<0.05; significance of 
difference between COPD sub groups: #  p<0.05; # #. p<0.01. 
0
10
20
30
40
50
60
I IIA IIX
Fiber type Category
P
ro
po
rti
on
of
 fi
be
rs
 (%
)
Controls
COPD
*
P
ro
po
rti
on
of
 fi
be
rs
 (%
)
Thesis_Remels_v1.pdf
 Expression and content of PPARs is reduced in skeletal muscle of COPD patients 
59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Expression of PPAR-α mRNA in skeletal muscle of cachectic (n=7) and non cachectic 
COPD patients (n=7) and healthy control subjects (n=9) controlled for by using 36B4 
as a housekeeping gene. Significance of difference: ** p<0.01. Error bars indicate the 
SD. Arbitrary units (AU) are depicted on the Y-axis. 
 
PPAR-δ 
There were no significant differences in the expression levels of PPAR-δ 
mRNA between patients and healthy control subjects. A trend towards lower 
PPAR-δ mRNA levels was observed in skeletal muscle of cachectic versus non 
cachectic patients (0.95±0.33 vs 1.29±0.28; p=0.085) (Table 4.2). At the protein 
level, content of PPAR-δ was significantly lower in skeletal muscle of COPD 
patients compared to healthy control subjects (1.67±0.85 vs 2.64±0.95; 
p=0.037) (Figure 4.3a, 4.3d). No significant differences in PPAR-δ protein 
content were observed between cachectic and non cachectic patients (Figure 
4.3b). 
PPAR-γ 
PPAR-γ mRNA levels were too low to be detected in skeletal muscle. PPAR-γ 
protein could be detected in human adipose tissue (as a positive control), but 
was below the detection limit in the muscle samples (data not shown). 
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Figure 4.3 A) Expression of PPAR-δ protein in skeletal muscle of COPD patients (n=14) and 
healthy control subjects (n=9). Significance of difference compared to controls: * 
p<0.05. Error bars indicate the SD. Arbitrary units (AU) are depicted on the Y-axis. B) 
Expression of PPAR-δ protein in skeletal muscle of cachectic (n=7) and non cachectic 
COPD patients (n=7). Note that vertical axis is slightly different in panel A and B C) 
Specificity of the antibody directed against human PPAR-δ was tested by viral 
transfection of human PPAR-δ protein into neonatal rat cardiomyocytes. From 1-3: 
increasing amount of virus was added to the cell system and increasing intensity of 
both bands at 50kDa (PPAR-δ) was observed. D) Representative sample of PPAR-δ 
using western blot. Equal amounts of protein were loaded in every lane. A standard 
sample was included in every blot to correct for blot to blot variation. 
 
Tfam 
We determined content and mRNA levels of Tfam, which is an essential factor 
involved in mitochondrial biogenesis. No significant differences in Tfam mRNA 
expression levels were found between patients and controls. However, Tfam 
mRNA levels were significantly lower in cachectic patients compared to non 
cachectic patients (0.78±0.27 vs 1.21±0.25; p=0.013). In addition, western blot 
analysis revealed a significantly lower content of Tfam protein in skeletal 
muscle of COPD patients compared to healthy controls (0.80±0.36 vs 
1.20±0.13; p<0.001). Moreover, content of the Tfam protein was also 
significantly lower in cachectic patients when compared with non cachectic 
patients (0.60±0.23 vs 0.95±0.37; p=0.023) (Figure 4.4). 
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Figure 4.4 A) Tfam protein content in skeletal muscle of COPD patients (n=14) and healthy 
control subjects (n=9). Significance of difference compared to controls: ** p<0.001. 
Error bars indicate the SD. Arbitrary units (AU) are depicted on the Y-axis.  B) Tfam 
protein content in skeletal muscle of cachectic (n=7) and non cachectic COPD patients 
(n=7). Significance of difference compared to controls: * p<0.05. C, D) Representative 
Sample of Tfam using western blot. Equal amounts of protein were loaded in every 
lane. A standard sample was included in every blot to correct for blot to blot variation. 
Tfam was identified as the 28kDa band. 
PGC-1α 
Expression of PGC-1α mRNA was lower in COPD patients compared to 
healthy controls (1.00±0.49 vs 1.38±0.23; p=0.044) (Figure 4.5). There were no 
differences in PGC-1α mRNA levels between cachectic and non cachectic 
patients. PGC-1α protein content could not be assessed due to a lack of 
commercially available high quality antibodies.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Expression of PGC-1α mRNA in skeletal muscle of COPD patients (n=14) and healthy 
control subjects (n=9) controlled for by using 36B4 as a housekeeping gene. 
Significance of difference compared to controls: * p<0.05. Error bars indicate the SD. 
PGC-1α expression levels are depicted as arbitrary units (AU) on the Y-axis. 
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Correlations 
Correlation analysis was performed to investigate if PPAR expression levels or 
protein content were associated with systemic inflammation, muscle oxidative 
capacity, muscle fiber type distribution or lung function. Expression levels of 
PPAR-α mRNA correlated negatively with circulating levels of TNF-α protein 
(r=-0.576; p=0.031) (Figure 4.6). Similar results were found for the sTNF-R55 
and the sTNF-R75 (r=-0.606; p=0.022 and r=-0.546; p=0.044). Concerning 
metabolic markers, PPAR-δ and PPAR-α mRNA levels in skeletal muscle 
correlated positively with the oxidative enzyme CS (r=0.587; p=0.005 and 
r=0.463; p=0.035). In addition, the proportion of MyHC type I fibers (%) 
correlated positively and significantly with skeletal muscle Tfam protein content 
(r=0.554; p=0.014).  No correlations were observed between PPAR expression 
levels or content and lung function parameters.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Correlation between blood circulatory levels of tumour necrosis factor alpha (TNF-α) 
protein and expression levels of PPAR-α mRNA in skeletal muscle of COPD patients 
(n=14). ▲ indicates cachectic COPD patients and ■ indicates non cachectic COPD 
patients. 
Discussion 
COPD is characterised by reduced skeletal muscle function. Muscle oxidative 
capacity is decreased which is related to a fiber type shift from type I oxidative 
to type IIx glycolytic fibers. In addition, oxidative capacity within intermediary 
type IIa fibers is also reduced18,19. As the PPAR transcription factors are 
involved in the regulation of muscular oxidative capacity, we determined PPAR 
content and expression levels in skeletal muscle of COPD patients. Here we 
report for the first time that PPAR-δ protein content is reduced in skeletal 
muscle of COPD patients. Like PPAR-α, PPAR-δ is a strong positive regulator 
of skeletal muscle oxidative metabolism as it is involved in the regulation of 
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proteins implicated in uptake, handling and oxidation of fatty acids as well as 
other oxidative enzymes11. Indeed, in the present study PPAR-δ and PPAR-α 
mRNA levels correlated positively with the activity of the oxidative TCA cycle 
enzyme CS consistent with involvement of these 2 PPAR subtypes in skeletal 
muscle oxidative metabolism.  
 
In addition to a decreased PPAR-δ protein content, mRNA levels of PGC-1α, a 
strong PPAR co-activator and key regulator of mitochondrial biogenesis, were 
also reduced in skeletal muscle of these patients20. It has been shown that 
PPAR-δ and PGC-1α both have the ability to redirect fiber type distribution in 
skeletal muscle to a more oxidative phenotype11,21,22. Given that COPD patients 
are characterised by increased amount of type IIx glycolytic fibers, it is tempting 
to suggest that the reduction in PPAR-δ and PGC-1α is causally related to this 
fiber type shift. Although no significant correlations were found between PPAR, 
PGC-1α and fiber type composition, there was a significant positive correlation 
between the PGC-1α-regulated Tfam protein and type I oxidative fibers. 
Consistent with involvement of a reduced PPAR content in the reduction of 
oxidative capacity in COPD is the finding that UCP-3 is reduced in COPD6. 
Several reports show that UCP-3 is a PPAR regulated gene23. Moreover, 
Schrauwen et al. reported that administration of rosiglitazone, a potent PPAR-γ 
agonist, restored muscular UCP-3 levels in diabetic patients24. These 
observations further strengthen the suggestion that PPARs do play a role in 
skeletal muscle abnormalities as observed in COPD.  
 
Next to a regulatory role in skeletal muscle morphology, PGC-1α is also 
involved in the regulation of Tfam, which in turn controls the expression of 
mitochondrial-encoded genes involved in mitochondrial biogenesis and 
respiration25. Interestingly, in the present study a lower expression of PGC-1α 
mRNA in skeletal muscle of COPD patients was accompanied by a reduced 
Tfam protein content. Decreased levels of PGC-1α thus may well be involved in 
the loss of muscular oxidative capabilities in COPD. Intriguingly, in other 
disease models, as congestive heart failure (CHF) and diabetes mellitus (DM), 
a decreased oxidative capacity of skeletal muscle is also associated with a 
decreased expression of PGC-1α mRNA26,27. Due to a lack of specific 
antibodies, we were unable to verify whether PGC-1α protein levels were 
indeed reduced in skeletal muscle of COPD patients, but this remains an 
interesting topic for future research. 
 
Although we did observe a lower content of PPAR-δ and Tfam protein in 
skeletal muscle of COPD patients, no significant differences in the expression 
levels of PPAR-δ or Tfam mRNA were observed in skeletal muscle between 
patients and control subjects. This suggests the presence of a post 
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transcriptional mechanism controlling PPAR-δ and Tfam protein levels in 
skeletal muscle. The interaction of PPARs with specific pathways involved in 
protein degradation, e.g. the ubiquitin proteasome pathway, has been the 
subject of limited investigation. Therefore, the identity and nature of the post 
transcriptional mechanism involved here remains obscure. In addition, PPAR-γ 
mRNA and protein were undetectable in our samples supporting other reports 
that, if present at all, PPAR-γ content and expression in skeletal muscle is very 
low. 
 
Besides a disturbed oxidative phenotype, skeletal muscle function in COPD is 
also severely impaired by muscle atrophy. Strikingly, a lower expression of 
PPAR-α mRNA was observed in skeletal muscle of cachectic COPD patients 
compared to non cachectic patients and healthy controls. Also, PPAR-α mRNA 
levels correlated negatively with levels of TNF-α and subunits of the TNF-α 
receptor in the current COPD population. Systemic inflammation has been 
recognised as an important risk factor for the loss of skeletal muscle mass8,9. 
Interestingly, there are also reports that describe a negative effect of TNF-α on 
the activity of PPAR-α in vivo28. Our results confirm a link between PPAR-α and 
inflammation-related cachexia although the exact mechanisms of the observed 
reduction are unclear and deserve further investigation.  
 
The reason for the decreased content or expression of the PPARs in skeletal 
muscle of COPD patients may be multifaceted. As skeletal muscle is very 
responsive to metabolic and mechanical influences the observed reduction in 
PPAR-δ and Tfam protein content and the decreased expression of PGC-1α 
and PPAR-α may represent an adaptation of the muscle cells due to 
physiological and pathological changes including inactivity, hypoxia and 
inflammation. Furthermore, differences in expression levels or protein levels 
can be more pronounced in patients suffering from the cachexia syndrome. A 
sedentary lifestyle which is often adopted by COPD patients due to disease-
related exercise limitations could underlie the reduced content of PPAR-δ 
protein and reduced PGC-1α mRNA levels in skeletal muscle as it has been 
shown that PPAR-δ and PGC-1α are strongly up regulated by physical 
exercise22,29,31. Hypoxia and inflammation, both commonly observed in COPD, 
may also contribute to lower PPAR expression levels or protein content as 
there are several reports that suggest a negative influence of these parameters 
on PPAR expression levels32,33. The specific contribution of these factors 
remains unknown and in vitro approaches will shed more light on the 
involvement of hypoxia and inflammation on PPAR expression levels and 
content. Intriguingly, DM and CHF, diseases characterised by systemic 
inflammation and increased levels of inactivity are also characterised by 
decreased muscular levels of PPAR and/or PGC-1α, suggesting a prominent 
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role for inflammation and physical activity levels in controlling PPAR and PGC-
1α levels26,27,34. As the PPARs, more specifically PPAR-α and PPAR-δ, are 
highly implicated in skeletal muscle oxidative metabolism, which is obviously 
impaired in COPD patients, they could serve as interesting therapeutic targets 
in this disorder. Increasing PPAR levels by means of exercise, fatty acid 
supplementation and/or pharmacological modulation could serve as a potential 
therapeutic strategy to alleviate exercise intolerance in this disorder. 
Conclusions 
We found a reduced expression of PGC-1α mRNA and a lower content of 
PPAR-δ protein in lower limb skeletal muscle of COPD patients compared to 
healthy controls. In addition, these reductions were accompanied by a 
decreased content of Tfam protein. These findings imply a disturbed regulation 
of muscular oxidative capacity as PPAR-δ, PGC-1α and Tfam are highly 
implicated in determining skeletal muscle oxidative capacity. Therefore, a 
disturbed expression and/or content of these regulatory factors may well 
underlie the disturbed skeletal muscle functioning in COPD. In addition, we 
suggest that not only occurrence of the disease but also the presence of 
cachexia and chronic inflammation affected PPAR mRNA and protein levels. 
Since the explanation for a lower expression and content of PPARs and PPAR 
related factors in skeletal muscle of COPD patients is complex, further 
investigation is required to unravel the exact mechanisms behind these 
observations. 
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Abstract 
Many patients with advanced chronic obstructive pulmonary disease (COPD) 
are characterised by muscle wasting, often referred to as cachexia, and loss of 
muscle oxidative phenotype (OXPHEN) i.e. intrinsic muscular features 
determining fatigue resistance and capacity for oxidative substrate metabolism. 
While inflammation has been implicated in cachexia, its impact on muscle 
OXPHEN is currently unknown. Markers and regulators of OXPHEN were 
investigated in vastus lateralis muscle biopsies of COPD patients and healthy 
smoking controls as well as in cultured muscle cells chronically stimulated with 
the pro-inflammatory cytokine TNF-α. Patients with increased muscle TNF-α 
mRNA levels compared to controls were characterised by a lower body mass 
index (23.6±3.6 vs 27.2±4.8 kg/m2), a lower fat-free mass index (16.7±1.5 vs 
18.2±2.4 kg/m2) and a significant decrease in gene expression levels of 
markers and regulators of muscle OXPHEN. In cultured muscle cells, 
mitochondrial protein content and myosin heavy chain isoform I (but not II) 
protein and mRNA levels were reduced upon chronic TNF-α stimulation. In 
addition, TNF-α reduced mitochondrial respiration in a nuclear factor κB- (NF-
κB) dependent manner. Importantly, TNF-α signalling through the NF-κB 
pathway also decreased promoter trans-activation of regulators of 
mitochondrial biogenesis and muscle OXPHEN. In conclusion, this is the first 
report that links impaired muscle OXPHEN to inflammatory signalling in COPD. 
Furthermore, these results provide strong evidence demonstrating that 
inflammatory stimuli such as TNF-α severely impair muscle OXPHEN in a NF-
κB-dependent manner. 
Thesis_Remels_v1.pdf
TNF-α impairs regulation of muscle oxidative phenotype 
71 
Introduction 
Cachexia is a complex and disabling syndrome that occurs in the course of 
many chronic diseases and cancer1,2. Nevertheless, it receives limited attention 
in clinical practice because the accelerated muscle wasting, that distinguishes 
this condition from malnutrition, is being considered irreversible with current 
intervention strategies. More insight in the etiology of this syndrome is thus 
urgently needed. The prevalence of cachexia is high in chronic obstructive 
pulmonary disease (COPD) which is therefore an interesting clinical model for 
translational research on this topic. Besides cachexia, COPD, but also other 
chronic inflammatory diseases as congestive heart failure (CHF), are 
characterised by an impaired muscle oxidative phenotype (OXPHEN)3. Muscle 
OXPHEN encompasses oxidative fiber types I and IIa (determining fatigue 
resistance) and mitochondrial oxidative metabolism (essential for providing 
adequate energy supply for sustained physical activity)4. Therefore, unlike 
muscle mass which mainly determines strength, OXPHEN determines exercise 
endurance capacity and fatigability of the muscle and is considered as an 
important factor determining exercise capacity and quality of life of patients. 
 
Previously we demonstrated that expression levels of master regulators of 
muscle OXPHEN including peroxisome proliferator-activated receptors 
(PPARs), PPAR-γ co-activator 1α (PGC-1α) and mitochondrial transcription 
factor A (Tfam) were reduced in lower limb muscle of COPD patients, being 
most pronounced in the cachectic subgroup. Intriguingly, expression levels of 
these markers correlated negatively with TNF-α levels in plasma5. A causal 
relationship between inflammation and muscle wasting has been firmly 
established in experimental models6. However, whether local inflammatory 
signalling negatively affects muscle OXPHEN has surprisingly not yet been 
addressed thus far. Nevertheless, two recent clinical trials provide indirect 
support for this notion, as anti-inflammatory modulation, using either nutritional 
or pharmacological approaches, in COPD improved exercise capacity7 and 
exercise endurance8 respectively. These observations sparked further 
investigation of the inverse relation between inflammatory signalling and 
determinants/regulators of muscle OXPHEN. Using a translational approach, 
we explored if altered regulation of skeletal muscle OXPHEN in COPD could 
be the resultant of local inflammation. Subsequently, we aimed to elucidate 
underlying mechanisms. We hypothesised that impaired regulation of OXPHEN 
could result directly from TNF-α-induced activation of nuclear factor κB 
(NF-κB), a master signalling pathway relaying inflammatory signals. 
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Subjects and Methods 
Subjects 
First we analysed mRNA expression levels of selected regulatory- and target 
genes implicated in skeletal muscle OXPHEN in quadriceps muscle biopsies of 
COPD patients stratified by muscle TNF-α mRNA levels and healthy age-
matched smoking controls. Data was extracted from the ENIGMA (European 
Network for Investigating the Global Mechanisms of Muscle Abnormalities in 
COPD - www.pul.unimaas.nl/enigma) database containing more than 100 
muscle samples from patients with advanced COPD and 10 healthy age-
matched smoking controls. A diagnosis of COPD was established on the basis 
of the guidelines of the Global Initiative for Chronic Obstructive Lung Disease31. 
The inclusion and exclusion criteria established in this study were identical in 
the four participating centers (the Netherlands, Spain, United Kingdom and 
Poland). All individuals were Caucasian. Patients were exclusively receiving 
inhaled medication (long acting β2 agonists, anticholinergics and low dose 
inhaled corticosteroids). Patients receiving oral corticosteroid treatment were 
not included in the study. Written consent was obtained from all subjects and 
the study was approved by the ethical review boards of the different European 
centers.  
Collection and processing of muscle tissue 
Post absorptive muscle biopsies of the vastus lateralis were obtained under 
local anesthesia. The specimens were immediately snap-frozen in liquid 
nitrogen and stored at −80°C until use. The frozen biopsies were weighed and 
subsequently homogenised using a Polytron PT 1600 E (Kinematica AG, 
Littau/Luzern, Germany). The ‘‘high TNF-α’’ COPD subgroup was defined as 
having muscle TNF-α mRNA levels, corrected for a normalisation factor 
calculated on expression levels of 5 housekeeping genes, greater than the 
mean + 2 x standard deviation of that of the control group. 17 Patients 
complied with this. Another 17 patients, with muscle TNF-α gene expression 
levels comparable to control subjects, were randomly selected from the 
remaining patients in the database.  
Cell culture 
The murine skeletal muscle cell line C2C12 was obtained from the American 
Type Culture Collection (ATCC CRL1772; Manassas, VA, USA). Myoblasts 
were cultured as described previously28. 
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Transfections and plasmids 
For assessment of PPAR transcriptional activity, C2C12 cells were stably or 
transiently transfected with the human CPT-1 B promoter (HCBP) luciferase 
plasmid (pSG5, Stratagene, La Jolla, CA, USA) (PPAR reporter cell line). As a 
control, cells were stably or transiently transfected with equal amounts of empty 
vector PcDNA3.1 (Invitrogen, Rockville, MD, USA). For assessment of Tfam or 
NRF-1 promoter activity, cells were transiently transfected with a mtTFA-
RC4wt/pGL332 or p4xNRF-1Luc33 luciferase promoter construct. 
Enzyme activity assay 
Activity levels of creatine kinase (CK) were measured as described previously1. 
Enzyme activity levels were corrected for total protein content (Biorad, 
Hercules, CA, USA). 
Mitochondrial respiration 
Respiration was measured using a respirometer (Oxygraph 2K, Oroboros 
Instruments, Austria). Cells were permeabilised using 1 µl of digitonin 
(0.5 µg/ml final concentration) and substrates were added in chronological 
order (volume; final concentration): malate (5 μl; 2 mM), palmitoyl-carnitine 
(10 μl; 50 μM) and ADP (20 μl; 5mM). At the end of the substrate trace a 
titration with the uncoupling agent FCCP was performed (1 μl; 0.5 μM titration). 
Oxygen consumption (pmol/ml·s) was calculated as a negative time derivative 
of oxygen concentration (nmol/ml). Respiration rates were corrected for total 
protein content to correct for variability in cellular input. Additional details are 
provided in the data supplement. 
Western blot analysis 
Abundance of OXPHOS proteins and MyHC distribution was evaluated by 
Western blotting. Whole cell lysates were prepared as described previously35.   
Electrophoretic mobility shift assay (EMSA) 
NF-κB DNA binding activity was assessed in nuclear extracts by analysis of 
complexes binding to an oligonucleotide containing a κB consensus sequence 
(Santa Cruz, Santa Cruz, CA, USA). Shifted complexes were quantified by 
phospho-imager analysis (Biorad). Supershift reactions were performed by pre-
incubation of the nuclear extracts with an antibody specific to the RelA subunit 
of NF-κB (Santa Cruz). 
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Statistics 
Data was analysed according to the guidelines of Altman et al.36 using SPSS 
(Statistical Package for the Social sciences, SPSS Inc., Chicago, IL, USA). 
Non-parametric tests, analysis of variance (ANOVA) or correlation analysis 
(Pearson) was used when appropriate. Data are represented as the mean ± 
SD. A two-tailed probability value of less than 0.05 was considered to be 
significant. 
Results 
Reduced muscle oxidative gene expression in COPD patients 
with muscle inflammation 
Patient characteristics after stratification by muscle TNF-α transcript levels are 
summarised in Table 5.1. Between patient subgroups, no differences were 
observed in lung function. Patients with high muscle TNF-α levels however 
revealed a lower body mass index (BMI) and fat-free mass index (FFMI) 
compared to control subjects indicative for (pre)cachexia. Moreover, in these 
patients muscle mRNA expression levels of genes involved in mitochondrial 
oxidative metabolism such as citrate synthase (CS), β-hydroxyacyl-CoA 
dehydrogenase (HAD) and cytochrome c oxidase subunit 4 (COXIV) were 
lower (p≤0.001) while expression of the glycolytic gene hexokinase 2 (HKII) 
was higher (p=0.005) compared to patients with normal muscle TNF-α mRNA 
levels (Figure 5.1). Accordingly, muscle TNF-α transcript levels correlated 
negatively with transcript levels of CS and HAD and positively with transcript 
levels of HKII (r=-0.614, r=-0.514 and r=0.624 respectively; p≤0.001). 
Furthermore, these patients were characterised by lower muscle expression 
levels of several key regulators of skeletal muscle OXPHEN (PPAR-α, PGC-1α 
and Tfam) compared to patients with normal TNF-α expression levels in muscle 
(p=0.001; p=0.003 and p=0.004 respectively) (Figure 5.1). 
 
Thesis_Remels_v1.pdf
TNF-α impairs regulation of muscle oxidative phenotype 
75 
Table 5.1  Patient characteristics and skeletal muscle gene expression. 
 Healthy Controls 
(n=10) 
COPD patients 
(normal TNF-α) (n=17)
COPD patients 
(high TNF-α) (n=17) 
Patient characteristics    
   FEV1 (% predicted)  82.8 ± 7.6  37.6 ± 16.1 **  36.6 ± 12.4 ** 
   Age (y)  54.7 ± 10.4  60.5 ± 8.3  62.0 ± 9.0 
   Sex (M/F) 8/2 16/2 16/2 
   Weight (kg)  77.5 ± 17.5  75.1 ± 14.9  67.2 ± 13.3 
   BMI (kg/m2)  27.2 ± 3.7  25.9 ± 4.7  23.8 ± 3.5 * 
   FFMI (kg/m2)  18.3 ± 2.3  17.5 ± 2.5  16.7 ± 1.5 * 
Muscle gene expression    
   TNF-α (AU)  0.038 ± 0.024  0.041 ± 0.018  0.147 ± 0.065 # ** 
Gene expression levels for TNF-α were normalised by calculating a normalisation factor based on 
expression levels of 5 housekeeping genes (cyclophilinA, β2-microglobuline, Glyceraldehyde-3-
Phosphate Dehydrogenase, hypoxanthine-guanine phosphoribosyltransferase and β-actin) using 
geNorm software. Gene expression was quantified and expressed as arbitrary units (AU). Values 
are expressed as mean ± SD; significance compared to controls: * p≤0.05, ** p≤0.001; significance 
of difference between COPD sub groups: # p<0.001; FEV1: Forced expiratory volume in one 
second; BMI: Body mass index; FFMI: Fat-free mass index; TNF-α: Tumour necrosis factor alpha. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Oxidative gene expression is reduced in skeletal muscle of COPD patients with 
high muscle TNF-α mRNA expression. Transcript levels of oxidative genes and 
their regulators were assessed in control subjects (n=10) and COPD patients 
characterised by high (n=17) or normal (n=17) muscle TNF-α mRNA expression. 
Gene expression levels were normalised by calculating a normalisation value based 
on five housekeeping genes (cyclophilinA, β2-microglobuline, Glyceraldehyde-3-
Phosphate Dehydrogenase,  hypoxanthine-guanine phosphoribosyltransferase and 
β-actin) using geNorm software. Significance compared to controls: * p≤0.05, 
** p≤0.001; All data are expressed as mean ± SD. HAD: β-hydroxyacyl-CoA 
dehydrogenase; CS: Citrate synthase; COXIV: Cytochrome c oxidase subunit 4; HKII: 
Hexokinase II; PPAR-α: Peroxisome proliferator-activated receptor α; PGC-1α: 
Peroxisome proliferator-activated receptor γ co-activator 1 α; Tfam: Mitochondrial 
transcription factor A. 
 
** * ** * * *
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TNF-α impairs skeletal muscle OXPHEN in vitro 
To investigate if chronic elevations in local TNF-α levels can affect skeletal 
muscle OXPHEN in vitro, mitochondrial O2 consumption, oxidative 
phosphorylation (OXPHOS) protein content as well as myosin heavy chain 
(MyHC) I and II protein and mRNA distribution were assessed in C2C12 
myotubes in response to chronic TNF-α stimulation. 
 
As illustrated in Figure 5.2A, myotubes chronically treated with TNF-α 
displayed significantly lower basal and maximal mitochondrial O2 consumption 
rates compared to vehicle-treated cells (TNF-α stimulation 3 or 5 days following 
initiation of differentiation yielded similar results; Supporting Information Fig. 
S1). Since a decreased muscle respiratory capacity upon TNF-α stimulation 
may be caused by reduced levels of proteins involved in the mitochondrial 
oxidative phosphorylation chain, protein abundance of subunits of OXPHOS 
complexes I-V were quantified. Chronic TNF-α exposure resulted in decreased 
protein levels of subunits of OXPHOS complexes I, II, III, and V (Complex IV 
was not detectable) (Figure 5.2B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 TNF-α impairs oxidative capacity in C2C12 cells. C2C12 myoblasts were 
differentiated for three days in differentiation medium (DM). Myotubes were stimulated 
with vehicle (BSA: Control) or TNF-α (10 ng/ml) for an additional 120h. Cells were 
harvested and mitochondrial respiration rates as well as OXPHOS protein content 
were determined. All parameters were corrected for total protein content. A) The 
following substances were added to the respiration chambers in the following order 
and final concentration: digitonin (1 μl; 0.5 µg/ml), malate (5 µl; 2 mM), palmitoyl-
carnitine (10 μl; 50 μM) and ADP (20 μl; 5mM) followed by FCCP (1 μl; 0.5 µM 
titration) and oxygen consumption was measured. B) Proteins involved in the 
mitochondrial respiration chain were quantified by Western blot analysis. Protein 
levels are given as arbitrary units (AU). All data are expressed as mean ± SD from 
triplicate samples (experiments n=3). Significance of difference: * p≤0.05; ** p≤0.001. 
 
 
Next, MyHC isoform distribution in myotubes chronically treated with TNF-α 
was investigated. A selective reduction of MyHC slow (type I) protein 
abundance was observed compared to vehicle-treated cells while no significant 
Thesis_Remels_v1.pdf
TNF-α impairs regulation of muscle oxidative phenotype 
77 
effect of TNF-α on MyHC fast (type II) protein levels was found (Figure 5.3A, 
5.3B). To further investigate the differential effect of chronic TNF-α stimulation 
on muscle MyHC isoform distribution, mRNA levels of the different MyHC 
isoforms were assessed. As depicted in Figure 5.3C, MyHC I mRNA levels 
decreased significantly whereas MyHC IIb transcript abundance increased after 
TNF-α stimulation.  
 
Since development of muscle OXPHEN parallels the process of myogenic 
differentiation9 and TNF-α is known to inhibit early differentiation10, the 
response of several differentiation markers upon chronic TNF-α stimulation was 
investigated. Myogenic index, which reflects the proportion of nuclei 
incorporated into myotubes and serves as a marker of morphological 
differentiation, was not significantly altered (50.4%±2.8 vs 51.2%±3.4) and 
creatine kinase activity, as a marker of biochemical differentiation, remained 
unchanged upon chronic TNF-α treatment (0.47±0.08 vs 0.43±0.09) (starting 
TNF-α stimulation after 3 or 5 days of differentiation respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.3 TNF-α alters MyHC profile in C2C12 cells. C2C12 myoblasts were differentiated for 
three days in DM. Myotubes were stimulated with vehicle (BSA: Control) or TNF-α 
(10 ng/ml) for 120h. Cells were harvested and MyHC profile was determined at the 
protein and mRNA level. A, B) MyHC protein expression was assessed and corrected 
for total protein content. GAPDH protein levels were used as a loading control. 
C) Gene expression levels were normalised for cyclophilinA as a representative 
housekeeping gene. Values are expressed as mean ± SD. Significance compared to 
control: * p≤0.05, ** p≤0.001. All data are expressed as mean ± SD from triplicate 
samples (experiments n=3). MyHC I, IIa, IIx, IIb: Myosin Heavy Chain isoform I, IIa, IIx 
or IIb; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase. 
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TNF-α reduces expression levels of regulators of muscle OXPHEN 
We also investigated whether TNF-α is able to directly repress expression of 
regulators of skeletal muscle OXPHEN as observed in patient biopsies. As 
shown in Figure 5.4, chronic TNF-α treatment resulted in significantly 
decreased mRNA levels of PPAR-α, PGC-1α and Tfam, similar to observations 
in patients (Figure 5.4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 TNF-α reduces expression of regulators of skeletal muscle OXPHEN. C2C12 
myoblasts were differentiated for three days in DM. Myotubes were stimulated with 
vehicle (BSA: control) or TNF-α (10 ng/ml) for an additional 120h. Gene expression 
levels were normalised for cyclophilinA as a representative housekeeping gene. 
Gene expression was quantified and expressed as % of control from triplicate 
samples (experiments n=3). Values are expressed as mean ± SD. significance 
compared to controls: * p≤0.05, ** p≤0.01. PGC-1α: peroxisome proliferator-
activated receptor γ co-activator 1α; Tfam: mitochondrial transcription factor A; 
PPAR-α: peroxisome proliferator-activated receptor α. 
 
TNF-α reduces transcriptional activity and promoter trans-
activation of major regulators of skeletal muscle OXPHEN 
Chronic TNF-α stimulation of myotubes resulted in reduced (-50%) basal 
(Figure 5.5A) and ligand-induced PPAR transcriptional activity in myotubes 
(Supporting Information Figure 5.S2A). Additionally, PPAR transcriptional 
activity in myoblasts induced by over-expression of PPAR-α, δ, γ, or PGC-1α 
was inhibited by TNF-α to the same extent (Supporting Information Figure 
5.S2B). TNF-α also reduced nuclear respiratory factor 1 (NRF-1) as well as 
Tfam promoter activity levels in myoblasts by approximately 50% (Figure 5.5B).  
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Figure 5.5 TNF-α reduces activity levels of major regulators of muscle OXPHEN. A) C2C12 
myotubes stably transfected with a PPAR-sensitive promoter reporter construct 
(containing the cis-acting PPAR responsive element of the CPT-1 promoter) were 
differentiated for three days in DM. Myotubes were stimulated with vehicle (BSA: 
Control) or TNF-α (10 ng/ml) and harvested every 24h. B) C2C12 myoblasts were 
transiently transfected with a Tfam or a NRF-1 promoter reporter construct and 
stimulated with TNF-α (10 ng/ml) or vehicle (BSA: control) for 24h. Cells were lysed; 
luciferase activity was determined and normalised to β-galactosidase (transient 
transfection) or total protein (stable reporter cell line). Significance of difference: 
* p≤0.05; ** p≤0.01. Results are depicted as fold induction over control. All data are 
expressed as mean ± SD from triplicate samples (experiments n=3). DM: 
Differentiation medium; Tfam: Mitochondrial transcription factor A; NRF-1: Nuclear 
respiratory factor 1. 
NF-κB activation is sufficient and required for impaired 
transcriptional regulation of muscle OXPHEN by TNF-α 
Involvement of NF-κB signalling in the reduced activity levels of major 
regulators of muscle OXPHEN by TNF-α was investigated. Effectiveness of 
inflammatory cytokines and constructs encoding NF-κB subunits was confirmed 
using a stable NF-κB reporter cell line (Supporting Information Figure 5.S3). As 
illustrated in Figure 5.6A, expression of the super repressor mutant form of the 
inhibitory κB α protein (IκBα-SR) fully abolished the effect of TNF-α on PPAR 
transcriptional activity, showing the requirement of intact NF-κB signalling for 
the effects of TNF-α. Conversely, activation of NF-κB using constitutive active 
IκB kinase β (c.a. IKK-β) was sufficient to inhibit PPAR transcriptional activity, 
which again was restored when the IκBα-SR was introduced (Figure 5.6A). 
Also, as illustrated in Figure 5.6B, induction of PPAR transcriptional activity by 
PPAR-α or PGC-1α over-expression was attenuated when plasmids encoding 
the RelA NF-κB subunit were co-transfected. Since PGC-1α stimulates 
oxidative capacity via the transcriptional regulators of mitochondrial biogenesis 
NRF-1 and Tfam11, we investigated the effect of TNF-α/NF-κB signalling on 
NRF-1 (Figure 5.6C) and Tfam (Figure 5.6D) promoter trans-activation. TNF-α 
reduced NRF-1 and Tfam promoter activity levels by 50% which was fully 
restored by blockade of NF-κB signalling through introduction of the IκBα-SR 
construct. Moreover, transfection of a c.a. IKK-β construct also resulted in a 
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50% reduction in reporter activities which in turn was reversed when the 
IκBα-SR was co-introduced in the cell (Figure 5.6C, 5.6D). Introduction of the 
IκBα-SR construct without TNF-α showed increased PPAR transcriptional 
activity or NRF-1/Tfam promoter activity levels compared to control cells. 
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Figure 5.6 Involvement of NF-κB signaling in TNF-α-induced deregulation of oxidative 
capacity. C2C12 myoblasts were co-transfected with A) a PPAR-sensitive promoter 
reporter construct (containing the cis-acting PPAR responsive element of the CPT-1 
promoter) in combination with empty vector (e.v. pCDNA 3.1; control), an IκBα super 
repressor (SR) and/or a constitutive active IκB kinase β (c.a. IKK-β ) construct and 
treated with vehicle (BSA: Control) or TNF-α (10 ng/ml) for 24h. B) a PPAR reporter 
(CPT-1) in combination with e.v. (pCDNA3; control) or plasmids encoding PGC-1α or 
PPAR-α, with/without RelA (V-Rel Avian Reticuloendotheliosis Viral Oncogene 
Homolog A). C2C12 myoblasts were transiently transfected with C) a NRF-1 promoter 
reporter construct or D) a Tfam promoter reporter construct in combination with e.v. 
(pCDNA3.1; control), a SR and/or constitutive active IKK-β construct and/or stimulated 
with TNF-α (10 ng/ml) for 24h. Cells were lysed; luciferase activity was determined 
and normalised to β-galactosidase. Data is presented as mean ± SD (experiments 
n=3). Error bars indicate the SD. Significance of difference: * p≤0.01. Results are 
depicted as fold induction over control.  
NF-κB activation is required for impaired mitochondrial respiratory 
capacity by TNF-α 
To elucidate whether NF-κB activation is required for TNF-α-induced 
impairment of mitochondrial respiration in muscle, we measured mitochondrial 
respiratory capacity of L6 myotubes (stably expressing a control vector or an 
IκBα-SR plasmid) in response to chronic TNF-α stimulation. Basal and TNF-α-
induced RelA DNA-binding was assessed by gel shift and found to be 
abrogated in myotubes stably expressing the IκBα-SR construct (Supporting 
Information Figure 5.S4). As shown in Figure 5.7, impaired respiratory capacity 
of L6 muscle cells upon chronic TNF-α stimulation was fully restored by stable 
blockade of the NF-κB signalling pathway (Figure 5.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 NF-κB activation is required for TNF-α-induced impairment of skeletal muscle 
respiratory capacity. Control L6 muscle cells or L6 muscle cells with abrogated 
NF-κB signalling, through stable expression of the IκBα-SR construct, were 
differentiated for three days in DM. Myotubes were stimulated with vehicle (BSA: 
Control) or TNF-α (10 ng/ml) for 120h. For respiration measurements, the following 
substances were added to the respiration chambers in the following order and final 
concentration: digitonin (1 μl; 0.5 µg/ml), malate (5 µl; 2 mM), palmitoyl-carnitine 
(10 μl; 50 μM) and FCCP (1 μl; 0.5 µM titration). Cells were harvested and oxygen 
consumption was determined. Respiration rates were corrected for total protein 
content. Data are expressed as mean ± SD from triplicate samples (experiments n=3). 
Significance of difference: * p≤0.05; ** p≤0.01. 
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Discussion 
This study demonstrates that COPD patients with increased muscle TNF-α 
mRNA expression are not only characterised by cachectic features but also by 
decreased expression levels of markers and regulators of muscle OXPHEN. 
Moreover, our in vitro data reveal that TNF-α has a direct negative impact on 
muscle OXPHEN and its regulation which is dependent on NF-κB signalling. It 
is therefore feasible that this mechanism contributes to or mediates the loss of 
muscle OXPHEN in patients with advanced COPD, but possibly also in CHF.  
 
To establish whether a disturbed regulation of muscle OXPHEN in advanced 
COPD patients with evidence of an increased muscle inflammatory status 
could be a direct effect of TNF-α, we chronically stimulated cultured muscle 
cells with the pro-inflammatory cytokine TNF-α. This resulted in an induction of 
TNF-α mRNA transcript levels in myotubes (data not shown), in line with the 
auto-amplificatory signalling described for this cytokine and illustrates that 
increased TNF-α mRNA levels in the biopsies may reflect autocrine or 
circulating cytokine actions. Similar to the data obtained in the patient group, 
our in vitro data showed that TNF-α signalling inversely relates to and actually 
decreases several parameters of skeletal muscle OXPHEN, including 
mitochondrial respiration rates and OXPHOS protein content. Interestingly, a 
recent study demonstrated decreased mitochondrial respiration, due to 
blockade of the electron transport chain, in vastus lateralis muscle of COPD 
patients12. Decreased mitochondrial respiration following TNF-α stimulation has 
been reported in experimental models previously13-15. However, in these 
particular studies only the acute effects of TNF-α were studied. Other studies 
revealed inhibition by TNF-α at several sites of the electron transport chain 
including complex II, III and V16,17. In contrast, the changes in respiration 
observed in our study are more likely chronic adaptations resulting from 
decreased expression of OXPHOS proteins after sustained incubation with 
TNF-α, as the half-life of these proteins is several days18. 
 
Loss of type I (slow, oxidative) fibers in peripheral skeletal muscle is a very 
consistent finding in COPD4,19 and is related to disease severity as described in 
a recent meta-analysis4. Unfortunately, fiber type data are not available in our 
COPD patient database but based on disease severity, a decreased content of 
type I fibers must be assumed.  
 
The exact mechanism underlying this change in fiber type composition, which 
contributes significantly to exercise intolerance in patients, remains unknown. 
Intriguingly, chronic TNF-α treatment of cultured myotubes in the present study 
resulted in a selective reduction of oxidative (type I) MyHC isoform protein 
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levels. Since it is known that inflammatory stimuli such as TNF-α can activate 
the proteolytic ubiquitin 26S-proteasome pathway20 it is possible that MyHC 
type I protein is selectively targeted for degradation by this pathway. However, 
increased gene expression levels of MuRF1 and Atrogin, the two E3 ligases 
that target muscle specific proteins for degradation21 were not observed after 
chronic TNF-α stimulation. As MyHC I mRNA levels were reduced while 
expression levels of MyHC IIb were increased after chronic TNF-α stimulation, 
the reduced protein content of MyHC type I most likely resulted from altered 
transcriptional control. 
 
Previous work from our group showed that expression levels of PPARs and 
their co-activator PGC-1α are reduced in peripheral skeletal muscle of COPD 
patients and correlate negatively with plasma inflammatory markers2. As the 
PGC-1α/PPAR signalling pathway has been shown to be a key regulatory 
pathway controlling muscle OXPHEN22 it is feasible that the observed 
detrimental effects of TNF-α stimulation on muscle OXPHEN are mediated 
through alterations in PPAR and PGC-1α expression and/or activity levels. Our 
in vitro observations indeed demonstrate that TNF-α treatment of myotubes 
results in reduced PPAR transcriptional activity as well as PPAR mRNA 
expression levels.  Moreover, in the present study, decreased muscle 
PPAR/PGC-1α mRNA expression levels were found in skeletal muscle of 
COPD patients with high levels of muscle TNF-α mRNA, establishing the 
pathophysiological relevance of our in vitro findings. Based on these 
observations, it is plausible that inflammation-associated alterations in the 
PPAR/PGC-1α/NRF-1/Tfam signalling axis underlie a decreased skeletal 
muscle OXPHEN in COPD and perhaps also in other chronic inflammatory 
diseases. The observation that COPD patients with elevated TNF-α mRNA 
levels in muscle were also characterised by a lower BMI and decreased muscle 
mass suggests that inflammatory signalling might be associated with both 
cachexia and impairment of muscle OXPHEN.  
 
More mechanistic insight in the effect of TNF-α on skeletal muscle OXPHEN 
was provided by the finding that genetic blockade of the NF-κB signalling 
pathway inhibited TNF-α-induced reductions in mitochondrial respiratory 
capacity and PPAR transcriptional activity in cultured muscle cells. Moreover, 
activating NF-κB signalling by over-expression of c.a. IKK-β, was sufficient to 
reproduce the effect of TNF-α on PPAR transcriptional activity. Similarly, RelA 
over-expression attenuated PGC-1α-induced PPAR transcriptional activity. 
Although PPARs have been shown to be able to interfere with the NF-κB 
pathway23,24, few studies have in fact reported a negative impact of NF-κB 
signalling on the PGC-1 α/PPAR pathway25,26 and so far no data is available in 
skeletal muscle. Our findings now demonstrate that the NF-κB pathway 
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mediates TNF-α-induced inhibition of skeletal muscle mitochondrial respiratory 
capacity and PPAR transcriptional activity in vitro. In addition, promoter activity 
levels of NRF-1 and Tfam, two important regulators of mitochondrial 
biogenesis27, were also reduced upon TNF-α stimulation in a NF-κB-dependent 
manner. In line with these findings, a recent study showed decreased mRNA 
transcript levels of Tfam, NRF-1, but also PGC-1α, in mouse skeletal muscle 
satellite cells after TNF-α stimulation15. These observations suggest that, in 
addition to decreased PPAR activity, specific components implicated in 
regulation of mitochondrial biogenesis could also be impaired by TNF-α-
induced NF-κB activation. As Tfam mRNA levels were decreased in COPD 
patients with increased muscle TNF-α mRNA in the present study, NF-kB-
mediated impairment of PGC1α/PPAR signalling may also be of relevance in 
patients. 
 
Detrimental effects of TNF-α signalling are not restricted to impaired muscle 
OXPHEN. Loss of skeletal muscle mass6 and impaired myogenic 
differentiation, both mediated through the NF-κB pathway6,28,29, are well 
documented in skeletal muscle. Importantly, we show that the impairment of 
skeletal muscle OXPHEN mediated by TNF-α in the present study is not a 
consequence of impaired myogenic differentiation or decreased protein 
content. To the best of our knowledge this is the first report demonstrating a 
clear negative interaction between inflammatory mediators as TNF-α, 
subsequent NF-κB signalling and skeletal muscle OXPHEN.  
 
In light of these results and the fact that anti-inflammatory modulation in COPD 
improved exercise capacity7 and exercise endurance8, targeted inhibition of the 
NF-κB pathway could prove to be beneficial in multiple chronic inflammatory 
conditions characterised by disturbed muscle OXPHEN. Interestingly, our 
group recently demonstrated that PPAR-γ activation by Rosiglitazone, which is 
currently in use for the treatment of type 2 diabetes Mellitus (T2DM), potently 
inhibited cytokine-induced NF-κB activation in cultured muscle cells. Moreover, 
Rosiglitazone treatment of T2DM patients has been shown to increase skeletal 
muscle OXPHEN and restore PGC-1α/PPAR expression levels30.  
 
In conclusion, data presented in the present manuscript collectively 
demonstrates that chronically elevated TNF-α levels potently reduce both 
structural and metabolic aspects that determine OXPHEN of skeletal muscle. 
This inflammation-associated impairment of muscle OXPHEN resulted from 
disturbed regulatory processes, as TNF-α down-regulated expression and 
activity levels of main regulators of muscle oxidative capacity and mitochondrial 
biogenesis. In addition, our in vitro data shows that deregulation of skeletal 
muscle OXPHEN by chronic TNF-α stimulation occurs in a NF-κB-dependent 
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manner providing a mechanistic explanation. These results put recently 
published outcomes of nutritional and pharmacological anti-inflammatory 
therapy in COPD in a new perspective7,8 and may provide new leads for 
alleviation of exercise intolerance in COPD and possibly also other chronic 
inflammatory disorders. 
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TNF-α reduces mitochondrial respiration and alters 
MyHC composition in fully differentiated myotubes  
MyHC slow (type I) protein content (Figure 5.S1A, 5.S1B) and mitochondrial 
respiration rates (Figure 5.S1C) were significantly reduced after 120h TNF-α 
treatment of fully differentiated myotubes (day 5) compared to vehicle- 
(Control) treated cells similar to observations after chronic TNF-α treatment of 3 
days differentiated myotubes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.S1 TNF-α reduces mitochondrial respiration and alters MyHC profile. C2C12 
myoblasts were differentiated for 5 days in DM. Myotubes were stimulated with 
vehicle (BSA: Control) or TNF-α (10 ng/ml) for 120h. Cells were harvested and 
MyHC profile and mitochondrial respiratory capacity were determined. All 
parameters were corrected for total protein content A, B) MyHC protein distribution 
was assessed and GAPDH (or tubulin, not shown) protein levels were used as a 
loading control. C) The following substances were added to the respiration 
chambers in the following order and final concentration: digitonin (1 μl; 0.5 µg/ml), 
malate (5 µl; 2 mM), palmitoyl-carnitine (10 μl; 50 μM) and ADP (20 μl; 5mM) 
followed by FCCP (1 μl; 0.5 µM titration) and oxygen consumption was measured. 
Values are expressed as mean ± SD; Significance compared to controls: * p ≤ 0.05. 
All from triplicate samples for 3 independent experiments. MyHC: Myosin heavy 
chain; TNF-α: tumour necrosis factor alpha; GAPDH:  Glyceraldehyde-3-Phosphate 
Dehydrogenase. 
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TNF-α reduces ligand- as well as vector-induced 
PPAR-dependent transcriptional activity in C2C12 
cells 
Chronic TNF-α treatment reduced ligand-induced (PPAR-δ: GW501516; 
PPAR-α: WY14643; PPAR-γ: Rosiglitazone) PPAR-dependent transcriptional 
activity in myotubes by 50% (Figure 5.S2A). Additionally, PPAR-dependent 
transcriptional activity in myoblasts, induced by transient over-expression of 
PPAR-α, δ, or γ, or PGC-1α, was inhibited by TNF-α to the same extent (Figure 
5.S2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.S2 TNF-α reduces PPAR-dependent transcriptional activity. A) C2C12 cells stably 
transfected with a PPAR-sensitive luciferase reporter construct (containing the cis-
acting PPRE of the CPT-1 promoter) were differentiated into myotubes for 5 days. 
Myotubes were stimulated with specific PPAR activators (PPAR-γ: Rosiglitazone 75 
µM; PPAR-δ: GW501516 1 µM; PPAR-α: WY14643 50 µM) for 24h in combination 
with vehicle (BSA: Control) or TNF-α (10 ng/ml). B) C2C12 myoblasts were co-
transfected with a PPAR reporter construct (containing the cis-acting PPRE of the 
CPT-1 promoter) and empty pcDNA 3.1 vector (e.v.) or plasmids encoding PPAR-γ, 
PPAR-δ, PPAR-α or PGC-1α and stimulated with vehicle (BSA: Control) or TNF-α 
(10 ng/ml) for 24h. Cells were lysed; luciferase activity was determined and 
normalised to total protein content (stable cell line) or β-galactosidase activity 
(transient transfections). PPAR-dependent transcriptional activity is expressed as 
fold change compared to vehicle control (no ligand, A) or BSA-treated e.v. control 
(B). Significance of difference: * p≤0.05; ** p≤0.01. Data are expressed as mean ± 
SD. Error bars indicate the SD. Shown are the representative data of 3 independent 
experiments. 
Functional verification of NF-κB modulation in 
C2C12 myoblasts   
Functionality of constructs encoding components of the NF-κB pathway (IκBα-
SR, RelA and c.a. IKK-β) was verified using C2C12 myoblasts transiently 
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transfected with a NF-κB reporter construct, stimulated with TNF-α and/or co-
transfected with the respective constructs. As shown in Figure 5.S3, TNF-α as 
well as c.a. IKK-β and RelA constructs were capable of inducing NF-κB 
transcriptional activity in myoblasts. The IκBα-SR construct inhibited TNF-α- as 
well as c.a. IKK-β-induced NF-κB transcriptional activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.S3 Functionality of NF-κB-encoding constructs. C2C12 myoblasts were co-
transfected with a NF-κB reporter (6κB-luciferase) construct in combination with e.v. 
(pCDNA3.1; control), a constitutive active IKK-β or RelA construct, alone or in 
combination with an IκBα super repressor (SR) construct, or treated with vehicle 
(BSA: Control) or TNF-α (10 ng/ml) for 24h. Cells were lysed; luciferase activity was 
determined and normalised to β-galactosidase. Data is presented as mean ± SD. 
Error bars indicate the SD. Significance of difference: * p≤0.01. Results are depicted 
as fold change over control. Shown are the representative data of 3 independent 
experiments. TNF-α: tumour necrosis factor alpha; SR: super repressor; c.a. IKK-β: 
constitutively active IKK beta; RelA: V-Rel Avian Reticuloendotheliosis Viral 
Oncogene Homolog A. 
Functional verification of NF-κB modulation in L6 
myotubes 
L6 skeletal muscle cells were stably transfected with an IκBα-SR construct or 
empty vector plasmid (PcDNA 3.1; control). Responsiveness of the control and 
the IκBα-SR cell line to TNF-α stimulation was verified with an electric mobility 
shift assay (EMSA) designed to measure RelA DNA binding capacity. As 
depicted in Figure 5.S4, L6 control myotubes showed increased RelA DNA 
binding after TNF-α stimulation. In contrast, IκBα-SR myotubes revealed 
markedly lower RelA DNA binding capacity compared to the control cells after 
TNF-α stimulation. Supershift analysis (panel B) demonstrates the presence of 
RelA in the main complex after TNF-α stimulation. 
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Figure 5.S4 Inhibition of TNF-α-induced RelA translocation in IκBα-SR L6 myotubes. L6 
myoblasts were stably transfected with an empty vector plasmid (PcDNA3.1) or with 
an IκBα-SR construct and differentiated for 5 days in differentiation medium. 
Myotubes were stimulated with vehicle (BSA: Control) or TNF-α (10 ng/ml) for 1h. 
Cells were lysed and nuclear extracts were prepared to assess A) NF-κB DNA 
binding activity by electric mobility assay (EMSA). B) Supershift analysis using a 
RelA (V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog) A) antibody 
(lane 2) or an isotype control antibody (lane 3) was used to assess complex sub-
composition compared to no antibody (lane 1). n.s.: Non-significant band. 
Subjects and Methods 
Collection and processing of muscle tissue 
The specimens were immediately snap frozen in liquid nitrogen and stored at 
−80°C until use. The frozen biopsies were weighed and subsequently 
homogenised using a Polytron PT 1600 E (Kinematica AG, Littau/Luzern, 
Germany).   
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Chemicals and reagents 
TNF-α (Calbiochem, Nottingham, United Kingdom) was dissolved in 0.1% BSA 
which also served as a vehicle control (0.005% final concentration). Digitonin, 
malate, palmitoyl-carnitine, ADP and FCCP (all from Sigma Aldrich, 
Zwijndrecht, Netherlands) were dissolved according to MiPNet protocols 
(Oroboros Instruments, Innsbruck, Austria). Rosiglitazone-maleate (Alexis 
Biochemicals, Lausen, Switzerland), WY14643 (Biomol, Plymouth Meeting, PA, 
USA) and GW501516 (Alexis Biochemicals) were all dissolved in 100% DMSO 
to a stock solution of 75 mM, 25 mM and 5 mM respectively. 
Transfection and plasmids 
Cells were grown to be 50% confluent and transfected by nanofectin according 
to manufacturer’s instructions (PAA, Pasching, Austria). For construction of the 
stable PPAR reporter cell line, transfection was performed in the presence of 
3.75 µg HCBP plasmid DNA and 0.25 µg of a plasmid containing the neomycin 
resistance gene (pSV2-Neo, Stratagene, La Jolla, CA, USA). For selection of 
positive clones, cells were cultured in growth medium (GM) containing 
800 µg/ml G418 (Calbiochem). To investigate the involvement of NF-κB 
signalling, plasmids encoding IκBα-SR (pSFFV-NEO-IκBα-SR) (constitutively 
expressed under control of the SFFV-LTR); kind gift from Dr. Rosa Ten (Mayo 
Clinic, Rochester, MN, USA), RelA or a constitutive active form of IKK-β (c.a. 
IKK-β); kind gifts from Dr. Michael Karin; University of California, San Diego, La 
Jolla, CA, USA) were transiently transfected into C2C12 myoblasts according 
to the same protocol. For the assessment of NF-κB transcriptional activation, 
C2C12 cells were stably transfected with a 6κB-TK luciferase plasmid (NF-κB 
reporter)5. Plasmids encoding different PPAR isoforms (PPAR-δ, PPAR-γ or 
PPAR-α) or PGC-1α were all kind gifts from Dr. J Auwerx (CNRS/INSERM, 
Lille, France), Dr. P. Grimaldi (INSERM U636, Nice, France) and Dr. D. Kelly 
(Washington University School of Medicine St. Louis, USA) respectively. For 
creation of L6 cells stably expressing the IκBα-SR construct, a similar approach 
as used for the creation of C2C12 stable cell lines was applied. PcDNA3.1 
empty vector again was used as a control. 
Reporter assays 
The PPAR reporter cell line was plated in 35 mm dishes and allowed to grow to 
70% confluency. After induction of differentiation, cells were differentiated into 
myotubes for 3 or 5 days after which cells were stimulated. Stimuli were 
refreshed together with medium every 48h. After stimulation, cells were 
washed 2x with cold PBS, and subsequently lysed by adding (100 µl) 1x 
Reporter Lysis Buffer (Promega, Madison, WI, USA) and incubation on ice for 
10 min. Cell lysates were centrifuged (14000 rpm, 1 min) and supernatants 
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were snap frozen and stored at -80°C for later analysis. Luciferase activity was 
measured according to manufacturer’s instructions (Promega) and corrected 
for total protein content (Biorad, Hercules, CA, USA). For transient transfection 
assays, C2C12 myoblasts were plated at 60% confluency in 35 mm dishes and 
transfected according to manufacturer’s instructions (PAA). 24 h after 
transfection, differentiation was induced with differentiation medium and cells 
were stimulated with TNF-α (10 ng/ml) for 24-120 h. Luciferase (Promega) and 
β-galactosidase (Tropix, Bedford, MA, USA) were measured according to 
manufacturer’s instructions. 
Mitochondrial respiration 
C2C12 differentiated myotubes were harvested in trypsin, washed twice with 
MIRO5 respiration medium (37ºC) and, after a 5 min centrifugation at 500 rpm, 
resuspended in 2.5 ml of MIRO5 respiration medium. 2.0 ml of cell suspension 
was used for the measurement of mitochondrial respiration. The remaining cell 
suspension was used for determination of total protein content (Biorad). The 
amplified signal from the oxygen sensor was recorded at 0.5 Hz (DatLab 
acquisition software, Oroboros Instruments). The respiration medium was 
equilibrated with air in the oxygraph chambers at 37°C and stirred until a stable 
signal was obtained for calibration at air saturation. After calibration the 
medium was replaced by aerated cell suspensions at a volume of 2.0 ml. After 
insertion, cells were permeabilised using 1 µl of digitonin (0.5 µg/ml final 
concentration) and substrates were added in chronological order (volume; final 
concentration): malate (5 μl; 2 mM) and palmitoyl-carnitine (10 μl; 50 μM). At 
the end of the substrate trace a titration with the uncoupling agent FCCP was 
performed (1 μl; 0.5 μM titration). Oxygen consumption (pmol/ml·s) was 
calculated as a negative time derivative of oxygen concentration (nmol/ml). 
Respiration rates were corrected for total protein content to correct for 
variability in cellular input.  
Western blot analysis 
25 µg or 10 µg of protein (OXPHOS and MyHC respectively) was loaded per 
lane and separated on a 10% polyacrylamide gel (Mini Protean 3 system; 
Biorad), followed by transfer to a 0.45 µm nitrocellulose membrane (Biorad 
Hercules) by electro-blotting. The membrane was blocked for 1 h at room 
temperature in 5% (w/v) non-fat dry milk. Nitrocellulose blots were washed in 
PBS-Tween 20 (0.05%), followed by overnight incubation (4°C) with a 
polyclonal antibody specific for OXPHOS proteins (Cell Signalling, Beverly, MA, 
USA) or MyHC type I or II isoforms (Sigma Aldrich). The antibody used for 
detection of OXPHOS proteins was directed against the ND6 subunit of 
complex I, the 30 kDa Ip subunit of complex II, subunit II of COXII and the 
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alpha subunit of the F1F0 ATP synthase (complex V). After three wash steps of 
20 min each, the blots were probed with a peroxidase-conjugated secondary 
antibody (Vector Laboratories, Burlingame, CA, USA) and visualised using 
SuperSignal West Pico chemiluminescent substrate (Pierce Biotechnology, 
Rockford, IL, USA) according to the manufacturer's instructions.  
Preparation of nuclear extracts 
C2C12 myotubes were harvested in ice-cold buffer A (20 mM HEPES: pH 7.8; 
20 mM KCl; 4mM MgCl2; 0.2 mM EDTA: pH 8.0; 1 mM DTT; 0.2 mM 
NaVanadate; 0.4 mM PMSF; 0.3 mg/ml Leupeptin; 0.2 mM NaF) and 
transferred to Eppendorf tubes. Cells were kept on ice for 15 min followed by 
45 min incubation on a rotating platform at 4ºC. Buffer B (Nonidet P40) was 
added, samples were mixed vigorously and centrifuged (5 min; 14000 rpm). 
Supernatant was removed (cytoplasmatic fraction), pellets were washed in 
buffer A+B, mixed and centrifuged (5 min; 14000 rpm. Supernatant was 
removed and nuclei were lysed in buffer C (100 mM HEPES: pH 7.8; 100 mM 
KCl; 600 mM NaCl; 0.2 mM EDTA: pH 8.0; 20% glycerol; 1 mM DTT; 0.2 mM 
NaVanadate; 0.4 mM PMSF; 0.2 mM NaF) by 20 min incubation at a rotating 
platform at 4ºC. Samples were centrifuged (5 min; 14000 rpm), supernatant 
was transferred to a new Eppendorf tube and stored at -80ºC. 
Electrophoretic mobility shift assay (EMSA) 
2 µg of nuclear protein was used per binding reaction and protein-DNA 
complexes were resolved on a 5% polyacrylamide gel in 0.25X Tris-borate-
EDTA buffer at 120V for 2h. Gels were dried and exposed to film (X-Omat Blue 
XB-1, Kodak, Rochester, NY, USA).  
May-Grunwald Giemsa staining 
Cells were grown on Matrigel-coated 60 mm dishes and after stimulation 
experiments with TNF-α, cells were washed 2x in PBS (room temperature), 
fixed in methanol and stained in May-Grunwald Giemsa (Sigma Aldrich) 
according to manufacturer’s instructions. 
Quantitative PCR (QPCR)  
Total RNA was extracted using the acid guanidium thiocyanate-phenol-
chloroform extraction method (Ambion Ltd., United Kingdom). RNA 
concentration was determined using a spectrophotometer. 0.4 µg of RNA per 
sample was reverse transcribed into cDNA according to the manufacturer’s 
instructions (Biorad). cDNA was PCR amplified with SYBR green mix 
(Westburg, Leusden, the Netherlands) on a Biorad PCR apparatus. Primers 
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were designed to generate a PCR amplification product of 100 to 150 bp. 
Specificity of the amplification was verified by melt curve analysis and 
evaluation of efficiency of PCR amplification. For cDNA synthesized from 
human biopsies, transcript levels for the constitutive housekeeping gene 
products cyclophilinA, hypoxanthine phosphoribosyltransferase (HPRT), β2-
microglobuline, β-actin and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were quantitatively measured in each sample to control for sample-
to-sample differences in RNA concentration. Gene expression levels were 
normalised by calculating an average value of the 5 housekeeping genes using 
Genorm software (Primerdesign, Southampton, USA). For cDNA synthesized 
from C2C12 myotubes, transcript levels of cyclophilinA were determined as a 
representative housekeeping gene in each sample to control for sample-to-
sample differences in RNA concentration. Gene expression was quantified and 
expressed as arbitrary units (AU). 
Primer details 
Primers used for human gene expression profiling in skeletal muscle of patients 
and healthy controls as well as primers used for determination of gene 
expression in mouse C2C12 cells are summarised in Table 5.S1. 
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Table 5.S1  Human/mouse primers. 
Primer Forward 5’-3’ Reverse 5’-3’ 
CS GATGTGTCAGATGAGAAGTTACGAGACT TGGCCATAGCCTGGAACAA 
COXIV CGTTCGAGCCCCTGTTCA CCATGGATGAGAAAGTCGAGT 
HAD TGGCTTCCCGCCTTGTC TGGAGCCGGTCCACTATCTTC 
HKII TCAAGTGGACAAAAGGCTTCAA CCGGTGGATCGCTTCCT 
PPAR-α CAGAACAAGGAGGCGGAGGTC AGGTCCAAGTTTGCGAAGC 
PGC-1α ATGCAGTGGTCTCAGTACCCA TCTTCGCTTTATTGCTCCATGAA 
Tfam ATAACGTTTATGTAGCTGAAAGATTCCA TCAGAGTCAGACAGATTTTTCCAGTTT 
MuRF1 GCGAGGTGGCCCCATT GATGGTCTGCACACGGTCATT 
Atrogin GAAGAAACTCTGCCAGTACCACTTC CCCTTTGTCTGACAGAATTAATCG 
TNF-α TCAATCGGCCCGACTATCTC CAGGGCAATTGATCCCAAAGT 
CyclophilinA CTCGAATAAGTTTGACTTGTGTTT CTAGGCATGGGAGGGAACA 
GAPDH GCACCACCAACTGCTTAGCA TGGCAGTGATGGCATGGA 
HPRT AGAATGTCTTGATTGTGGAAGA ACCTTGACCATCTTTGGATTA 
β-actin  AAGCCACCCCACTTCTCTCTAA AATGCTATCACCTCCCCTGTGT 
Β2-microglobulin TGACTTTGTCACAGCCCAAGATA AATGCGGCATCTTCAAACCT 
Mouse primer details 
 Forward 5’-3’ Reverse 5’-3’ 
MyHC I CCAAGGGCCTGAATGAGGAG GCAAAGGCTCCAGGTCTGAG 
MyHC IIA CGATGATCTTGCCAGTAATG ATAACTGAGATACCAGCG 
MyHC IIb 
MyHC IIx                
ACAAGCTGCGGGTGAAGAGC 
GACAAACTGCAATCAAAGG                          
CAGGACAGTGACAAAGAACG 
TTGGTCACTTTCCTGCACTT 
   
PPAR-α AGTGCCCTGAACATCGAGTGT AAGCCCTTACAGCCTTCACATG 
PGC-1α AAACCACACCCACAGGATCAG TCTTCGCTTTATTGCTCCATGA 
Tfam CGGAGTTCCCACGCTGG CCGTCCGGTTCGTCTCAC 
CyclophilinA TTCCTCCTTTCACAGAATTATTCCA CCGCCAGTGCCATTATGG 
Definition of abbreviations: CS: citrate synthase; COXIV: cytochrome c oxidase subunit 4; HAD: β-
hydroxyacyl CoA-dehydrogenase; HKII: Hexokinase 2; PPAR-α: Peroxisome proliferator-activated 
receptor alpha; PGC-1α: Peroxisome proliferator-activated receptor gamma co-activator 1 alpha; 
Tfam: Mitochondrial transcription factor A; MuRF1: Muscle ring finger 1; TNF-α: Tumour necrosis 
factor alpha; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HPRT: Hypoxanthine 
phosphoribosyltransferase; MyHC: Myosin heavy chain. 
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Abstract 
Skeletal muscle pathology associated with a chronic inflammatory disease 
state (e.g. skeletal muscle atrophy and insulin resistance) is a potential 
consequence of chronic activation of nuclear factor kappa B (NF-κB). It has 
been demonstrated that peroxisome proliferator-activated receptors (PPARs) 
can exert anti-inflammatory effects by interfering with transcriptional regulation 
of inflammatory responses. The goal of the present study therefore was to 
evaluate if PPAR activation affects cytokine-induced NF-κB activity in skeletal 
muscle. Using C2C12 myotubes as an in vitro model of myofibers we 
demonstrate that PPAR-, and specifically PPAR-γ, activation potently inhibits 
inflammatory mediator-induced NF-κB transcriptional activity in a time- and 
dose-dependent manner. Furthermore, PPAR-γ activation by Rosiglitazone 
strongly suppresses cytokine-induced transcript levels of the NF-κB-dependent 
genes intra-cellular adhesion molecule 1 (ICAM-1) and CXCL1 (KC), the 
murine homologue of interleukin 8 (IL-8), in myotubes. To verify if muscular NF-
κB activity in human subjects is suppressed by PPAR-γ activation, we 
examined the effect of 8 weeks Rosiglitazone treatment on muscular gene 
expression of ICAM-1 and IL-8 in type 2 diabetes mellitus patients. In these 
subjects, we observed a trend towards decreased basal expression of ICAM-1 
mRNA levels. Subsequent analyses in cultured myotubes revealed that the 
anti-inflammatory effect of PPAR-γ activation is not due to decreased RelA 
translocation to the nucleus or reduced RelA DNA binding. These findings 
demonstrate that muscle-specific inhibition of NF-κB activation may be an 
interesting therapeutic avenue for treatment of several inflammation-associated 
skeletal muscle abnormalities. 
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Introduction 
There is increasing evidence in the literature that chronic activation of nuclear 
factor kappa B (NF-κB), which is an essential signalling pathway involved in 
conveying inflammatory signals, is causally related to skeletal muscle 
pathology. Wasting of skeletal muscle mass is commonly observed in chronic 
inflammatory diseases and has been associated with increased morbidity and 
mortality1,2. Several studies have shown that systemic inflammatory cytokines, 
such as tumour necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), 
are proximal markers of cachexia3-5. More specifically, quadriceps muscle 
biopsies of severely cachectic patients with chronic obstructive pulmonary 
disease (COPD) and chronic heart failure were characterised by activation of 
the NF-κB signalling pathway6,7. Moreover, forced activation of NF-κB in 
skeletal muscle causes profound muscle wasting that resembles clinical 
cachexia while inhibition of NF-κB signalling has proven to be sufficient to block 
inflammation-induced protein degradation in cultured skeletal muscle 
myotubes5,8. In type II diabetes mellitus (T2DM) skeletal muscle insulin 
resistance is associated with decreased protein abundance of the inhibitory 
protein of NF-κB, IκBα9, and increased transcript levels of NF-κB-dependent 
genes, including IL-8 in skeletal muscle10,11. These observations indicate that 
anti-inflammatory agents, capable of inhibiting NF-κB signalling, could be 
useful for treatment of inflammation-associated skeletal muscle abnormalities 
in chronic disease states. 
 
Interestingly, it is known that activation of peroxisome proliferator-activated 
receptors (PPARs) can exert anti-inflammatory effects in several cell types as 
smooth muscle cells, endothelial cells and macrophages12,13. PPARs are a set 
of nuclear receptors implicated in a multitude of physiological processes14. 
They display transcriptional activity and are tissue-selectively expressed15. To 
date, three PPAR subtypes have been identified: PPAR-α, PPAR-δ and 
PPAR-γ16. Anti-inflammatory properties of the PPARs include the potential to 
interfere with transcriptional pathways involved in inflammatory responses e.g. 
modulation of NF-κB signalling. Several mechanisms have been described 
including inhibition of IκBα degradation, reduction of RelA (p65) nuclear 
translocation and diminished binding of RelA to the DNA17,18. Data on the 
potential of PPARs to interfere with NF-κB signalling in skeletal muscle 
however is lacking. Therefore, in the present study we investigated if PPAR 
activation in skeletal muscle is able to modulate inflammatory mediator-induced 
NF-κB activity.  
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Our results reveal that PPAR-γ activation suppresses cytokine-induced NF-κB 
transcriptional activity and –target gene expression in skeletal muscle, 
independent of nuclear translocation and DNA binding  
Subjects and methods 
Cell culture 
The murine skeletal muscle cell line C2C12 was obtained from the American 
Type Culture Collection (ATCC# CRL1772, Manassas, VA, USA). These cells 
are able to undergo differentiation into spontaneously contracting myotubes 
upon growth factor withdrawal19. C2C12 cells were cultured as described 
previously20. Cells were treated with a sub-maximal dose of TNF-α (1ng/ml) or 
IL-1β (1ng/ml) and/or PPAR agonists at day 6 of differentiation. 
Chemicals and reagents 
Tetradecylthioacetic acid (TTA) (Sigma Aldrich, Zwijndrecht, the Netherlands) 
was dissolved in 100% ethanol to a final concentration of 100 mM and coupled 
to 0.4% fatty acid free bovine serum albumin (BSA) (Sigma Aldrich, 
Zwijndrecht, the Netherlands) in differentiation medium (DM) by 30’ incubation 
at 37ºC before use. Rosiglitazone-maleate (Alexis Biochemicals, Lausen, 
Switzerland), WY14643 (Biomol, Plymouth Meeting, PA, USA), GW501516 
(Alexis Biochemicals, Lausen, Switzerland) and GW1929 (Sigma Aldrich, 
Zwijndrecht, the Netherlands) were all dissolved in 100% dimethyl sulfoxide 
(DMSO) to a stock solution of 50 mM, 5mM, 25mM and 20 mM respectively. 
TNF-α and IL-1β (both from Calbiochem, San Diego, CA, USA) were dissolved 
in 0.1% Bovine serum albumine (BSA). 
Transfections and plasmids 
For the assessment of NF-κB transcriptional activation, C2C12 cells were 
stably transfected with the 6κB-TK luciferase plasmid (NF-κB reporter) as 
described previously20. For assessment of PPAR transcriptional activation, 
C2C12 cells were stably transfected with a Human CPT-1 B promoter (HCBP) 
luciferase reporter plasmid (pSG5, Stratagene, La Jolla, CA, USA) (PPAR 
reporter). Cells were grown to 70% confluency and transfected using 
Lipofectamine according to manufacturers’ instructions (Invitrogen, Carlsbad, 
CA, USA). Transfection was performed in the presence of 3.75 µg HCBP 
plasmid DNA and 0.25 µg of a plasmid containing the neomycin resistance 
gene (pSV2-Neo, Stratagene, La Jolla, CA, USA). For selection of positive 
clones, cells were cultured in GM containing 800µg/ml G418 (Calbiochem, San 
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Diego, CA, USA). Transient transfections were all performed by Lipofectamine 
according to manufacturers’ instructions (Invitrogen, Carlsbad, CA, USA). 
Reporter assays 
The NF-κB- or the PPAR sensitive reporter cell lines were plated in 35 mm 
dishes and allowed to grow to 70-80% confluency. Cells were differentiated for 
6 days and then treated with the various stimuli. After the appropriate 
incubation times cells were washed 2x with cold phosphate buffered saline 
(PBS), and subsequently lysed by adding (100 µl) 1x Reporter Lysis Buffer 
(Promega, Madison, WI, USA) and incubation on ice for 10 min. Cell lysates 
were centrifuged (13,000 g, 1 min), and supernatants were either snap-frozen 
and stored at -80°C for later analysis or placed on ice for immediate analysis. 
Luciferase activity was measured according to manufacturers’ instructions 
(Promega, Madison, WI, USA) and corrected for total protein content (Biorad, 
Hercules, CA, USA). For assessment of the inhibitory potential of PPAR 
activation on NF-κB transcriptional activation, cells from the NF-κB sensitive 
reporter cell line were incubated with PPAR activators prior to the 
administration of the inflammatory stimulus (TNF-α or IL-1β). 
RNA isolation, cDNA synthesis and QPCR 
Total RNA from C2C12 myotubes was extracted using the acid guanidium 
thiocyanate-phenol-chloroform extraction method (Ambion Ltd., Ijssel, The 
Netherlands). RNA concentration was determined using a spectrophotometer. 
One microgram of RNA per sample was reverse-transcribed into cDNA 
according to the manufacturers’ instructions (Reverse-IT-TM 1st strand 
synthesis, Abgene, Leusden, The Netherlands). Transcript levels of intra-
cellular adhesion molecule 1 (ICAM-1) and the chemokine CXCL1 (KC: 
keratinocyte-derived chemokine) were determined in C2C12 samples using a 
Biorad quantitative PCR apparatus (Biorad, Hercules, CA, USA). Transcript 
levels for the constitutive housekeeping gene product cyclophillineA were 
quantitatively measured in each sample to control for sample-to-sample 
differences in RNA concentration. ICAM-1 and IL-8 mRNA levels were 
determined in cDNA generated from skeletal muscle from diabetic subjects 
treated with Rosiglitazone. Gene expression was quantified and expressed as 
arbitrary units (AU). Total RNA was extracted from these skeletal muscle 
biopsies using Trizol reagent (Invitrogen, Breda, The Netherlands). One 
microgram of RNA was reverse-transcribed to cDNA using random hexomer 
primers and a stratascript enzyme (Stratagene, Amsterdam, The Netherlands). 
Reverse transcription and quantitative PCR (QPCR) were performed using an 
MX3000p thermal cycler system and Brilliant SYBER Green QPCR Master Mix 
(Stratagene, Amsterdam, The Netherlands). To control for any variations in the 
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efficiencies of the reverse transcription and PCR, acidic ribosomal 
phosphoprotein PO (36B4) was used as an internal control. The number of 
cycles at which the best-fit line through the log linear portion of each amplified 
curve intersects the noise band is inversely proportional to the log copy number 
11. This value is referred to as the critical threshold (CT) value. The ΔCT was 
calculated by subtracting the CT for 36B4 from the CT for the gene of interest. 
The relative expression of the gene of interest is calculated using the 
expression 2"ΔCT and reported as arbitrary units. All PCR runs were performed 
in triplicate. 
Preparation of nuclear extracts and Western blot analysis 
Nuclear extracts were prepared as described previously21. For Western blot 
analysis 4x Laemmli sample buffer (0.25 M Tris·HCl, pH 6.8; 8% (w/v) SDS, 
40% (v/v) glycerol, 0.4 M DTT, and 0.04% (w/v) bromophenol blue) was added 
to nuclear extracts followed by boiling of the samples for 5 min at 100 ºC and 
storage at –20°C. Total protein was assessed using the Biorad DC protein 
assay kit (Biorad, Hercules, CA, USA) according to the manufacturers' 
instructions. 15 µg (RelA) or 2 µg (HIS-3) of protein was loaded per lane and 
separated on a 10% or 12 % polyacrylamide gel (Mini Protean 3 system; 
Biorad, Hercules, CA, USA) (RelA and HIS-3 respectively), followed by transfer 
to a 0.45 µm nitrocellulose membrane (Biorad Hercules, CA, USA) by electro 
blotting. The membrane was blocked for 1 h at room temperature in 5% (w/v) 
non-fat dry milk. Nitrocellulose blots were washed in PBS-Tween 20 (0.05%), 
followed by overnight incubation (4°C) with a polyclonal antibody specific for 
RelA (Santa Cruz, Santa Cruz, CA, USA) or HIS-3 (Abcam, Cambridge, UK). 
After three wash steps of 20 min each, the blots were probed with a 
peroxidase-conjugated secondary antibody (Vector Laboratories, Burlingame, 
CA, USA) and visualised using SuperSignal West Pico chemiluminescent 
substrate (Pierce Biotechnology, Rockford, IL, USA) according to the 
manufacturers' instructions. 
Electrophoretic Mobility Shift Analysis (EMSA) 
DNA binding activity of NF-κB was assessed in nuclear extracts by analysis of 
complexes binding to an oligonucleotide containing a κB consensus sequence 
(Santa Cruz, Santa Cruz, CA, USA). 2 µg of nuclear protein was used per 
binding reaction and protein-DNA complexes were resolved on a 5% 
polyacrylamide gel in 0.25X Tris-borate-E DTA buffer at 120V for 2 h. Gels 
were dried and exposed to film (X-Omat Blue XB-1, Kodak, Rochester, NY, 
USA). Shifted complexes were quantified by phosphor-imager analysis (Biorad, 
Hercules, CA, USA). To determine the sub-composition of the complexes, 
supershift reactions were performed by pre-incubation of the nuclear extracts 
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with an antibody specific to the RelA subunit of NF-κB (Santa cruz, Santa cruz, 
CA, USA) or a negative IgG antibody. 
Chromatin Immunoprecipitation Assay (ChIP) 
After removal of the medium, 1% Formaldehyde (Fisher Scientific,Pittsburgh, 
USA) was added to the cells for 10 min at room temperature. Cross-linking was 
stopped by the addition of glycine (5 min) to a final concentration of 0.125 M. 
Cross-linked cells were washed 2 times with PBS, scraped and resuspended in 
SDS buffer (100 mM NaCl; 50 mM Tris-HCl, pH 8.1; 5 mM EDTA, pH 8.0; 
0.02% NaN3 and 0.5% SDS). Lysates were snap-frozen on dry ice. After 
thawing, the cells were pelleted (6 min; 500 g) at room temperature. Cells were 
subsequently sonicated (10 Amp; 16 cycles; 20 sec on, 100 sec off). Samples 
underwent Proteinase K and DNAse treatment and DNA was isolated using 
Phenol-chloroform isoamyl alchohol precipitation. Sonication efficiency was 
verified on a 2% agarose gel. The supernatant was precleared ( 20 min; 4ºC) 
with protein A beads blocked with herring sperm. After removal of the beads by 
micro centrifugation (30 min; 14000 g; room temperature), 4 µg of RelA 
antibody (Abcam, Cambridge, UK) was added overnight at 4ºC with continuous 
mixing. A polyclonal antibody directed against HA was used as a control 
antibody (Santa cruz, Santa cruz, CA, USA). Antibody-protein-DNA complexes 
were isolated by immunoprecipitation with blocked protein A beads. Following 
extensive washing, bound DNA fragments were eluted and analysed by 
subsequent Real Time PCR. Primers were designed around the RelA binding 
site in the ICAM-1 promoter. Forward: 5’- GATGTCCTTTCCGGTTGCAG-3’; 
Reverse:  5’-CAGGGAAATTCCCGGAGTACA-3’. 
Human subjects 
To validate results from the in vitro setting we investigated transcript levels of 
NF-κB target genes in skeletal muscle of diabetic subjects who received 
Rosiglitazone treatment as reported previously22,23. In summary, ten middle-
aged obese men with type 2 diabetes mellitus participated in this study. 
Subjects had no major health problems beside their diabetes, and did not use 
any medication known to interfere with the results of the study. The Medical 
Ethical Review Committee of Maastricht University approved the study 
protocol, and all subjects gave their written informed consent before the start of 
the study. After baseline measurements, diabetic subjects received 
Rosiglitazone (2x4 mg per day) for 8 weeks. At the end of this 8-week period, 
all measurements were repeated. Eight weeks of Rosiglitazone treatment was 
effective in restoring insulin sensitivity in these subjects. 
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Collection and processing of muscle tissue 
Post absorptive muscle biopsies of the lateral part of the quadriceps femoris 
were obtained under local anaesthesia by using the needle biopsy technique. 
The specimens were immediately snap-frozen in liquid nitrogen and stored at 
−80°C until use. The frozen biopsies were weighed and subsequently 
homogenised using a Polytron PT 1600 E (Kinematica AG, Littau/Luzern, 
Germany) for RNA extraction.  
Statistical analysis 
Data was analysed according to the guidelines of Altman et al.24 using SPSS 
(Statistical Package for the Social sciences, SPSS Inc., Chicago, IL, U.S.A). An 
unpaired student’s t-test was used for the in vitro data while a paired non-
parametric tests was used for the gene expression analysis in skeletal muscle 
of Rosiglitazone treated diabetic patients. Data are represented as the mean 
± SD or median ± range when appropriate for in vitro and in vivo data 
respectively. A two-tailed probability value of less than 0.05 was considered to 
be significant. 
Results 
NF-κB activation by inflammatory cytokines  
Transcriptional activation of NF-κB was evaluated in a stable reporter cell line. 
In order to test responsiveness to inflammatory cytokines, C2C12 myotubes 
were stimulated with various concentrations of TNF-α for 4 h. Stimulation with 
TNF-α resulted in a dose-dependent increase in NF-κB transcriptional activity 
(Figure 6.1A). In order to assess whether this cell line was also responsive to 
inflammatory stimuli other than TNF-α, a similar stimulation experiment was 
performed using various concentrations of IL-1β for 4 h yielding similar results 
(Figure 6.1B). These data demonstrate that TNF-α and IL-1β potently induce 
NF-κB transcriptional activity in differentiated myotubes.  
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Figure 6.1 NF-κB activation by inflammatory cytokines. C2C12 myotubes from the NF-κB 
sensitive reporter stable cell line were stimulated with A) increasing concentrations of 
TNF-α (0.001; 0.01; 0.1; 1 or 10 ng/ml) or vehicle (0.1% BSA) or B) increasing 
concentrations of IL-1β (0.001; 0.01; 0.1; 1 or 10 ng/ml) or vehicle (0.1% BSA) for 4 h. 
Cells were lysed, luciferase activity was determined and normalised to total protein 
content. Significance of difference compared to control: * p≤0.05; ** p≤0.01. Each 
condition was performed in triplicate within an experiment. Shown are mean + SD of 3 
independent experiments. 
Induction of PPAR transcriptional activity by specific PPAR 
ligands 
Responsiveness of C2C12 myocytes to PPAR agonists was verified using a 
PPAR sensitive promoter reporter. Administration of the general PPAR agonist 
TTA for 24 h to undifferentiated C2C12 myoblasts transiently transfected with a 
PPAR sensitive reporter luciferase plasmid resulted in a dose-dependent 
increase in PPAR-dependent transcriptional activity (Figure 6.2A). Treatment of 
C2C12 myoblasts with specific PPAR agonists (PPAR-α: WY14643; PPAR-δ: 
GW501516 or PPAR-γ: Rosiglitazone) for 24 h also resulted in a dose-
dependent increase in PPAR transcriptional activity with a maximal induction at 
50 µM, 1 µM and 75 µM respectively (data not shown). This data shows that all 
PPAR activators used were able to induce PPAR transcriptional activity in 
C2C12 myoblasts. Next, a cell line containing the PPAR sensitive reporter 
construct stably integrated in the genome was developed to validate the ability 
of the agonists to activate PPAR-dependent transcriptional activity in 
differentiated C2C12 myotubes. Stimulation of C2C12 myotubes with TTA 
(100µM) or specific synthetic PPAR activators (WY14643: 50 µM; GW501516: 
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1µM or Rosiglitazone: 75µM) resulted in an induction of PPAR transcriptional 
activity in a time-dependent manner with maximal inductions after 48 h 
incubation (Figure 6.2B). These data demonstrate that all PPAR activators 
used in this study induce PPAR-dependent transcriptional activity in C2C12 
myoblasts and myotubes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Induction of PPAR transcriptional activity by specific PPAR ligands A) C2C12 
myoblasts were transiently transfected with the PPAR sensitive reporter construct 
and treated with increasing concentrations of TTA or vehicle (ethanol) for 24 h. 
Cells were lysed and luciferase activity was determined and normalised to 
β-galactosidase activity to correct for differences in transfection efficiency. B) 
C2C12 myotubes stably transfected with the PPAR sensitive reporter construct 
were treated with TTA (100 µM), WY14643 (50 µM), GW501516 (1µM), 
Rosiglitazone (75 µM) or vehicle (DMSO: specific agonists or ethanol: TTA) for 48 
h. Cells were lysed; luciferase activity was determined and normalised to total 
protein content. Significance of difference compared to control: * p≤0.05; ** p≤0.01. 
Each condition was performed in triplicate within an experiment. Shown are mean + 
SD of 3 independent experiments. 
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PPAR-γ activation inhibits NF-κB transcriptional activation 
To assess the anti-inflammatory potential of PPAR agonists in skeletal muscle, 
C2C12 myotubes containing the NF-κB sensitive reporter were treated with 
general or specific PPAR ligands prior to exposure to pro-inflammatory 
cytokines. Pre-treatment with TTA (100 µM) resulted in a time-dependent 
inhibition of TNF-α-induced NF-κB transcriptional activity with a maximal 
inhibitory effect at 30 min pre-incubation time (Figure 6.3). 
 
To assess if the three PPAR isoforms have a differential inhibitory capacity on 
TNF-α-induced NF-κB activation, pre-incubation experiments were performed 
with specific PPAR agonists. Pre-incubation with a PPAR-α (WY14643, 50 µM) 
or a PPAR-δ (GW501516, 1 µM) activator had no significant inhibitory effect on 
TNF-α-induced NF-κB transcriptional activity (data not shown) while PPAR-γ 
activation (Rosiglitazone, 75 µM) resulted in a time- (Figure 6.4A) and dose- 
(Figure 6.4B) dependent inhibition of TNF-α-induced NF-κB transcriptional 
activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 PPAR activation inhibits NF-κB transcriptional activity. C2C12 myotubes 
(differentiated for 6 days) from the NF-κB sensitive reporter stable cell line were pre-
treated (time in minutes) with TTA (100 µM) or vehicle (0.1% ethanol final 
concentration) prior to 4 h incubation with TNF-α (1 ng/ml). Cells were lysed, 
luciferase activity was determined and normalised to total protein content. 
Significance of difference compared to TNF-α-treated cells: * p≤0.05; ** p≤0.01. 
Each condition was performed in triplicate within an experiment. Shown are mean + 
SD of 3 independent experiments. 
 
 
In line with the observed inhibitory effect of Rosiglitazone on TNF-α-induced 
NF-κB transcriptional activity, Rosiglitazone also inhibited IL-1β-induced NF-κB 
transcriptional activity in a dose- and time-dependent manner. Here the optimal 
inhibitory effect was observed at 2 h pre-incubation using a concentration of 
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200 µM Rosiglitazone (Figure 6.5A). To confirm that Rosiglitazone-mediated 
inhibition of cytokine-induced NF-κB transcriptional activity did occur through a 
PPAR-γ-dependent mechanism, another structurally unrelated PPAR-γ agonist 
(GW1929) was used in the same experimental set-up. Pre-incubation of C2C12 
myotubes from the NF-κB sensitive reporter cell line with 20 µM of GW1929  
resulted in a time-dependent inhibition of TNF-α-induced NF-κB transcriptional 
activity with a maximal inhibitory effect (approximately 40% inhibition) at 1 h 
pre-incubation (Figure 6.5B). These data show that ligand-induced PPAR-γ 
activation potently inhibits pro-inflammatory cytokine-induced NF-κB 
transcriptional activity in skeletal muscle cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 PPAR-γ activation by Rosiglitazone inhibits TNF-α-induced NF-κB 
transcriptional activity. C2C12 myotubes (differentiated for 6 days) from the NF-
κB sensitive reporter stable cell line were pre-incubated (time in minutes) A) with 
Rosiglitazone (75 µM) or vehicle (DMSO) prior to 4 h incubation with TNF-α 
(1 ng/ml), or B) with an increasing dose of Rosiglitazone or vehicle (DMSO) for 1 h 
prior to 4 h incubation with TNF-α (1 ng/ml).  Cells were lysed, luciferase activity 
was determined and normalised to total protein content. Significance of difference 
compared to TNF-α-treated cells: *p≤ 0.05; ** p≤0.01. Each condition was 
performed in triplicate within an experiment. Shown are mean + SD of 3 
independent experiments. 
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Figure 6.5 PPAR-γ activation inhibits TNF-α- as well as IL-1β-induced NF-κB 
transcriptional activity. C2C12 myotubes (differentiated for 6 days) from the NF-
κB sensitive reporter stable cell line were pre-treated A) 1 h with an increasing dose 
of Rosiglitazone or vehicle (DMSO) prior to 4 h incubation with IL-1β (1ng/ml), or B) 
with GW1929 (20µM) or vehicle (DMSO) for an increasing amount of time prior to 
4 h incubation with TNF-α (1 ng/ml). Cells were lysed, luciferase activity was 
determined and normalised to total protein content. Significance of difference 
compared to TNF-α-treated cells: * p≤0.01.  Each condition was performed in 
triplicate within an experiment. Shown are mean + SD of 3 independent 
experiments. 
PPAR-γ activation reduces TNF-α-induced transcript levels of NF-
κB target genes 
In order to investigate the functional relevance of the NF-κB reporter data, we 
investigated if TNF-α-induced expression of endogenous NF-κB target genes 
was affected by PPAR-γ activation in C2C12 myotubes. Expression of ICAM-1 
(intra-cellular adhesion molecule 1) and the expression of the chemokine KC 
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(keratinocyt-derived chemokine, which is the mouse homologue of human IL-8) 
significantly increased in C2C12 myotubes following stimulation with TNF-α for 
24 h. Pre-treatment of the cells with Rosiglitazone for 1 h abolished the TNF-α-
induced upregulation of KC and ICAM-1 mRNA levels (Figure 6.6). These 
observations show that PPAR-γ activation can reduce NF-κB target gene 
transcript levels in skeletal muscle and demonstrate that data obtained in the 
NF-κB reporter is functionally relevant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 PPAR-γ activation reduces TNF-α-induced transcription of NF-κB target 
genes. C2C12 myotubes (differentiated for 6 days) were pre-treated (1 h) with 
Rosiglitazone (150 µM) followed by a 24 h incubation with TNF-α (1 ng/ml). ICAM-1 
and KC mRNA levels were assessed and corrected for the housekeeping gene 
cyclophilinA. Expression levels are depicted as % of TNF-α-induced transcript 
levels. Each condition was performed in triplicate within an experiment. Shown are 
mean + SD of 3 independent experiments. Significance of difference: * p<0.001.  
 
 
NF-κB target genes in skeletal muscle of Rosiglitazone-treated 
type II diabetic subjects 
To verify if muscular NF-κB activity in human subjects is suppressed by PPAR-
γ activation, we examined the effect of 8 weeks Rosiglitazone treatment on 
muscular gene expression of ICAM-1 and IL-8 in type 2 diabetes mellitus 
patients. Subjects characteristics before and after Rosiglitazone treatment are 
summarised in Table 6.1. No differences were observed in IL-8 mRNA 
expression levels (data not shown). A trend towards lower ICAM-1 mRNA 
expression levels was observed in skeletal muscle after Rosiglitazone 
treatment (0.155 ± 0.0150 AU vs 0.137 ± 0.006 AU; p=0.074) (Figure 6.7).  
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Table 6.1 Subject characteristics before and after Rosiglitazone treatment. Data are presented 
as mean ± SD. 
 Before After 
Age (years) 61.8 ± 3.7 / 
Body weight (kg) 90.2 ± 9.1 90.8 ± 10.0 
Body mass index (kg/m2) 30.2 ± 3.3 30.4 ± 3.4 
Glucose (mmol/l) 9.8 ± 2.2 8.3 ± 1.4 
HbA1c(%) 7.3 ± 0.7 7.7 ± 1.1 
Si 0.012 ± 0.0019 0.032 ± 0.019 ** 
γ-GT (U/l) 43.4 ± 35 22.8 ± 11.2 * 
* p<0.05, ** p<0.01 after vs before treatment. Si: insulin sensitivity; γ-GT: γ-glutamyltranspeptidase; 
HbA1c: Hemoglobine A1c, aAfter 2-week cessation of any pre-existing antidiabetic medication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 ICAM-1 expression levels are reduced in skeletal muscle of Rosiglitazone-
treated type II diabetic subjects. Expression of ICAM-1 mRNA in skeletal muscle 
of type 2 diabetes mellitus patients (n=10) before and after an 8 week Rosiglitazone 
treatment (2 x 4 mg/day). Phosphoprotein PO (36B4) mRNA levels were used for 
normalisation. ICAM-1 expression levels are depicted as arbitrary units (AU) on the 
Y-axis.  
 
PPAR-γ activation does not reduce TNF-α-induced nuclear 
translocation or DNA binding of NF-κB 
In order to explore potential mechanisms by which PPAR-γ activation can exert 
its anti-inflammatory effects, we investigated TNF-α-induced NF-κB (RelA) 
nuclear translocation in response to pre-incubation with Rosiglitazone. As 
shown in Figure 6.8, a pronounced increase in nuclear translocation of RelA 
was observed after 1 h of TNF-α stimulation However, no reduction in TNF-α-
induced RelA nuclear translocation was observed after pre-incubation with 
Rosiglitazone.  
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Figure 6.8 PPAR-γ activation by Rosiglitazone does not inhibit TNF-α-induced RelA 
nuclear translocation. C2C12 myotubes were differentiated for 6 days and treated 
with vehicle (Control), TNF-α (1 ng/ml; 1 h), Rosiglitazone (150 µM; 1 h pre-
incubation) or Rosiglitazone + TNF-α. Cells were lysed and nuclear extracts were 
prepared to assess A) nuclear protein levels of RelA and Histon-3 (loading control) 
by Western blotting. B) RelA and His-3 bands were quantified and expressed as a 
ratio. Significance of difference: * p<0.001. Each condition was performed in 
duplicate or triplicate within an experiment. Shown are mean + SD of 3 independent 
experiments. A representative Western blot is depicted. 
 
 
In addition to nuclear translocation assays. EMSA analyses were performed. 
Figure 6.9A and 6.9C show that RelA DNA binding upon stimulation with TNF-α 
increased dramatically. Pre-treatment with Rosiglitazone did not reduce NF-κB 
DNA-binding in response to TNF-α. Analysis of the sub-composition of the 
retarded complexes by supershift assay in Figure 6.9B revealed that the major 
complex induced by TNF-α (upper band) contained RelA. A negative control 
antibody was used in lane 3. ChIP assays were performed to investigate in vivo 
DNA binding of RelA to the ICAM-1 promoter. As indicated in Figure 6.9D, 
stimulation of C2C12 myotubes with TNF-α potently induced binding of RelA to 
its binding site in the ICAM-1 promoter. Pre-incubation with Rosiglitazone did 
not reduce but rather increased TNF-α-induced binding of RelA to its binding 
site in the ICAM-1 promoter. Aggrecan was included as a non-target of RelA 
and no differences were observed between the different experimental 
conditions (data not shown). These results indicate that TNF-α-induced NF-κB 
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transcriptional activity is suppressed by PPAR-γ activation by a mechanism 
downstream of RelA DNA-binding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 PPAR-γ activation by Rosiglitazone does not inhibit TNF-α-induced RelA DNA 
binding. C2C12 myotubes were differentiated for 6 days and treated with vehicle 
(Control), TNF-α (1 ng/ml; 1 h), Rosiglitazone (150 µM; 1 h pre-incubation) or 
Rosiglitazone + TNF-α. Cells were lysed and nuclear extracts were prepared to 
assess A) RelA DNA binding activity by EMSA. A representative EMSA is depicted. 
B) Supershift analysis using no antibody (lane 1), a RelA antibody (lane 2) or a IgG 
control antibody (lane 3) to assess complex sub-composition. C) Bands containing 
the DNA-RelA complex were quantified. D) Cells were cross-linked, harvested and 
RelA binding to the ICAM-1 promoter was quantified by ChIP. All results from chip 
assays are corrected for non-specific precipitation using HA as a negative control 
antibody. Significance of difference: * p<0.05; ** p<0.0001. Each condition was 
performed in triplicate within an experiment. Shown are mean + SD of 3 
independent experiments. 
Discussion 
The present study reveals that PPAR-γ activators potently inhibit TNF-α- and 
IL-1β-induced NF-κB transcriptional activity in skeletal muscle cells. This anti-
inflammatory effect of PPAR-γ activators is not due to decreased RelA 
translocation to the nucleus or reduced RelA DNA binding. In addition,  
Rosiglitazone decreased transcript levels of known NF-κB target genes in vitro, 
while a trend towards decreased basal expression of ICAM-1 was observed in 
skeletal muscle of Rosiglitazone-treated type 2 diabetic subjects.  
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We used C2C12 cells as an experimental model for skeletal muscle19 as 
previous reports have demonstrated that insulin resistance25 and atrophy26 are 
induced by inflammatory stimuli in myotubes of this cell line. Moreover, it has 
been established that all three different PPAR proteins are present in C2C12 
cells27. All synthetic agonists (Rosiglitazone, GW1929, WY14643 and 
GW501516) used in our study, are specific activators of PPAR-γ, PPAR-α and 
PPAR-δ respectively28. We demonstrated that the PPAR activators used in this 
study are capable of inducing PPAR transcriptional activity in skeletal muscle 
myoblasts. Importantly, for all activators, this response was maintained in fully 
differentiated C2C12 myotubes, which has only been reported for PPAR-α in 
one previous study29. In addition, other work demonstrated the potential of 
PPAR activators to induce DNA binding of the PPARs to their responsive 
elements in C2C12 myotubes but did not investigate the actual transcriptional 
activity of these proteins in response to PPAR activators27. 
  
All three PPAR subtypes have been implicated in the regulation of 
inflammatory responses30. In skeletal muscle however, reports on anti-
inflammatory effects of PPAR activation are rather scarce. For example, anti-
inflammatory properties have been ascribed to the fatty acid analogue TTA 
previously, but so far not in muscle31. In the present study we demonstrate anti-
inflammatory effects of TTA in skeletal muscle, based on its inhibitory actions 
on cytokine-induced NF-κB transcriptional activity. The inhibitory effect of TTA 
on NF-κB transcriptional activity was transient in nature, which could be due to 
metabolic processing of the fatty acid analogue as it can be degraded through 
the ω-oxidation pathway32. 
 
Although the PPAR-α and PPAR-δ activators we used did induce PPAR-
dependent transcriptional activation, we did not observe any effect of PPAR-δ 
or PPAR-α activation on TNF-α-induced NF-κB activity in skeletal muscle cells. 
In contrast, one recent study reported an inhibitory effect of PPAR-δ activation 
on NF-κB transcriptional activity in C2C12 myotubes33. These authors used a 
different activator of PPAR-δ (GW0742) compared to the PPAR-δ activator 
used in this study (GW501516), although both activators have been shown to 
be highly specific for PPAR-δ34. In addition, the duration of TNF-α treatment 
was 4-fold longer compared to our study. With respect to PPAR-α, anti-
inflammatory potential has been investigated and demonstrated in spleen cells 
and smooth muscle cells but not previously in skeletal muscle35,36.  
 
In contrast to PPAR-α and PPAR-δ, PPAR-γ ligands potently inhibited cytokine-
induced NF-κB activity in skeletal muscle cells in the present study. 
Concentrations of Rosiglitazone that were applied were comparable to 
concentrations used in other studies culturing skeletal muscle cells37,38. 
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Moreover, stimulation with Rosiglitazone in this concentration range was 
previously reported to potently induce PPAR-γ transcript levels in skeletal 
muscle cells37,38. Since non-specific effects of Rosiglitazone have been 
described39, we used the structurally unrelated agonist GW1929 to alternatively 
activate PPAR-γ. In line with anti-inflammatory properties of Rosiglitazone as a 
PPAR-γ activator, GW1929 also potently inhibited pro-inflammatory cytokine-
induced NF-kB activation, which suggested this effect was indeed mediated by 
PPAR-γ. In line with our study, agonist-induced PPAR-γ activation was shown 
to repress NF-κB activation in other cell types, e.g. macrophages and T-cells in 
vitro40,41. 
 
In order to assess the functional relevance of the NF-κB reporter data, we 
investigated the effect of Rosiglitazone on the transcription of known 
endogenous NF-κB target genes42. We observed that TNF-α-induced KC and, 
more pronounced, ICAM-1 mRNA levels were significantly attenuated by 
Rosiglitazone in fully differentiated C2C12 myotubes. This observation is in 
concordance with a recent report showing down-regulated ICAM-1 mRNA 
levels in lung epithelial cells in response to different PPAR-γ agonists43. In 
addition, another study demonstrated that Rosiglitazone can attenuate NF-κB-
dependent ICAM-1 production in smooth muscle cells44. To verify these in vitro 
observations in an appropriate and relevant clinical setting, we explored IL-8 
and ICAM-1 mRNA levels in skeletal muscle of diabetic subjects, who received 
Rosiglitazone treatment as an anti-diabetic therapy. ICAM-1 levels tended to be 
lower when compared to levels prior to Rosiglitazone administration, but did not 
reach statistical significance possibly due to a lack of statistical power. 
Additionally, the effective dose of Rosiglitazone that reaches the muscle in the 
patients unfortunately was not measured; however, it is conceivable that this 
dose is lower than the dose made available to the cells in our in vitro 
experiments. Therefore, this may explain differential results obtained in patients 
and in vitro cultured cells. Previously, it has been shown that Rosiglitazone 
treatment of patients with type 2 diabetes mellitus reduced circulating 
inflammatory markers such as C-reactive protein (CRP), metalloproteinase 
(MMP)-9/gelatinase B, and TNF-α45. Our data now shows that Rosiglitazone 
treatment possibly also reduces transcript levels of NF-κB target genes in 
skeletal muscle, although this observation should be confirmed in a larger 
patient population. Additionally, it must be noted that expression of PPAR-γ in 
human skeletal muscle still is controversial. Expression levels in the 
musculature are low but appear of physiological importance as muscle-specific 
deletion of PPAR-γ induced insulin resistance in mice46. Therefore, future 
studies are necessary to clarify the exact role of PPAR-γ in human skeletal 
muscle and its implication in the observed effects of Rosiglitazone 
administration on skeletal muscle gene expression of T2DM patients. 
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Concentrations of Rosiglitazone that were used in the present study exceed the 
EC50 that has been described for this thiazolidinedione suggesting that the 
inhibiting effect on NF-κB activation may not depend primarily on PPAR-γ 
transcriptional activity. Indeed, the inflammation-modulating properties of the 
PPARs may not require their transcriptional activity, but could rather be 
mediated through the ability of PPARs to interfere with inflammatory signalling 
cascades, including NF-κB35,47. Interestingly, high concentrations of 
Rosiglitazone have been shown to induce PPAR-γ mRNA expression in 
skeletal muscle cells23 and, in concordance with a transrepression mechanism 
of NF-κB modulation by PPAR-γ in skeletal muscle (as has been reported 
previously in other cell types48), GW1929 did not induce PPAR transcriptional 
activity (data not shown) but did interfere with NF-κB signalling. These data 
clearly demonstrate that the PGC-1α/PPAR pathway is able to interfere with 
the relaying of inflammatory signals through the NF-κB pathway. 
 
Several different transrepression mechanisms have been described to be 
mediated by the PPARs36,47,49. These include their ability to physically 
associate with various transcription factors (including NF-κB) and the ability to 
successfully compete for limiting amounts of co-activators. Since Rosiglitazone 
pre-treatment did not reduce TNF-α-induced RelA nuclear translocation or DNA 
binding, the mechanism by which PPAR-γ activation inhibits NF-κB mediated 
gene transcription in skeletal muscle should be located downstream of DNA 
binding. This may include impaired recruitment of transcriptional co-factors to 
the NF-κB-DNA complex47. Alternatively removal of repressor complexes of the 
NF-κB transcriptional machinery may be prevented by PPAR-γ following its 
ligand-induced SUMOylation48. 
 
In conclusion, we show a strong inhibitory effect of agonist-mediated PPAR-γ 
activation on inflammatory mediator-induced NF-κB transcriptional activity in 
skeletal muscle, independent of RelA nuclear translocation and DNA binding. 
The exact mechanism by which this occurs remains obscure but warrants 
further investigation as muscle-specific inhibition of NF-κB activity may be an 
interesting therapeutic venue for treatment of several inflammation-associated 
skeletal muscle abnormalities. 
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Prologue 
According to definitions of the World Health Organization (WHO), chronic 
diseases are not only characterised by their respective primary organ 
impairment, but also by disability and handicap1. In COPD, progressive 
exercise intolerance is a common symptom leading to disability. It is yet well 
established that, in addition to respiratory impairment, skeletal muscle 
dysfunction is an important determinant of decreased exercise capacity in this 
disorder. Skeletal muscle function in COPD is impaired due to muscle wasting 
and loss of muscle oxidative phenotype (OXPHEN i.e. lower slow twitch fiber 
expression, mitochondrial content and oxidative enzyme activity). Besides 
ageing and inactivity, low grade inflammation has been identified as a 
determinant of exercise intolerance in COPD. Experimental models clearly 
show a causal relation between inflammation and wasting of muscle mass2, 
although clinical validation of this relationship in COPD patients is currently 
limited. Surprisingly however, the role of inflammatory signals in loss of skeletal 
muscle OXPHEN remains largely unexplored.  
 
The overall aim of this thesis therefore was to explore the molecular basis of 
loss of skeletal muscle OXPHEN using a translational approach with COPD as 
clinical model. Analyses in patient muscle biopsies yielded leads for the 
underlying pathobiology of COPD-associated loss of OXPHEN, e.g. the 
interaction between inflammation and regulators of skeletal muscle OXPHEN. 
Subsequent in vitro studies using cultured skeletal muscle cells revealed 
causality between inflammatory signalling and loss of muscle OXPHEN and the 
molecular basis of this relationship was partly resolved. Moreover, in vitro 
experiments yielded a tempting therapeutic angle to suppress inflammatory 
signalling in muscle by either nutritional or pharmacological modulation. 
PPARs and COPD 
As outlined in chapter 2, the PGC-1α/PPAR signalling cascade has emerged 
as a key regulatory pathway involved in positive regulation of OXPHEN of 
muscle fibers. In addition, chapter 3 demonstrates that PGC-1α, PPARs and 
its downstream targets, e.g. mitochondrial transcription factor A (Tfam) and 
nuclear respiratory factor 1 (NRF-1), are associated with the development of 
skeletal muscle OXPHEN during the process of myogenic differentiation in 
cultured muscle cells. Therefore, in chapter 4, expression levels and protein 
content of these mediators were investigated in skeletal muscle biopsies of 
COPD patients. It was observed that protein content of PPAR-δ and Tfam as 
well as mRNA transcript levels of PGC-1α and PPAR-α were lower in skeletal 
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muscle of COPD patients compared to healthy controls. In light of the key role 
of the PGC-1α/PPAR pathway in regulation of skeletal muscle OXPHEN, the 
observed disturbances in this pathway in the musculature of COPD patients 
may well underlie the loss of muscle OXPHEN in these patients. As the loss of 
lower limb OXPHEN is considered to be an important underlying aspect of 
impaired muscle endurance and mechanical efficiency in COPD, it is tempting 
to speculate that lower levels of PGC-1α and the PPARs in skeletal muscle of 
COPD patients contribute to functional impairment in this disorder. 
 
As COPD is to be considered a multi-component systemic disease, the cause 
of the decreased content or expression levels of constituents of the PGC-
1α/PPAR pathway in skeletal muscle of COPD patients may be multifaceted. 
Medication, malnutrition, oxidative stress, hypoxia, inactivity, and inflammation 
must all be considered. Maintenance medication in many COPD patients 
consists of inhaled corticosteroids and long acting β2-agonists. The inhaled 
steroid fluticasone has been shown to decrease PPAR expression levels in 
nasal polyposis3. Also, fluticasone as well as the β2-agonist salmeterol, have 
been shown to increase binding of PPARs to other nuclear receptors, thereby 
possibly inhibiting their respective primary functions4. Reports on muscle PPAR 
levels upon treatment protocols for COPD patients involving corticosteroids or 
β2-agonists however are lacking and any effects of these drugs on PPAR 
levels in the musculature of patients therefore remain highly speculative. 
Malnutrition due to decreased appetite or (unbalanced) increased energy 
requirements is commonly observed in COPD patients5. Poly-unsaturated fatty 
acids (PUFAs), found e.g. in fatty fish, are known activators of the PGC-
1α/PPAR pathway6. An increased dietary PUFA intake to balance malnutrition-
induced changes therefore might positively influence the PGC-1α/PPAR 
pathway in muscle of COPD patients. Presence of oxidative stress in skeletal 
muscle of COPD patients has been demonstrated7. Oxidative stress can impair 
PPAR signalling8 and thus might also contribute to an impaired content of the 
PGC-1α/PPAR pathway in lower limb muscles of COPD patients. Hypoxia, 
feasibly via activation of hypoxia inducible factor 1 alpha (HIF-1α), has been 
shown to down-regulate PPAR-α levels9,10, but reports on the role of HIF-1α in 
PPAR regulation in muscle are lacking. Since the PGC-1α/PPAR pathway is 
activated by physical activity11-13 and COPD patients are characterised by a low 
physical activity level14,15, it is conceivable that inactivity will contribute to 
decreased levels of these mediators in skeletal muscle of COPD patients. 
Unfortunately, objective assessment of physical activity level was not 
performed in chapter 4 limiting any conclusions about the involvement of this 
determinant. Instead, inflammatory markers in plasma of these patients 
however were investigated. Intriguingly, it was found that PPAR expression 
levels in muscle were inversely related to circulating levels of TNF-α and its 
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receptors in plasma which suggest that patients’ systemic inflammatory status 
may influence regulation of muscle OXPHEN. It must be recognised that this 
observation is purely associative but is however in line with studies 
demonstrating that levels of inflammatory mediators are inversely related to 
exercise capacity, which is determined, in part, by muscle OXPHEN. A 
limitation of chapter 4 concerned the fact that muscle inflammatory status was 
not investigated, which precluded any interpretations regarding a potential 
contribution of muscle inflammatory signalling in relation to decreased muscle 
OXPHEN. To adequately resolve this issue, constituents and regulators of 
skeletal muscle OXPHEN were investigated after stratification of biopsies of 
COPD patients for normal and high muscular inflammatory signalling based on 
differential TNF-α expression in chapter 5. 
Battle between PPARs and NF-κB 
Chapter 5 demonstrates that COPD patients with high muscle TNF-α mRNA 
levels display decreased transcript levels of constituents of the PGC-1α/PPAR 
pathway in their skeletal muscle. This suggests that inflammation, and in 
particular TNF-α, can interfere with regulation of skeletal muscle OXPHEN. 
This however obviously is purely associative. A possible venue to address 
causality between TNF-α and impaired regulation of skeletal muscle OXPHEN 
in humans might be administration of an agent capable of removing TNF-α. 
Recently a phase II trial has been performed with the chimeric mouse/human 
monoclonal anti-TNF-α antibody Infliximab in patients with mild-to-moderate 
COPD17. The intention-to-treat analysis failed to demonstrate any short term 
beneficial effects on lung function and lung inflammation and even revealed 
undesirable side effects as pulmonary malignancies18. Post-hoc analysis 
however did reveal a significant positive effect of the intervention on exercise 
capacity in the sub-group of cachectic patients.  
 
One important consideration regarding (de)regulation of muscle OXPHEN in 
COPD and in particular the role of inflammation herein is how the presence of a 
systemic inflammatory process correlates with inflammatory status of the 
muscle. In addition, since the PGC-1α/PPAR pathway is considered to be one 
of the main molecular mediators of physical activity-induced muscle 
remodeling, a role for physical inactivity, next to a possible role for 
inflammation, in altering muscular levels of PGC-1α and the PPARs should 
also be considered. Indeed, as described above, COPD patients are 
characterised by disuse of the musculature by physical inactivity19. Since PGC-
1α/PPAR expression11,20 and signalling relies in part on physical activity-
induced Ca2+ signalling21, physical inactivity (sedentary lifestyle) feasibly also 
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contributes to the loss of muscle OXPHEN in COPD via decreased PPAR 
signalling22. The present thesis however focused on the effect of inflammatory 
events in the regulation of skeletal muscle OXPHEN. To address causality of 
the association between high TNF-α and decreased muscle expression levels 
of oxidative genes and their regulators found in patients, an in vitro approach in 
which cultured skeletal muscle cells were chronically stimulated with TNF-α 
was applied in chapter 5. These experiments demonstrated that chronic TNF-α 
treatment of skeletal muscle cells impaired total cellular respiration rates and 
shifted myosin heavy chain composition towards a more glycolytic distribution 
resulting in a decreased skeletal muscle OXPHEN. This revealed a direct link 
between increased TNF-α signalling and impairment of OXPHEN of muscle 
cells. Interestingly, decreased intrinsic mitochondrial respiratory rates in COPD 
patients with a low body mass have been described recently23,24. Another 
study, using COPD patients without active muscle wasting, demonstrated that 
impaired respiratory capacity in COPD was not due to intrinsic mitochondrial 
abnormalities but is probably explained by lower amounts of mitochondria25. 
These studies suggest that both lower amounts of mitochondria as well as 
impaired intrinsic mitochondrial function might be of relevance for impaired 
skeletal muscle respiratory capacity in COPD. Respiration rates in chapter 5 
were not corrected for mitochondrial content of the muscle cells and therefore 
no conclusions regarding intrinsic mitochondrial (dys)function in response to 
chronic TNF-α exposure can be drawn. However, protein content of the 
complexes of the mitochondrial respiratory chain was decreased suggesting a 
decreased mitochondrial content upon TNF-α stimulation. Interestingly, Puente-
Maestu et al. investigated intrinsic mitochondrial respiratory capacity in 
peripheral- as well as respiratory muscles and found similar impairments in 
mitochondrial function between the muscles. This is suggestive of a systemic- 
rather than a local factor in the etiology of impaired mitochondrial function in 
COPD. Since the patients included in their study were matched for physical 
activity levels with healthy controls, these authors suggested a role for a 
systemic factor e.g. systemic inflammation or (intermittent) hypoxia in 
impairment of mitochondrial function in COPD patients24.  
 
The exact molecular mechanism by which TNF-α impairs skeletal muscle 
OXPHEN is unclear. To address this, the proximal part of the TNF-α signalling 
pathway was investigated in chapter 5. Upon binding to its receptor, TNF-α 
initiates an intra-cellular signalling cascade, i.e. the classical NF-κB pathway, 
resulting in degradation of the inhibitor IκBα leading to transduction of the 
inflammatory signal to the nucleus of the cell. These events result in nuclear 
translocation of RelA (the main subunit of the classical NF-κB pathway involved 
in inflammatory signalling) and subsequent transcription of its target genes. 
This leads to the notion that inflammatory events, as elevated levels of pro-
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inflammatory cytokines, for example TNF-α but possibly also other 
inflammatory cytokines as IL-1β, impair skeletal muscle OXPHEN through 
activation of the NF-κB signalling pathway. To address this, mechanistic 
experiments were performed in chapter 5. These demonstrated that the 
impairing effect of chronic TNF-α stimulation on skeletal muscle OXPHEN was 
indeed mediated through and depended on activation of the classical NF-κB 
signalling route, as the effect of TNF-α depended on IκBα degradation. 
Moreover, these experiments convincingly showed that the classical NF-κB 
pathway can interfere with the PGC-1α/PPAR pathway. Activation of the NF-κB 
pathway has been shown to decrease PGC-1α expression in muscle26 and 
PPAR-δ activity in heart muscle27. Together with results from chapter 5, this 
shows that the inflammatory classical NF-κB pathway can interfere with 
pathways regulating OXPHEN in muscle (PGC-1α/PPAR), thereby feasibly 
contributing to an impaired skeletal muscle OXPHEN. In this context it would 
be very interesting to investigate skeletal muscle OXPHEN in mice with altered 
levels of components of the classical NF-κB signalling pathway specifically in 
skeletal muscle tissue. These transgenic mouse models have been developed 
but have thus far only been applied in research concerning skeletal muscle 
mass regulation2.  
 
Interaction between NF-κB and the PGC-1α/PPAR pathway has been 
described in several tissues. The main mechanism described in literature 
involves a physical interaction between RelA and the different PPAR subtypes. 
Firstly, physical interaction with RelA has been shown to inhibit PPAR-α 
transcriptional activity through diminished DNA binding capacity28,29. Secondly, 
RelA has also been shown to physically interact with PPAR-δ, resulting in 
impaired DNA binding and diminished transcriptional activity30 (in muscle cells) 
leading to a loss of oxidative capacity27. Thirdly, PPAR-γ DNA binding and 
transactivation is disturbed by RelA31,32. In contrast to RelA, the p50 subunit of 
NF-κB is unable to physically interact with the PPAR proteins30. In addition, NF-
κB activation has been shown to be causally related to decreased PGC-1α 
mRNA transcript levels in response to palmitate stimulation of cultured skeletal 
muscle cells26. Thus, activation of classical NF-kB signalling resulting in the 
nuclear presence of RelA appears to repress PPAR-mediated transactivation 
via a direct physical interaction between RelA and PPARs. The exact 
mechanism operating in muscle upon chronic exposure to elevated TNF-α 
levels however merits further investigation. 
 
In addition to data described in chapter 5, a significant body of evidence 
supports the presence of an interaction between the NF-κB and PGC-1α/PPAR 
signalling pathways. The exact mechanisms operating in skeletal muscle 
however remain unknown. Interestingly, interplay between the classical NF-κB 
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and the PGC-1α/PPAR signalling axes has been suggested to be bi-directional. 
Since NF-κB activation is elevated in skeletal muscle of COPD patients33 and 
activation of this pathway has been shown to have several detrimental effects 
on muscle tissue including skeletal muscle atrophy2, impaired myogenic 
differentiation34 and a disturbed OXPHEN (chapter 5), we investigated the 
potential of the PPARs to interfere with inflammatory signalling through the 
classical NF-κB pathway in skeletal muscle cells in chapter 6. This led to the 
observation that pharmacological activation of PPAR-γ potently inhibited 
inflammatory cytokine-induced classical NF-κB activation in cultured skeletal 
muscle cells. These findings were translated into a clinically relevant setting, by 
including type 2 diabetes mellitus (T2DM) patients treated with Rosiglitazone 
as an anti-diabetic therapy. Although group size was limited, a trend towards 
decreased expression of NF-κB target genes was illustrative of the 
pathophysiological relevance of the in vitro findings. Anti-inflammatory potential 
of PPAR-γ activation has been shown in other tissues and several mechanisms 
have been proposed ranging from inhibition of IκBα degradation35, reduction in 
RelA translocation to the nucleus36 and diminished DNA binding of key 
components of the NF-κB pathway37. The anti-inflammatory effects mediated 
by PPAR-γ activation in skeletal muscle described in chapter 6 however 
appeared to be independent of RelA nuclear translocation or DNA binding 
suggestive of a transrepression mechanism. 
 
Several different transrepression mechanisms have been described to be 
mediated by the PPARs28,38,39. These include their ability to physically 
associate with various transcription factors (including NF-κB) and the ability to 
successfully compete for limiting amounts of co-activators. Since Rosiglitazone 
pre-treatment did not reduce TNF-α-induced RelA nuclear translocation and 
DNA binding, the mechanism by which PPAR-γ activators inhibit NF-κB activity 
in skeletal muscle should be located downstream of DNA binding. This may 
include impaired recruitment of transcriptional co-factors to the NF-κB-DNA 
complex38. Alternatively, removal of repressor complexes of the NF-κB 
transcriptional machinery may be prevented by PPAR-γ following its ligand-
induced SUMOylation40. In the latter case, ligand-dependent SUMOylation of 
the PPAR-γ ligand-binding domain targets PPAR-γ to nuclear receptor 
corepressor (NCoR)-histone deacetylase-3 (HDAC3) complexes on 
inflammatory gene promoters. As a result, NCoR complexes are not cleared 
from the promoter and target genes are maintained in a repressed state. This 
mechanism provides an explanation for how an agonist-bound nuclear receptor 
like PPAR-γ can be converted from an activator of transcription to a promoter-
specific repressor of the NF-κB signalling pathway40. Which of the proposed 
transrepression mechanisms is activated in skeletal muscle tissue upon PPAR-
γ activation remains to be established. Clarification of the exact mechanism 
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might be therapeutically relevant since it may identify specific targets for 
pharmacological intervention. 
 
In addition, causality between PPAR-γ activation and anti-inflammatory effects 
of Rosiglitazone administration to skeletal muscle cells was not fully elucidated 
as only pharmacological modulation (and not genetic manipulation) of PPAR-γ 
was applied, However, two different, structurally unrelated, pharmacological 
PPAR-γ activators both potently inhibited NF-κB activation suggesting that the 
observed effects are indeed PPAR-γ-mediated. Still we cannot fully exclude 
that anti-inflammatory actions of the PPAR-γ activators that we used in the 
present study were PPAR-γ-independent and therefore caution needs to be 
exercised in ascribing a role for PPAR-γ in these effects on the basis of the 
action of its ligands. 
 
Extrapolation of the results described in chapter 6 to the in vivo clinical setting 
of COPD patients also warrants caution. Indeed, in chapter 4, it was shown 
that PPAR-γ protein in skeletal muscle of COPD patients (and healthy controls) 
was undetectable, suggesting that, if present at all, PPAR-γ protein content of 
human skeletal muscle is probably very low41. Other reports in literature 
however do suggest the presence of PPAR-γ protein in human skeletal 
muscle42. Since, PPAR-γ is mainly implicated in storage of fatty acids and 
adipocyte cell differentiation it is highly expressed in adipose tissue43. 
Therefore, the possibility emerges that PPAR-γ measured in skeletal muscle 
tissue might originate from intramuscular fat tissue. On the other hand, skeletal 
muscle-specific knock-out of PPAR-γ resulted in diminished insulin sensitivity in 
mice44 and impaired skeletal muscle differentiation in cultured muscle cells45. 
Furthermore, treatment of mice with muscle-specific ablation of PPAR-γ with 
the insulin sensitizing thiazolidinediones (TZD), which are potent PPAR-γ 
activators, failed to improve insulin sensitivity  in contrast to what is observed in 
wild type mice44. This reveals a crucial role for muscle PPAR-γ in maintaining 
insulin sensitivity. Feasibly, PPAR-γ protein content in human skeletal muscle 
is very low but still remains physiologically relevant. 
 
The identification of a bi-directional interplay between the classical NF-κB 
pathway and the PGC-1α/PPAR signalling cascade in skeletal muscle offers 
important novel insights and is illustrative of the complex nature of intracellular 
signalling pathways. Indeed, simplified representations of these pathways are 
inherently incomplete as interactions between these pathways, especially in 
disease related states, may significantly influence functional (disease-related) 
outcome measures. This is illustrated by e.g. the dual role of the classical NF-
κB pathway in regulation of skeletal muscle abnormalities in chronic 
inflammatory diseases. In addition to the detrimental role of classical NF-κB 
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signalling on the regulation of skeletal muscle OXPHEN, described in the 
present thesis, this pathway has also been implicated in the process of skeletal 
muscle wasting. Wasting of skeletal muscle mass is observed in several 
chronic inflammatory disorders and has been linked to increased morbidity, 
disability and morbidity. Increased activation of classical NF-κB signalling has 
been shown in COPD patients suffering from severe muscle wasting33. In 
addition, transgenic mouse models have demonstrated a clear causal link 
between activation of classical NF-κB signalling and the process of skeletal 
muscle atrophy2. This dual role of the classical NF-κB pathway has broad 
implications for its conceived role in skeletal muscle dysfunction in chronic 
disease states. Indeed, based on data observed in literature and data 
presented in this thesis the notion unfolds that patients who suffer from a 
chronic inflammatory disorder as e.g. COPD, T2DM and cancer who display 
increased activation of the classical NF-κB pathway in their muscle are not only 
at risk for active loss of muscle mass but also for deregulation of OXPHEN of 
the remaining muscle. This severely compromises function of the peripheral 
musculature and hence mobility and quality of life of patients. This positions the 
classical NF-κB pathway as a central molecular mechanism underlying skeletal 
muscle abnormalities in COPD and possibly also in other chronic inflammatory 
diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Schematic representation of findings in chapter 3, 4, 5 and 6. Numbers represent 
the respective chapters. 
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Therapeutic perspectives 
Impaired skeletal muscle OXPHEN and a reduced exercise capacity is 
observed in COPD, chronic heart failure (CHF) and T2DM46,47 and severely 
compromises mobility and quality of life of patients. Interestingly, these 
disorders are all characterised by lower PGC-1α and/or PPAR expression 
levels in peripheral skeletal muscle48,49. Therefore, it is tempting to speculate 
that a decreased muscular content of the PGC-1α/PPAR pathway underlies 
disturbed muscle function and reduced mechanical efficiency in these 
disorders. The PGC-1α/PPAR pathway therefore may represent an interesting 
therapeutic target as experimental models show that its activation increases 
skeletal muscle OXPHEN,51 and restores mitochondrial dysfunction52,53. 
Although studies in humans are scarce, findings indirectly point toward 
beneficial effects of modulation of the PGC-1α/PPAR pathway on exercise 
capacity of human subjects. Direct activation of the PGC-1α/PPAR pathway 
can be achieved by pharmacological- as well as nutritional intervention and/or 
physical exercise. Since genetic polymorphisms in the PPAR-δ gene have 
been associated with maximal exercise capacity in human subjects54 and 
administration of the PPAR-δ agonist GW501516 to obese human subjects 
increased skeletal muscle oxidative capacity55, studies describing the effects of 
oral administration of a synthetic PPAR-δ agonist e.g. GW501516, on skeletal 
muscle exercise capacity or endurance of COPD patients could give valuable 
information regarding the therapeutic potential of PPAR modulation in COPD. 
An important consideration in use of pharmacological PPAR activators however 
is safety. Indeed, several adverse effects of PPAR-δ activation have been 
described including potential carcinogenicity in rodents, signs of myopathy and 
rhabdomyolysis, weight gain, fluid retention, peripheral oedema and potential 
increased risk of cardiac failure56. Future in depth investigations are required to 
evaluate safety and efficacy of synthetic PPAR activators in improving exercise 
capacity in human subjects. Alternatively, nutritional components can be used 
to activate the PGC-1α\PPAR pathway in skeletal muscle. Obviously, 
concerning safety, nutritional intervention is preferred compared to the use of 
synthetic substances. Interestingly, a randomised clinical trial from our group 
demonstrated that nutritional supplementation with poly unsaturated fatty acids 
(PUFAs), as adjunct to exercise training, in COPD patients markedly enhanced 
their exercise capacity compared to the placebo treated group57. As PUFAs are 
known PPAR activators58,59, the positive effect of PUFA nutritional 
supplementation on skeletal muscle exercise capacity in COPD might well be 
mediated through the PGC-1α/PPAR pathway. This however remains 
speculative. Measurements of PPAR levels and/or activity before and after 
PUFA supplementation in this study would have been helpful in elucidating the 
molecular mechanisms underlying the observed beneficial effects on muscle 
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exercise capacity. Studies suggest that the magnitude of pharmacological 
activation of PPAR activity far exceeds that of PPAR activation by nutritional 
components. In this context, pharmacological modulation of the PGC-1α/PPAR 
pathway is exceedingly interesting compared to nutritional modulation. 
However, we explored the potential for several fatty acids, including PUFAs, to 
activate PPAR transcriptional activity in cultured adult skeletal muscle cells and 
compared it with the potency of a well known pharmacologic PPAR-δ activator. 
These experiments showed that PUFAs, as eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), were capable of inducing PPAR transcriptional 
activity with efficiency comparable to that of the synthetic PPAR-δ agonist 
GW501516 (Figure 7.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 PUFAs induce PPAR transcriptional activity in C2C12 myotubes. C2C12 
myoblasts were differentiated for 3 days in DM. Myotubes were stimulated with 
vehicle (ethanol: Control), poly-unsaturated fatty acids (EPA: 100μM or DHA: 
250 μM) or a synthetic PPAR-δ activator (GW501516; positive control +) for 48h. 
Cells were lysed; luciferase activity was determined and normalised to total protein. 
Error bars indicate the SD. * p≤0.001.  
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Moreover, incubation with the PUFA DHA resulted in an increase in the activity 
levels of enzymes involved in substrate oxidation, including citrate synthase 
(CS) (Krebs cycle) and β-hydroxyacyl CoA-dehydrogenase (HAD) (fatty acid β-
oxidation) demonstrating functional relevance (Figure 7.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 PUFAs induce oxidative enzyme activity in C2C12 myotubes. C2C12 myoblasts 
over-expressing PPAR-δ were differentiated for 3 days in DM. Myotubes were 
stimulated with vehicle (ethanol: Control), poly-unsaturated fatty acids (EPA: 100μM 
or DHA: 250 μM) or a synthetic PPAR-δ activator (GW501516; positive control +) 
for 48h. Cells were lysed; oxidative enzyme activity was determined and normalised 
to total protein. Error bars indicate the SD. * p≤0.05. 
 
 
However, there are some considerations for translation of these findings to 
human subjects. First of all, before binding to transcription factors, PUFAs must 
be absorbed in the intestine and delivered to cells. Subsequently, they must 
enter the cell and the nucleus. PUFA concentrations within the cell determine 
their potency to act as transcription modulators and depend on many different 
factors. Since dietary components interact first with the gastrointestinal tract, 
the mechanisms which regulate the bioavailability at the site of physiological 
activity of a nutritional molecule are fundamental to understand its bioactive 
role. Concentrations of specific fatty acids delivered directly to cultured muscle 
cells in our in vitro system may be relatively high (100-250 μM) compared to 
expected concentrations of specific fatty acids ultimately reaching skeletal 
muscle cells after nutritional modulation in the in vivo situation. Therefore, 
future studies addressing the potential of fatty acid nutritional modulation to 
improve exercise capacity in chronic inflammatory disorders should also focus 
on investigation of molecular mechanisms (PGC-1α/PPAR signalling) and 
measuring intracellular fatty acid levels in myocytes. 
 
In addition to pharmacological or nutritional intervention, physical exercise is an 
evidence-based, practical and financially attractive approach to improve 
skeletal muscle OXPHEN, function and hence quality of life of patients. Most 
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COPD patients indeed improve their exercise capacity upon training. However, 
a subgroup of COPD patients fails to improve exercise capacity upon 
pulmonary rehabilitation60,61. Strikingly, this discrepancy is not explained by 
differences in lung function61. It can be speculated that, since a subset of 
COPD patients is characterised by increased levels of muscle TNF-α62 
(chapter 5), an increased inflammatory status of the muscle over rides the 
ability of the muscle to adapt favorably to exercise.  
 
For example, chapter 3 suggests a role for the PGC-1α/PPAR pathway in the 
development of skeletal muscle OXPHEN during skeletal muscle 
differentiation, as would be observed upon muscle regeneration after muscle 
loss following acute exacerbations in COPD or after damage induced by e.g. 
exercise training. Chapter 3 suggests a role for PGC-1α in development of 
muscle OXPHEN in myogenesis. Interestingly, MyoD, a pivotal regulator of 
myogenesis, binds to the promoter of the PGC-1α gene and activates it 
illustrating that PGC-1α is indeed recruited to build up OXPHEN during 
myogenic differentiation63. Chapter 5 demonstrates that TNF-α can inhibit 
PGC-1α expression in muscle. Also, TNF-α-induced NF-κB activation has been 
shown to negatively regulate myogenic differentiation by inducing loss of MyoD 
mRNA34 and reducing MyoD protein stability64. Since the PGC-1α/PPAR 
pathway is up-regulated by physical exercise11,20,65, it is feasible that attenuated 
activation of this pathway upon physical activity under inflammatory conditions 
may contribute to non-responsiveness to exercise stimuli in a subgroup of 
COPD patients. Future studies are required to shed light on the involvement of 
inflammatory processes in exercise-induced muscle remodelling in chronic 
inflammatory disorders as COPD. In this context, anti-inflammatory properties 
of PPAR-γ activation in skeletal muscle (chapter 6) may have therapeutic 
potential. However, the molecular mechanism and the causality of PPAR-γ in 
the observed anti-inflammatory effects of PPAR-γ activators were not fully 
elucidated in chapter 6. Concerning the molecular mechanism involved it is of 
importance to establish the IC50 of PPAR-γ activators since the concentrations 
used in this study  are relatively high. In addition, PUFAs as EPA possess 
potent anti-inflammatory properties66,67, have been shown to activate PPAR-
γ58,68 and can reverse inflammation-induced muscle abnormalities69,71. 
Therefore, it is tempting to speculate that, in addition to direct PPAR-α or 
PPAR-δ activation by PUFA supplementation and physical exercise, anti-
inflammatory effects of PUFA supplementation, possibly mediated through 
PPAR-γ, indirectly contributed to the observed beneficial effects on exercise 
capacity of COPD patients57. It must be noted however that activation of the 
PPAR-γ isotype by oral thiazolidinediones (TZD) administration in T2DM 
subjects has been shown to be ineffective in restoring in vivo mitochondrial 
function72,73. Nevertheless, it can be suggested that direct activation of the 
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PGC-1α/PPAR pathway in combination with indirect activation (alleviation of 
inflammatory status) may prove to be beneficial in restoring muscle function in 
chronic inflammatory disorders. 
Future directions 
Although valuable new insights have emerged from this work, a number of 
issues remain unresolved and new questions arise. For example, chapter 5 
suggests a role for the classical NF-κB pathway in deregulation of skeletal 
muscle OXPHEN in chronic inflammatory disorders. However, the exact 
implication of this pathway and the precise mechanisms by which it interferes 
with the regulation of skeletal muscle OXPHEN remain unclear. Moreover, it 
appears that the impact of NF-κB signalling on skeletal muscle structure or 
function is not solely confined to detrimental effects. A recent report from 
Guttridge et al. yielded new and exciting results which opened novel insights in 
the involvement of the NF-κB pathway in regulation of muscle OXPHEN. They 
showed that the alternative NF-κB signalling pathway, which can be 
distinguished from the classical NF-κB pathway by different signalling proteins 
and activators, is positively involved in the development of cellular oxidative 
capacity during myogenesis74. This is in contrast with the detrimental role of the 
classical NF-κB pathway on muscle mass34 and muscle OXPHEN (chapter 5). 
As chapter 3 shows that the PGC-1α/PPAR pathway is also associated with 
myogenesis, interplay between the alternative NF-κB pathway and the PGC-
1α/PPAR pathway in this context is feasible. Since PGC-1α/PPAR 
expression11,20 and signalling21 relies in part on physical activity-induced Ca2+ 
signalling21, and physical inactivity results in decreased Ca2+ signalling75,76, 
physical inactivity (sedentary lifestyle) feasibly also contributes to the loss of 
muscle OXPHEN in COPD via decreased PPAR signalling22. Intriguingly, 
physical inactivity also results in activation of the alternative NF-κB pathway77. 
However, the exact role of the classical- and alternative NF-κB pathways in 
loss of muscle OXPHEN in response to disuse or chronic inflammation and the 
link with PGC-1α/PPAR signalling remain to be determined. More specifically, it 
remains to be firmly established whether activation of classical NF-κB signalling 
is sufficient or required for the effects of TNF-α on skeletal muscle OXPHEN. 
Secondly, it is unclear whether activation of the alternative NF-κB pathway will 
lead to an up-regulation of the PGC-1α/PPAR signalling pathway and 
consequently will attenuate inflammation-induced loss of skeletal muscle 
OXPHEN. Finally, whether and how classical- and alternative NF-κB signalling 
control muscle OXPHEN through (de)regulation of the PGC-1α/PPAR pathway 
remains to be explored. Investigation of parameters of skeletal muscle 
OXPHEN and constituents of classical- as well as alternative NF-κB signalling 
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and PGC-1α/PPAR pathway in several experimental mouse models can 
increase insights in this matter. These models include inflammatory models, 
such as muscle-specific IKK-β (classical NF-κB pathway) over-expressing 
mice2, Sp-C/TNF-α (muscle pathology induced by pulmonary inflammation)78 
and inactivity models (hind limb suspension), as well as the combination of 
these models. In human subjects, investigation of muscle inflammatory status 
and physical activity patterns combined with investigation of basal- as well as 
exercise-induced muscle OXPHEN and investigation of classical- as well as 
alternative NF-κB signalling and the PGC-1α/PPAR pathway can aid in 
unravelling the details about the involvement of these pathways in regulation of 
muscle OXPHEN and the role of inflammation and disuse herein.  
 
Another question that deserves attention is whether inflammatory markers in 
the circulation are linked to local inflammatory signalling in muscle of COPD 
patients. This can be addressed by assessing both plasma and muscle 
inflammatory status of a large group of COPD patients by measuring a 
multitude of inflammatory cytokines and investigating any possible correlations. 
If the presence of inflammatory mediators in plasma proves to be a determinant 
of skeletal muscle inflammatory status it can be used as a risk marker that 
could be measured relatively easily (blood sampling and determination of 
plasma inflammatory profile) and used to potentially tailor the treatment 
according to the need for anti-inflammatory interventions. Additionally, it 
remains to be determined whether classical NF-κB signalling is indeed elevated 
in skeletal muscle of COPD patients and related to impaired OXPHEN.  
 
As PPAR-γ activation in muscle blocks activation of the classical NF-κB 
pathway (chapter 6), which is implicated in deregulation of muscle OXPHEN 
(chapter 5), it remains to be determined whether PPAR-γ modulation can 
alleviate skeletal muscle dysfunction associated with an increased 
inflammatory status. By elucidation of the mechanism of the anti-inflammatory 
effect of PPAR-γ activation (transrepression) in skeletal muscle, future studies 
may identify the precise molecular mediators involved and subsequently 
identify new therapeutic targets to alleviate skeletal muscle inflammatory 
status.  
 
It also remains unresolved whether patients with increased muscle 
inflammatory status are characterised by decreased physical activity levels as 
a result of reduced muscle endurance. One can speculate that an impaired 
regulation of skeletal muscle OXPHEN, possibly mediated by inflammation 
(see chapter 5), increases lactate and CO2 production which can lead to more 
dyspnoea and increased fatigability and subsequent disuse of the musculature. 
Future studies investigating physical activity levels of COPD patients should 
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therefore include measurements of muscle inflammatory status (e.g. TNF-α 
levels and markers of activation of the classical NF-κB pathway) and 
investigate associations with physical activity levels of patients. 
  
In conclusion, data presented in the present thesis postulates the classical NF-
κB signalling pathway as an important pathway involved in impaired regulation 
of skeletal muscle OXPHEN under inflammatory conditions. Moreover, 
inflammation-induced disturbances of the PGC-1α/PPAR signalling pathway 
(mediated through the classical NF-κB pathway) may lie at the molecular basis 
of reduced exercise capacity of skeletal muscle in chronic inflammatory 
disorders as COPD but possibly also other inflammatory disorders as CHF and 
T2DM.  
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Summary 
Loss of exercise capacity is observed in several chronic inflammatory disorders 
as e.g. chronic obstructive pulmonary disease (COPD) and chronic heart failure 
(CHF). Exercise intolerance in these disorders contributes significantly to 
clinical outcome of these diseases as it impairs patients in their daily activities, 
diminishes quality of life and increases morbidity of the disease, independent of 
the primary organ dysfunction. Impaired exercise capacity in COPD might be 
caused by loss of muscle oxidative phenotype (OXPHEN) which includes a 
fiber type shift towards a more glycolytic distribution, diminished activity levels 
of enzymes involved in oxidative metabolism and a reduced mitochondrial 
content. The exact mechanisms underlying the loss of muscle OXPHEN in 
chronic inflammatory diseases as COPD to date remain unresolved. The aim of 
this thesis therefore was to investigate molecular mechanisms underlying loss 
of skeletal muscle OXPHEN in chronic inflammatory disorders using COPD as 
a model. Basic molecular mechanisms were investigated in vitro using cultured 
skeletal muscle cells and gathered knowledge was subsequently translated to 
human subjects by analysis of blood samples and muscle biopsies of patients.  
The PGC-1α/PPAR pathway and muscle OXPHEN in COPD  
In the last decade, the PGC-1α/PPAR pathway has emerged as a key 
regulatory pathway involved in determination of muscle OXPHEN. In addition, 
this signal transduction cascade has an array of other physiological impli-
cations including modulation of inflammatory responses. Since COPD is 
characterised by inflammation and clinically significant muscle pathology, 
chapter 2 discusses the potential therapeutic implications of the 
PGC-1α/PPAR pathway in combating COPD systemic pathology based on an 
extensive review of existing literature.  
 
The role of the PGC-1α/PPAR pathway in the regulation of OXPHEN in existing 
muscle fibres is widely established. The implication of this pathway in the 
development of OXPHEN during the process of myogenic differentiation 
however is largely unexplored. In chapter 3 we investigated multiple aspects of 
OXPHEN as well as temporal expression profiles of components of the 
PGC-1α/PPAR pathway in cultured C2C12 skeletal muscle cells during 
myogenesis. PPAR transcriptional activity as well as PGC-1α, Tfam, NRF-1 
and PPAR-α mRNA expression levels increased during myogenic 
differentiation paralleling the development of OXPHEN. PPAR-δ mRNA levels 
on the other hand remained constant during the entire differentiation process. 
This suggests that PGC-1α and PPAR-α might be implicated in the 
development of OXPHEN during myogenic differentiation, while the role of 
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PPAR-δ in regulation of skeletal muscle OXPHEN is possibly confined to pre-
existing muscle fibers. 
 
Activation or over-expression of the PGC-1α/PPAR pathway in skeletal muscle 
of mice results in increased proportions of oxidative fibers, higher activity levels 
of mitochondrial enzymes and a higher mitochondrial content. Notably, these 
changes are the opposite of what is observed in muscle tissue of COPD 
patients. Therefore, in chapter 4 we investigated muscular content and 
expression levels of key constituents of the PGC-1α/PPAR pathway in skeletal 
muscle of CODP patients and compared these to levels in skeletal muscle of 
healthy control subjects. This demonstrated that protein content of Tfam, which 
is the master regulator of mitochondrial biogenesis, and PPAR-δ as well as 
mRNA transcript levels of PGC-1α and PPAR-α were decreased in skeletal 
muscle of COPD patients compared to healthy controls which was most 
pronounced in the cachectic patients. Moreover, PPAR mRNA expression 
levels in muscle were inversely related to levels of inflammatory markers in 
plasma. This implies that a disturbed expression and/or content of these 
regulatory factors may well underlie the impaired muscle OXPHEN in COPD. 
Furthermore, it suggests that cachexia and impaired muscle OXPHEN may be 
intertwined processes, possibly with inflammation as a common denominator. 
Activation of the PGC-1α/PPAR pathway therefore may represent an 
interesting approach to alleviate exercise intolerance in COPD.  
Battle between PGC-1α/PPAR and NF-κB 
Chapter 4 demonstrated that PPAR expression levels in muscle of COPD 
patients were inversely correlated with circulating levels of TNF-α and its 
receptors. This suggests that systemic inflammatory status may influence 
regulation of muscle OXPHEN in COPD patients. To address this in more 
detail, the link between inflammation and regulation of skeletal muscle 
OXPHEN was investigated in chapter 5.  
 
Chapter 5 showed that COPD patients with increased muscle TNF-α 
expression had higher glycolytic gene expression while expression levels of 
oxidative genes and their major regulators (PGC-1α, PPAR-α and Tfam) were 
significantly lower compared to COPD patients with normal muscle TNF-α 
mRNA transcript levels. The ‘high TNF-α’ group was also characterised by a 
lower body mass index and fat-free mass index compared to healthy controls, 
indicative of (pre)cachexia. These findings lead to the notion that a sub-
population of COPD patients with increased muscle inflammatory status may 
be at risk, not only for wasting of muscle mass, but also for impairment of 
OXPHEN of the remaining muscle. To address causality of the association 
between TNF-α and decreased muscle oxidative gene expression found in 
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patients, an in vitro approach in which cultured skeletal muscle cells were 
chronically stimulated with TNF-α was applied. These experiments 
demonstrated that chronic TNF-α treatment of skeletal muscle cells impaired 
cellular respiration rates and shifted myosin heavy chain composition towards a 
more glycolytic distribution resulting in a decreased skeletal muscle OXPHEN. 
TNF-α also potently inhibited activity and expression levels of the 
PGC-1α/PPAR pathway. Importantly, we demonstrate that the effects of TNF-α 
on muscle OXPHEN depended on activation of one of the most important 
cellular cascades mediating inflammatory signals, the classical NF-κB pathway. 
This implicates the classical NF-κB pathway not only in skeletal muscle 
atrophy, as shown previously, but also in the loss of OXPHEN under chronic 
inflammatory conditions, which is an important novelty in understanding the 
etiology of muscle abnormalities in COPD.  
 
Interplay between the NF-κB pathway and the PGC-1α/PPAR signalling axis 
has been shown in several tissues. Chapter 6 was aimed at investigating a 
potential bi-directional nature of this interaction in skeletal muscle. While NF-κB 
activation inhibited PGC-1α/PPAR signalling in chapter 5, experiments in 
chapter 6 showed that pharmacological activation of PPAR-γ, but not PPAR-δ 
or PPAR-α, potently inhibited pro-inflammatory cytokine-induced NF-κB 
activation in cultured skeletal muscle cells. This was verified in T2DM patients 
receiving the PPAR-γ activator Rosiglitazone as anti-diabetic treatment. In line 
with in vitro findings of chapter 6, patients receiving Rosiglitazone tended to 
have decreased muscular transcript levels of a NF-κB target gene. 
Interestingly, anti-inflammatory effects mediated by Rosiglitazone-mediated 
PPAR-γ activation in skeletal muscle in vitro described in chapter 6 appeared 
to be independent of RelA nuclear translocation or DNA binding suggestive of a 
transrepression mechanism. 
 
In conclusion, the studies described in this thesis suggest that the PGC-
1α/PPAR pathway is impaired in skeletal muscle of COPD patients and that an 
increased muscle inflammatory status and subsequent inflammatory signalling 
through the NF-κB pathway impairs skeletal muscle OXPHEN. Collectively, this 
implies that inflammation-induced impairment of the PGC-1α/PPAR pathway 
might underlie impaired exercise capacity observed in COPD. Finally, 
activation of PPAR-γ blocks inflammatory signalling in skeletal muscle and 
therefore may represent an interesting therapeutic target to alleviate skeletal 
muscle dysfunction in chronic inflammatory disorders. 
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Samenvatting 
Chronisch inflammatoire aandoeningen zoals chronisch obstructieve longziekte 
(COPD) en chronisch hartfalen worden vaak gekenmerkt door een verlies van 
inspanningscapaciteit. Vermits dit resulteert in een verminderde bewegings-
vrijheid en een beperking van het dagelijks functioneren van patiënten draagt 
dit verlies aan inspanningscapaciteit sterk bij aan een verminderde kwaliteit 
van leven en verhoogde morbiditeit in deze aandoeningen, onafhankelijk van 
de primaire aandoening. De verminderde inspanningscapaciteit van patiënten 
met COPD kan mogelijk toegeschreven worden aan een veranderd oxidatief 
fenotype van de skeletspieren in de onderste ledematen. Deze veranderingen 
omvatten onder andere een vezelverschuiving naar een meer glycolytische 
verdeling, verlaagde activiteit van enzymen betrokken in oxidatief substraat-
metabolisme en een verminderde mitochondriële inhoud. De precieze mecha-
nismen die leiden tot een verminderd oxidatief fenotype van de spier in COPD 
patiënten blijven tot op heden echter onopgehelderd. Het doel van dit 
proefschrift was dan ook om de moleculaire mechanismen te onderzoeken die 
aan de basis liggen van het veranderde spier oxidatief fenotype in chronisch 
inflammatoire aandoeningen zoals COPD. Basale moleculaire mechanismen 
werden in vitro bestudeerd door gebruik te maken van gekweekte spiercellen. 
Kennis hieruit verkregen werd vervolgens vertaald naar de humane setting 
door het verzamelen en analyseren van bloed- en spiermonsters van COPD 
patiënten. 
De PGC-1α/PPAR cascade en spier oxidatief fenotype in COPD  
Recent onderzoek heeft aangetoond dat de PGC-1α/PPAR cascade een 
belangrijke regulator is van spier oxidatief fenotype. Daarnaast is gebleken dat 
deze signaalcascade betrokken is in verschillende andere fysiologische 
processen zoals bijvoorbeeld modulatie van inflammatoire signaaltransductie. 
Vermits COPD gekenmerkt wordt ontstekingsprocessen alsook een verstoord 
spiermetabolisme handelt hoofdstuk 2 over de mogelijke therapeutische rol 
van de PGC-1α/PPAR cascade in de behandeling van systemische afwijkingen 
geassocieerd met COPD. Dit overzicht is gebaseerd op een uitgebreide 
literatuurstudie. 
 
De rol van de PGC-1α/PPAR cascade in de regulatie van oxidatief fenotype 
van bestaande spiervezels is overtuigend aangetoond. De rol van deze 
signaaltransductieweg in de ontwikkeling van oxidatief fenotype gedurende 
differentiatie van spiercellen naar spiervezels is echter onbekend. In 
hoofdstuk 3 werden verschillende parameters alsook belangrijke regulatoren 
van spier oxidatief fenotype onderzocht in gekweekte C2C12 spiercellen die 
gedifferentieerd werden naar spiervezels. De transcriptionele activiteit van de 
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PPARs alsook mRNA expressie niveaus van PPAR-α, PGC-1α, Tfam en NRF-
1, die allen beschouwd worden als belangrijke regulatoren van spier oxidatief 
fenotype, stegen in parallel met de ontwikkeling van het oxidatief fenotype in 
deze cellen tijdens differentiatie. In tegenstelling, mRNA expressie niveaus van 
PPAR-δ bleven constant tijdens differentiatie ondanks een duidelijk beschreven 
rol van PPAR-δ in de regulatie van spier oxidatief fenotype. Dit suggereert dat 
PGC-1α en PPAR-α betrokken zijn in de ontwikkeling van spier oxidatief 
fenotype gedurende differentiatie terwijl de rol van PPAR-δ in de regulatie van 
spier oxidatief fenotype mogelijk beperkt is tot bestaande spiervezels. 
 
Het is overtuigend aangetoond dat activatie of over expressie van 
componenten van de PGC-1α/PPAR cascade, in de skeletspier van muizen, 
resulteert in een verhoogd spier oxidatief fenotype gekenmerkt door een 
toename in het aantal oxidatieve vezels en hogere activiteit van mitochondriële 
enzymen. Het is opmerkelijk dat deze veranderingen precies het omgekeerde 
zijn van de afwijkingen die vastgesteld zijn in de spieren van COPD patiënten.  
Daarom werd in hoofdstuk 4 onderzocht of skeletspieren van COPD patiënten 
gekenmerkt worden door veranderde expressie niveaus of eiwitinhoud van 
componenten van de PGC-1α/PPAR cascade vergeleken met gezonde 
controle personen. Deze experimenten toonden aan dat eiwitinhoud alsook 
mRNA expressieniveaus van bestanddelen van de PGC-1α/PPAR cascade, 
waaronder Tfam, PGC-1α en PPAR-α, verlaagd waren in de spieren van 
COPD patiënten vergeleken met gezonde controles. Een hoogst interessante 
bevinding was dat deze verlaging het meest uitgesproken was in de 
cachectische patiënten en omgekeerd evenredig was met de hoeveelheid 
ontstekingsmediatoren in plasma. Deze bevindingen geven aan dat 
veranderingen in de hoeveelheid van expressie niveaus en eiwitinhoud van 
bestanddelen van de PGC-1α/PPAR cascade mogelijk aan de basis liggen van 
het verminderde spier oxidatief fenotype geobserveerd in COPD patiënten. 
Aanvullend geven deze data aan dat cachexia en verstoord spier oxidatief 
fenotype mogelijk met elkaar verbonden zijn, met inflammatoire processen als 
mogelijk gemeenschappelijke basis. De therapeutische implicatie van deze 
bevindingen is dat activatie van de PGC-1α/PPAR cascade in de spieren van 
COPD patiënten een eventuele strategie kan zijn om inspanningsintolerantie in 
deze ziekte te behandelen. 
Strijd tussen PGC-1α/PPAR en NF-κB 
Hoofdstuk 4 van dit proefschrift toont aan dat PPAR expressie niveaus in de 
skeletspier van COPD patiënten omgekeerd gerelateerd zijn aan de 
hoeveelheid TNF-α en zijn receptoren in de circulatie. Dit geeft aan dat 
inflammatoire status van patiënten mogelijk de regulatie van spier oxidatief 
fenotype beïnvloedt. De relatie tussen inflammatoire processen en spier 
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oxidatief fenotype werd daarom in meer detail onderzocht in hoofdstuk 5. 
Experimenten uit hoofdstuk 5 toonden aan dat COPD patiënten met een 
verhoogde expressie van TNF-α in de spier gekenmerkt werden door 
verlaagde expressie niveaus van oxidatieve genen en hun regulatoren (PGC-
1α/PPAR) alsook door een verlaagde body mass index en vet-vrije massa 
(spier). Dit suggereert dat COPD patiënten met een verhoogde spier 
inflammatoire status het risico lopen niet alleen spiermassa maar ook spier 
oxidatief fenotype te verliezen. De relatie tussen inflammatie en verlaagde 
oxidatieve genexpressie werd bevestigd door de bevinding dat chronische 
TNF-α behandeling van gekweekte C2C12 cellen resulteerde in een 
verminderde celrespiratie, een verlaagde mitochondriële inhoud en een 
verschuiving naar een meer glycolytische vezelverdeling. TNF-α stimulatie van 
spiercellen in kweek had ook een verlaging van de activiteit en expressie 
niveaus van de PGC-1α/PPAR cascade tot gevolg. Een belangrijke observatie 
in hoofdstuk 5 was dat de effecten van TNF-α op spieroxidatief fenotype 
gemedieerd werden door 1 van de belangrijkste signaaltrans-ductiewegen 
betrokken in de transmissie van inflammatoire signalen namelijk de klassieke 
NF-kB signaalcascade. Dit impliceert de klassieke NF-κB signaalcascade niet 
alleen in het verlies van spiermassa, wat in het verleden overtuigend is 
aangetoond, maar ook in verlies van spier oxidatief fenotype, wat een 
belangrijk nieuw inzicht is in de ontwikkeling van spierafwijkingen in COPD. 
 
Het is bekend dat de NF-κB cascade en de PGC-1α/PPAR signaal-
transductieweg met elkaar kunnen interfereren. In hoofdstuk 6 werd 
onderzocht of activatie van de PGC-1α/PPAR cascade kan interfereren met 
inflammatoire cytokine-gemedieerde activatie van de NF-κB cascade in 
spiercellen. In hoofdstuk 5 is beschreven dat activatie van NF-κB de PGC-
1α/PPAR signaalweg kan remmen. In hoofdstuk 6 tonen we aan dat 
farmacologische activatie van PPAR-γ (Rosiglitazone), maar niet van PPAR-δ 
of PPAR-α, resulteert in een sterke inhibitie van NF-κB signalering in 
gekweekte spiercellen. Dit werd bevestigd in patiënten met type 2 diabetes 
mellitus die Rosiglitazone kregen als behandeling voor hun ziekte. De 
ontstekingsremmende effecten van Rosiglitazone behandeling in cellen bleken 
echter onafhankelijk van RelA translocatie naar de nucleus of binding aan het 
DNA, wijzend op een transrepressie mechanisme. 
 
Samengevat beschrijven de studies in deze thesis dat CODP patiënten 
gekenmerkt worden door verlaagde niveaus van componenten van de PGC-
1α/PPAR cascade in de spieren van hun onderste ledematen. Aanvullend 
geven de studies van deze thesis aan dat ontstekings-gemedieerde 
signaaltransductie de regulatie van spier oxidatief fenotype kan remmen. Dit 
suggereert dat ontstekings-gemedieerde remming van de PGC-1α/PPAR 
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cascade mogelijk aan de basis ligt van de verminderde inspanningscapaciteit 
van COPD patiënten. Ter afsluiting tonen we aan dat farmacologische activatie 
van PPAR-γ resulteert in een inhibitie van inflammatoire signalering wat 
mogelijk interessante therapeutische implicaties heeft gezien de, in deze thesis 
aangetoonde, negatieve effecten van inflammatoire signalering op spier 
oxidatief fenotype.   
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Dankwoord 
Waar is de tijd dat ik zenuwachtig in mijn pak zat te wachten voor het 
sollicitatiegesprek op het secretariaat Longziekten in Maastricht. Hier zit ik dan 
in het verre Ohio, zondagavond, schrijflampje aan, na te denken over hoe snel 
de tijd gaat en hoeveel mensen mij hebben bijgestaan in het tot stand komen 
van dit proefschrift… Hier is de plaats waar ik jullie allemaal op de gepaste 
manier kan bedanken. We have come a long way… 
 
Hoewel u niet rechtstreeks betrokken was in mijn project wil ik u bedanken 
Prof. Wouters voor de mogelijkheid om te promoveren op de afdeling 
Longziekten, ik moet eerlijk toegeven dat ik stiekem trots ben op een 
landgenoot als hoofd van de afdeling. Mijn promotieteam ben ik veel 
verschuldigd. Annemie, Ramon, Harry en Patrick, zonder jullie zou ik nu niet 
staan waar ik sta in mijn persoonlijke ontwikkeling en carrière en ik wil jullie 
daar dan ook op een gepaste manier voor bedanken. Annemie: het is 
ongelooflijk hoe je met schijnbaar gemak de spierlijn uit de grond gestampt 
hebt. Je staat altijd klaar met goede ideeën en raad. Onze gesprekken, al dan 
niet over werkgerelateerde onderwerpen, hebben me veel geleerd en ik hoop 
deze in de toekomst in dezelfde leuke sfeer verder te kunnen zetten. Harry en 
Ramon: ja mannen het is zover, dit is jullie plaats in het dankwoord. Jullie 
waren degene die me dagelijks begeleid hebben en sterk hebben bijgedragen 
aan een succesvolle en plezante promotieperiode. Woorden schieten me te 
kort om uit te drukken hoezeer ik genoten en hoeveel ik geleerd heb van onze 
samenwerking. Bij deze toch een bescheiden poging. Ramon: Je verbaast me 
steeds opnieuw met je kennis en inzichten. Je bent wat mij betreft de perfecte 
mentor: geduldig, stimulerend en altijd klaar om te helpen, hoewel je het steeds 
drukker en drukker krijgt de laatste jaren. Het was een waar genoegen met je 
te mogen samenwerken en laten we het succesvol afronden van deze eerste 
periode maar eens goed vieren met een biertje en een danspasje op mijn 
promotiefeest, want geef toe net zoals mij hou je daar toch ook van. Het kan 
niet altijd en alleen wetenschap zijn! Harry: voor jou zullen het dan alleen 
biertjes worden, maar ik wacht nog steeds op de dag dat ik je een danspasje 
zie wagen. Alle gekheid op een stokje…Harry: we hebben onze ups en downs 
gehad, maar ik ben zeer trots met jou in mijn promotieteam. Je stond altijd 
klaar om te helpen met wat dan ook. Ik heb veel geleerd van je nauwkeurigheid 
en soms eigenzinnige inzichten die zeker significant (T-test of non-
parametrisch) hebben bijgedragen aan deze thesis. Bedankt voor alles Harry: 
ik weet niet zeker of je wel weet hoezeer je geholpen hebt in mijn 
wetenschappelijke en persoonlijke ontwikkeling de afgelopen jaren, maar laat 
ik je dit zeggen, zonder jou was het niet hetzelfde geweest en zeker niet zo 
leuk! Tot slot mannen: het was altijd zalig jullie kamer binnen te lopen, waar het 
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naast werk toch ook vaak lachen geblazen was. Bedankt voor alles! Patrick, jij 
was er ook vanaf het prille begin bij en ook jou ben ik veel verschuldigd. 
Bedankt voor al je waardevolle input bij besprekingen, jouw visie op dingen 
heeft me veel bijgebracht. Van jou heb ik geleerd opportunistisch te zijn en 
straight forward te denken. Ik hoop dat we onze samenwerking kunnen 
verderzetten in de toekomst en ik wens je alle succes met je eigen onderzoek, 
want wat dat betreft ben je zeker 1 van mijn grote voorbeelden! 
 
Mijn collega’s van de afdeling Longziekten mogen natuurlijk niet ontbreken. Het 
is een komen en gaan geweest van vele leuke, interessante mensen 
gedurende de jaren, laat ik beginnen bij het begin… 
 
Jos, ja makker ik ben je zeker nog niet vergeten hoewel je nu ver weg woont in 
het mooie Vermont. Jij bent degene die me vele labtechnieken heeft geleerd in 
het begin en we kwamen er snel achter dat we naast het werk veel 
gemeenschappelijk hadden. Ik moet nog steeds lachen als ik denk aan onze 
stapavondjes op congres. Jij was mijn labmaatje toen je nog in Maastricht was 
en ik ben blij je ondertussen een vriend te noemen. Ik wens je alle succes en 
geluk samen met Kim en ik hoop dat we elkaar nog vaak kunnen zien ondanks 
de vele kilometers die we van elkaar verwijderd zijn. Ik ben er zeker van dat, 
hoelang het ook geleden zal zijn dat we elkaar zagen, het weer vanouds 
gezellig en vertrouwd zal zijn als we elkaar weer terugzien. Kim: keep an eye 
on this guy, he is one in a million! Jouw beurt Evi: we hebben altijd goed met 
elkaar kunnen opschieten. Als medebelg en goedlachse collega was jij altijd 
een frisse wind op de afdeling. Het is jammer dat we elkaar veel minder gaan 
zien nu ook jij de stap naar de Verenigde Staten hebt gezet. Je ambitie en 
gedrevenheid hebben me verbaasd en ik hoop dat je het goed doet en een 
fantastische tijd hebt in Baltimore, maar daar twijfel ik geen moment aan! Ook 
de feestjes samen met jou zal ik niet snel vergeten ☺. Pascal: je bent 
ondertussen verhuisd naar Groningen en als het goed is ook druk aan het 
schrijven aan je eigen proefschrift. Het was altijd lachen met jou, ik wens je alle 
succes toe met promoveren en breng ons nog eens een bezoekje in 
Maastricht, maar dan wel als ik weer terug ben. 
 
Het rijtje is lang dus laat ik snel verdergaan. Collega’s van het eerste moment 
Roelinka en Erica: het was leuk jullie te leren kennen en met jullie samen te 
werken. Hoewel jullie niet meer bij Longziekten in Maastricht werken wens ik 
jullie het allerbeste toe op alle vlakken! Dan de post-docs: Niki, Astrid (jaja je 
bent al post-doc nu, het gaat snel), Juanita en Mieke, jullie wil ik ook bedanken 
voor de leuke tijd samen. Jullie doen het allemaal heel goed en ik ben blij dat ik 
jullie vanaf volgend jaar mag vergezellen in het post-doc team van Long-
ziekten, het gaat vast een leuke verderzetting worden van onze samenwerking! 
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Marco: Ik wil jou ook graag bedanken voor alle hulp die ik de afgelopen jaren 
van jou heb gekregen. Je bent ondertussen hoofdanalist en dat is wat mij 
betreft volledig terecht! Jodil, jij mag natuurlijk ook niet ontbreken. Bedankt voor 
alle hulp met Western blots en andere labtechnieken in het begin van mijn 
promotieperiode. Het doet me deugd je gelukkig te zien met je wederhelft en 
als je toch ooit nog eens naar Canada verhuist vergeet ons in het verre 
Maastricht dan niet, het ga je goed! Chiel, Claudia, Anon, Frank, Gonda maar 
ook Johanna en Nadja, ik wil jullie ook bedanken voor de leuke samenwerking 
en hulp met labtechnieken. Dan onze nieuwe garde, hoewel jullie natuurlijk ook 
alweer een tijdje bezig zijn (de tijd gaat inderdaad snel). Céline, Ine, Nicky, 
Koen, Bram en Valéry, jullie maken van onze afdeling een leuke, jonge 
levendige groep. Ik geniet steeds opnieuw weer van onze leuke uitstapjes naar 
de stad om weer eens goed te gaan uit eten of een paar pintjes te gaan 
pakken. Laten we dit vooral blijven doen! Jullie weten ondertussen dat 
promoveren niet altijd van een leien dakje loopt maar ik zie en ervaar dat jullie 
stuk voor stuk harde en gemotiveerde werkers zijn, dus ik heb er alle 
vertrouwen in. Amanda, it was very nice to have the privilige of having you as a 
roommate. I hope you enjoyed Maastricht and I wish you all the best now you 
are back in London, we will definitely try to come and visit you soon. 
 
Esther, bedankt voor alle hulp met oxygraaf metingen en veel succes met 
afronden van je promotie. Melissa, Sabine en Kris, oud mede-studenten op de 
universiteit in Diepenbeek en allemaal in Maastricht terecht gekomen, ook jullie 
wil ik bedanken voor leuke tijden samen zowel in Diepenbeek als Maastricht! 
Nejla, jou wil ik bedanken voor vele dingen. Voor de jaartjes dat we samen zijn 
geweest en de mooie momenten die we hebben gedeeld. Het heeft niet mogen 
zijn tussen ons maar ik wens je alle geluk, liefde en succes toe in alles wat je 
doet! 
 
Jelle, the maestro, Achten. Uiteindelijk ook gestrand in Maastricht en geef toe 
het is fijn vertoeven hier! Sinds onze tijd in Diepenbeek is er veel gebeurd en 
veranderd voor ons allebei. Ik ben blij dat we nog steeds bevriend zijn en 
vereerd dat jij straks achter me staat als paranimf. They say: a true friend is 
hard to find, I say: zo moeilijk was het nu ook weer niet ☺ 
 
I would also like to thank the people from the Department of Cancer Genetics 
at Ohio State University, Ohio, USA. Denis, I would like to thank you for the 
opportunity to work in your lab for 7 months. I enjoyed every moment of it and 
learned a lot! Nadine, Jay, Jen, Jingxin, Bill, Wei, Jon, Eric and Kate thank you 
for all your help with lab stuff and for the good time I had while I was in Ohio! 
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If you work hard, play hard is what they say, en er is natuurlijk geen plezier en 
ontspanning zonder je vrienden. Hier komen ze dan: Wally, Ken, Ollie en 
Wendy, Ronald, Lea en Joke, Stephen en Tanja, Joris en Elie, De Ost, Wimpie 
en Elke, Barto, Vanhees en Joke, Domien en Isabella, Greetje en Sara, al de 
mannen van de wijk, AC en geert, Tompie, Beuk en Briers and last but not 
least mister Phillicious. Bedankt voor de supertijd de afgelopen jaren! Het is 
altijd een feestje als we samen zijn en laten we dat zo houden voor as long as 
possible. Het gaat me deugd doen jullie allemaal weer terug te zien als ik weer 
terug in België ben! 
 
En tot slot natuurlijk de belangrijkste personen. Mama, papa en Anneleen, jullie 
wil ik speciaal bedanken voor alle jaren van liefde en steun. Ik hoop dat ik jullie 
trots heb gemaakt, dat zal ik altijd proberen te blijven doen! Younes, je bent nu 
ook een deel van de familie, zorg goed voor mijn zusje! 
 
Als laatste de belangrijkste persoon: Bettine, lieve schat, jou beschouw ik als 
het grootste succes van mijn promotieperiode. Wie had gedacht dat dingen zo 
gingen lopen, nu zijn we ondertussen al bijna 2 jaar samen en het voelt nog 
steeds iedere dag beter en beter. Helaas was promoveren niet jouw ding, maar 
ik ben blij dat je nu je draai hebt gevonden als longarts in opleiding, ik ben trots 
op je!! Ik zal er altijd voor je zijn om je te steunen en van je te houden en ik kan 
niet wachten om samen met jou een toekomst uit te bouwen die ongetwijfeld 
vol liefde en geluk zal zijn.  
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